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ABSTRACT
Objectives To undertake a process evaluation of 
an adherence support intervention for people with 
cystic fibrosis (PWCF), to assess its feasibility and 
acceptability.
Setting Two UK cystic fibrosis (CF) units.
Participants Fourteen adult PWCF; three professionals 
delivering adherence support (‘interventionists’); five multi- 
disciplinary CF team members.
Interventions Nebuliser with data recording and 
transfer capability, linked to a software platform, 
and strategies to support adherence to nebulised 
treatments facilitated by interventionists over 5 months 
(± 1 month).
Primary and secondary measures Feasibility and 
acceptability of the intervention, assessed through 
semistructured interviews, questionnaires, fidelity 
assessments and click analytics.
Results Interventionists were complimentary 
about the intervention and training. Key barriers to 
intervention feasibility and acceptability were identified. 
Interventionists had difficulty finding clinic space 
and time in normal working hours to conduct review 
visits. As a result, fewer than expected intervention 
visits were conducted and interviews indicated this 
may explain low adherence in some intervention arm 
participants. Adherence levels appeared to be >100% 
for some patients, due to inaccurate prescription 
data, particularly in patients with complex treatment 
regimens. Flatlines in adherence data at the start of 
the study were linked to device connectivity problems. 
Content and delivery quality fidelity were 100% and 
60%–92%, respectively, indicating that interventionists 
needed to focus more on intervention ‘active 
ingredients’ during sessions.
Conclusions The process evaluation led to 14 key 
changes to intervention procedures to overcome barriers 
to intervention success. With the identified changes, it is 
feasible and acceptable to support medication adherence 
with this intervention.
Trial registration number ISRCTN13076797; Results.
BACKGROUND
Cystic fibrosis (CF) is a life- threatening, 
inherited condition affecting over 90 000 
people worldwide, primarily of Northern 
European ancestry.1 Median survival for 
people with cysticfibrosis (PWCF) is esti-
mated at 31 years2–6 with progressive lung 
function decline, caused by regular infection 
and damage to airways, being one of the main 
disease features.2
Preventative medications preserve lung 
function and reduce exacerbations.7–13 Low 
adherence to these medications is problem-
atic as this predicts exacerbations requiring 
intravenous antibiotics (IVAB).14 15 Exacer-
bations of this nature carry a risk of systemic 
side effects of both increased mortality,16 17 
and cost of care.18–20 In 2012, the total spend 
on CF in the UK was estimated to be £100 
million, with £30 million spent on inhaled 
antibiotics and mucolytics21; the UK CF popu-
lation received 1 71 907 days of IVAB with 93 
455 days received in hospital, costing an esti-
mated £27 million.22
Self- reported adherence to inhaled ther-
apies underestimates objectively measured 
adherence, with rates of 80% and 36% 
recorded, respectively23 and systematic data 
Strengths and limitations of this study
 ► This is a detailed evaluation of the feasibility of an 
adherence support system for people with cystic 
fibrosis.
 ► The use of mixed- methods provided indepth under-
standing of the processes involved in delivering the 
service, its value and factors that might influence its 
use, implementation and success.
 ► This was a small, two- centre study.
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collection suggests objective adherence to be closer to 
30%.24 As a result, clinicians are currently unable to iden-
tify PWCF with low adherence, in order to provide addi-
tional support. Hitherto, the most objective surrogate 
measure of adherence has been the medicines possession 
ratio (MPR). However, based on the experience of a CF 
service in Leeds, UK, MPR rates of 63%25 considerably 
overestimate adherence compared with nebuliser down-
load data of 36%.26
Treatment burden has long been recognised as a key 
barrier to medication adherence in CF,27 and reducing 
treatment burden is a key research priority for PWCF 
and clinicians, identified by the Cystic Fibrosis Foun-
dation and the James Lind Alliance.28 29 In response, a 
complex intervention was developed to support inhaled 
medication adherence in PWCF.30 This article presents 
the results of a process evaluation that was undertaken 
alongside a pilot randomisedcontrolled trial (RCT), the 
objectives of which were to determine the feasibility of a 
full- scale RCT.30 Here, we describe the resultant changes 
made to intervention procedures prior to that full- scale 
RCT.31 The specific objectives of the process evaluation 
were:
1. To triangulate qualitative and quantitative data col-
lected on intervention inputs, engagement, activities 
and contextual factors, alongside immediate and inter-
mediate outcomes recorded in the feasibility study, to 
understand and identify potential barriers to interven-
tion implementation and success.
2. To document and use these findings to guide chang-
es to intervention procedures, ahead of a future, full- 
scale RCT.
METHODS
The wider feasibility study
The process evaluation forms one part of a wider pilot 
study, which also assessed the feasibility of RCT proce-
dures and mechanisms of action (reported elsewhere30 32). 
The pilot RCT consisted of 33 intervention patients and 
31 control patients. Three trained interventionists in two 
UK CF centres delivered the intervention to PWCF in the 
intervention arm and followed them up for 5 months, ±1 
month.
Intervention description
The complex intervention to support adherence in CF 
was developed to enable PWCF to manage adherence to 
nebulised medication, with a view to shifting CF treatment 
from rescue in hospital settings to prevention, managed 
in the community. The full intervention development 
process is described in a separate article.30
The complex intervention consists of four key elements: 
the eTrack, CFHealthHub (CFHH) server, the CFHH 
Figure 1 Logic model. CF, cysticfibrosis; CHAOS, Confusion, Hubbub and Order Scale; COM- BMQ, Capability Opportunity 
Motivation Behaviour Beliefs about Medicines Questionnaire; FEV1,forced expiratory volume in 1 second; HRQoL, Health- 
Related Quality of Life; MDT, multidisciplinary team.
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Apps and the manualised behavioural intervention. A 
logic model (figure 1) was produced to reflect, in detail, 
constructs and processes by which the intervention was 
expected to function; this is in terms of inputs, engage-
ment, activities and outcomes. The logic model’s hashed 
numbers (#1, #2, etc) provide a reference for linking 
intervention materials and processes to logic model 
constructs in figure 1.
The eTrack (PARI Pharma GmbH, Starnberg, Germany; 
#4) is a microchipped nebuliser, enabling real- time moni-
toring of adherence to nebulised medications. Time-
stamped records of medications administered via the 
eTrack are sent to a 2net Hub (Qualcomm, San Diego, 
USA; #5) which transmits data to PARI.
Real- time inhalation data are received by the CFHH 
server infrastructure, stored securely and used for display 
in both a web- based interface and a mobile app (#6, see 
figure 2). Each of these displays adherence data along-
side tools to support behaviour change and educational 
content.33 Educational modules within CFHH include: 
‘What is Cystic Fibrosis?’; ‘What does my IV treatment 
do?’; ‘I'm not convinced that my nebuliser treatment 
works’; ‘What does my nebuliser treatment do and why 
should I take it?’; ‘Why is it important that I do my nebu-
liser treatment every day?’; and, ‘I have concerns about 
my nebuliser treatments’. The nebuliser medication 
information displayed to the user in these sections are 
tailored to them based on a baseline assessment of moti-
vation, so as not to overwhelm them.
Participants and their interventionists had access to 
adherence displays for monitoring (#13, #19, #20) and 
other CFHH content (#21–#26), such as education 
about treatments (#21) and problem solving in the face 
of adherence barriers (#26). Interventionists would use 
CFHH to facilitate delivery of manualised behavioural 
intervention sessions (#8, #17).
Interventionists (n=3) included a clinical psychologist, a 
physiotherapist and a social worker. They received specific 
training to deliver the manualised intervention sessions 
(#9). Training was delivered over 2 days, in face- to- face work-
shops. This was supplemented by online learning modules 
and a further 4- week training schedule. Interventionists 
were assessed with online theory tests and in a competency 
assessment which examined intervention delivery within the 
first five sessions.
Sessions were delivered either face- to- face or remotely, 
on a one- to- one basis. All intervention arm participants 
received an initial intervention visit and a minimum of 
one additional review visit over the period of the study 
(#18). The content of sessions varied by participant 
reported motivation; sessions for those with low motiva-
tion were tailored to promote relationship/confidence 
building and to support the participant in the exploration 
of relevant CFHH educational and information mate-
rial (#21, #22). Relevant material could be added to the 
participant’s personalised ‘Toolkit’. Sessions conducted 
with participants displaying higher motivation would also 
involve supporting the participant to set personalised 
adherence goals (#23, #24), and to make action plans 
(#25) and engage in problem solving including making 
coping plans where relevant (#26).
Figure 2 The digital platform. CFHH, CFHealthHub; PWCF, peoplewith cystic fibrosis.
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Design
A mixed- methods approach was used for the process eval-
uation. Although this pragmatic case study34 35 primarily 
works at the level of the programme, we also present a 
nested multiple case design, with cases at the level of the 
PWCF, and two embedded units of analysis—interviews 
with intervention participants and trial data.
Data sources
Quantitative and qualitative data sources were triangu-
lated to address process evaluation objectives. These are 
described using hashed numbers to relate data sources 
to aspects of the logic model (figure 1) for which they 
contributed data.
Qualitative data included verbal reports from project 
staff (#1. #2, #10, #16); semistructured interviews with 
interventionists and participants in the intervention and 
control arms of the pilot RCT (#8, #9, #12, #13, #14, #15, 
#16, #17, #19, #20, #21); minutes of meetings (#3); emails 
(#4), website development reports (#6); and fidelity 
assessments (#17). Semistructured interviews, conducted 
face- to- face, were digitally audio- recorded and tran-
scribed verbatim. The median length of interviews was 30 
min (range 11–87) for PWCF, 86 min (63–102) for inter-
ventionists and 62 min (51–66) for CF team members.
Quantitative data included implementation log entries 
and data management reports (#3), questionnaire data 
derived from secondary clinical outcome measures 
described in table 1 (#7, #28, #29, #30, #31, #32, #33); 
an interventionist- completed structured questionnaire 
on interventionist confidence post- training (#9); struc-
tured interventionist fidelity assessments in which audio- 
recordings of intervention sessions were coded using 
a fidelity scoring system which assessed whether each 
component of the intervention was delivered and the 
quality of that delivery (#11, #17); CFHH click analytics 
(#13, #14, #15, #18, #20, #21, #22, #23, #24, #25, #26); 
session frequency and duration records (#15); and 
adherence data taken from CFHH (#35). Quantitative 
or descriptive data were collected for the 23 logic model 
constructs listed in this paragraph as part of the trial 
protocol, as described in table 1.
Sampling
Participants were recruited for semistructured interviews. 
Participants included intervention arm participants 
(n=14), interventionists (n=3, 0.8 whole- time equiva-
lents at each centre) and members of the wider, multi-
disciplinary CF team (n=5). Participants were purposively 
sampled based on site, age, gender, deprivation index, 
objective and subjective adherence levels (service users) 
or site and professional category (professionals). Inter-
ventionists were interviewed twice—at the beginning and 
end of the study—patients once. PWCF who consented to 
be approached for interview were contacted by letter or 
email and, subsequently, telephone or email depending 
on preference. Professionals were contacted directly by 
the study team.
Data analysis
We conducted a Framework analysis of interview tran-
scripts,36 within NVivo (QSR International) using 
multiple frameworks including the Theoretical Domains 
Framework,37 a process evaluation framework38 and the 
logic model (figure 1).
Using a modified triangulation protocol,39 we integrated 
qualitative and quantitative datasets at the programme and 
the case level.40 We used a joint display table41 to summarise 
datasets for 35 logic model constructs in the Inputs (n=12), 
Engagement (n=6), Activities (n=7), Immediate outcomes 
(n=6) and Intermediate outcomes (n=2) columns (figure 1). 
The fit of data integration was categorised as ‘confirmation’ 
(quantitative and qualitative data provided similar findings); 
‘expansion’ (the datasets addressed different or comple-
mentary aspects of the phenomenon); or ‘discordance’ 
(the datasets were contradictory).42 We described similar 
and unique contributions, made by the two datasets, to the 
research question.39
In the 14 intervention participants, for whom both 
qualitative and quantitative process data were available, 
we produced case profiles,43 triangulating qualitative 
data with individual- participant adherence run charts44 
(online supplemental file 01) and other quantitative 
process data (see online supplemental file 02 Study 
protocol, pp29–31). We worked abductively, moving 
between behaviour change theories45 46 and contextual 
observations, agreeing plausible hypotheses to explain 
patterns which could be tested in future work.47–50
We produced a case- ordered descriptive matrix,51 with 
cases ranked by average adherence during the last month 
of the study, to understand how processes and outcomes 
were mediated by local and individual conditions. Adher-
ence levels of >80% were assessed as high; 50%–80% 
moderate; <50% low.14 52 We theorised that high life 
chaos, as measured by the Confusion, Hubbub and Order 
Scale (CHAOS)53 and low motivation would be associated 
with low adherence. We used four measures to under-
stand motivation: (1) a single item, scored on a 1–7 Likert 
scale—‘I want to do all of my nebuliser treatment’ (moti-
vation); (2) a single item, scored on a 1–7 Likert scale, 
which asked, ‘I am confident I can do all of my nebuliser 
treatments’ (‘confidence’); (3) the necessities and (4) 
concerns 5- point subscales of the Beliefs about Medicines 
Questionnaire nebuliser- specific (BMQ) instrument.54 
Interventionists assessed the participant’s motivation to 
increase adherence on a 1 to 7 scale after discussion with 
the patient; adequate motivation was necessary before 
participants could make action plans and do problem- 
solving activities.
Approach taken to modifying the intervention
Modifications to the intervention fell into three catego-
ries: the software platform; other information technology 
(IT) infrastructure; and the manual and training. Iden-
tified problems and solutions were tabulated following a 
modified approach of that taken by Bugge et al.31 Digital 
platform development was reviewed regularly using the 
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Table 1 Quantitative data contributing to the understanding of logic model constructs
# Logic model column/construct Quantitative
Inputs   
  3 Prescription data CFHH; problems documented in implementation log.
  7 COM- BMQ questionnaire responses COM- BMQ, incorporating the Beliefs about Medicines 
Questionnaire (Nebuliser adherence),54 one additional belief 
item, one intention item, one confidence item, and a list of 
barriers.
  9 Interventionist training programme Structured questionnaire on interventionist confidence after 
training programme.
  11 Competency/fidelity assessment Structured instrument for the assessment of interventionist 
competence.
Engagement
  13 Clinicians accessing adherence data CFHH click analytics.
  14 Adherence data tracking CFHH click analytics.
  15 Participant accessing CFHH CFHH click analytics.
  17 CFHH Intervention sessions delivered according to 
manual (fidelity)
Project- specific structured fidelity assessment instrument.
  18 Initial session, and then review at each clinic visit CFHH click analytics.
Activities
  Intervention components for all participants
   20 Self- monitoring adherence CFHH click analytics.
   21 Tailored education about treatment CFHH click analytics.
   22 Tailored patient stories (videos) CFHH click analytics.
  Intervention components for those with adequate motivation
   23 Personalised goal- setting CFHH click analytics.
   24 Goal review CFHH click analytics.
   25 Personalised action plan CFHH click analytics.
   26 Tailored problem solving CFHH click analytics.
Immediate outcomes
  For all participants
   28 Acute awareness of adherence/increased Motivation Subjective adherence single question (self- report estimate of 
adherence as a percentage); COM- BMQ.
   29 Increased necessity and decreased concern COM- BMQ and PAM-13.127
   30 Increased self- efficacy/motivation COM- BMQ single question about confidence to adhere; PAM-
13.
  For those with adequate motivation
   31 Increased self- efficacy/motivation COM- BMQ single question about confidence to adhere; PAM-
13.
   32 Increased habit/reduced chaos SRBAI automaticity- specific subscale of the Self Report Habit 
index to capture habit- based behaviour patterns128; CHAOS 
6- item: measure of life chaos.53
   33 Reduced barriers No change in the group averages for The Beliefs about 
Medicines Questionnaire—specific (Nebuliser adherence, 
BMQ 21- item54).
Intermediate outcomes
  35 Increased adherence Nebuliser data (CFHH)
CFHH, CFHealthHub; CHAOS, Confusion, Hubbub and Order Scale; COM- BMQ, Capability Opportunity Motivation Behaviour 
Beliefs about Medicines Questionnaire; PAM-13, Patient Activation Measure 13; SRBAI, Self- Report Behavioural Automaticity 
Index.
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‘Must have, Should have, Could have, and Won't have 
but would like’ (MoSCoW),55 often used in agile software 
development.56 57
Patient and public involvement
Recruitment for the patient and public involvement 
(PPI) group was achieved by advertising within CF units 
and on the People in Research website, as well as via 
group members themselves. Cross- infection between 
PWCF58 was prevented by arranging meetings via telecon-
ference. The PPI group gave feedback on intervention 
data sharing policies, usability and presentation of the 
website/user guide. In addition, the PPI group piloted 
the participant information materials and one individual 
gave feedback on the trial protocol and interview guides 
(online supplemental file 02).
Ethics and al approval
The study received approval from London Brent 
Research Ethics Committee (16/LO/0356). The funder 
was not involved in the trial design, patient recruitment, 
data collection, analysis, interpretation, or presentation, 
writing or editing of the report or the decision to submit 
for publication. The corresponding author had full access 
to all the data in the study and had final responsibility for 
the decision to submit for publication.
RESULTS
In what follows, we address contextual factors that affected 
implementation and participant responses, then follow 
the columns (inputs, engagement, activities, immediate 
and intermediate outcomes) of the logic model. Online 
supplemental file 03, tables A–G summarises quantitative 
process outcomes for 14 case study participants, ranked 
by objective adherence at the end of the trial. Hashed 
numbers (#1, #2, etc) indicate cross references to the 
logic model (figure 1) and supporting evidence in online 
supplemental fle 04, which summarises data triangulation 
at the level of individual logic model constructs. Both 
qualitative and quantitative data were available for 13/34 
logic model constructs, providing confirmation of (n=2) 
or expansion on (n=11) inferences drawn from quanti-
tative data. A case- ordered descriptive matrix based on 
logic model columns (online supplemental file 05) and 
run charts annotated with key events (online supple-
mental file 01) provides an integrated analysis at the level 
of the participant for 14 ‘case studies’, cross referenced 
by participant numbers (R02/52, R01/54, etc).
Contextual factors affecting implementation and participant 
responses
The key factor affecting implementation was the mixed 
economy of CF drug delivery systems: the e- Flow (PARI 
Pharma GmbH, Starnberg, Germany); the iNeb (Philips 
Healthcare, Eindhoven, Netherlands); and a number of 
dry powder delivery systems. The e- Flow is the only device 
able to deliver all the wet nebulised drugs that are used 
in CF care. The e- Track we used in this trial was a version 
of the e- Flow developed to transfer time- stamped and 
date- stamped data. Most patients at site R01 used e- Flows; 
switching consenting participants over to the e- Track was 
generally unproblematic. The e- Flow’s competitor, the 
iNeb, cannot deliver aztreonam and requires double- 
chamber filling to deliver tobramycin, so it is not suitable 
for all patients. The data transfer version of the iNeb, 
the BiNeb, is a prototype for which limited numbers are 
available. We were unable to secure approval to integrate 
the BiNeb into CFHH in time to incorporate it into this 
study. At site R02 where iNebs were commonly used, 
those who were familiar with and liked the iNeb were less 
keen to swap to an alternative device; some who swapped 
to the e- Track, later wanted to move back to the iNeb. 
A minority of patients use dry powder delivery systems, 
none of which have data transfer versions. We were unsuc-
cessful in engaging any of the companies producing dry 
powders in time to get dry powder systems integrated 
into CFHH, meaning that dry powder users could not be 
recruited to this feasibility study. Making nebulisers with 
data recording and transfer capability available within 
hospitals following local delivery took prolonged engage-
ment with medical engineering departments to obtain 
local safety approvals. For more than one participant, the 
strength of their mobile data signal affected 2net Hub 
connectivity with the central server (Implementation log, 
19 October 2016).
Through meetings with site staff, the team identified 
a range of human factors that also affected implementa-
tion, in particular: the availability of out- patient rooms; 
the need to clean rooms after each consultation for cross- 
infection control purposes; and the expectation that, 
during hospital visits, outpatients will see the whole each 
member of the multidisciplinary team (MDT) separately. 
The struggle for clinic space and patient convenience 
resulted in more home visits than anticipated for consent 
and review meetings, informed by local lone- working 
policies. Reorganisation of one CF Centre, involving the 
transfer of patients from the care of one local hospital 
to another, had created discontent among some patients 
involved in the trial.
Inputs
The study chief investigator reported introducing local 
site investigators, centre directors and MDTs to CFHH 
(#1). Through case reports, he conveyed that relying 
on forced expiratory volume in 1 second, symptoms and 
body mass index for CF management alone is inadequate 
and that objective adherence data could help overcome 
the ‘lamppost syndrome’,59 also known as the ‘streetlight 
effect’60 61 or ‘drunkard’s search’ (p1162)—a type of avail-
ability bias.63 The chief investigator reported feeling that 
site investigators at both centres were fully bought in, but 
that one clinician (not an investigator) believed that the 
disparities between subjective and objective adherence23 
were overstated (#2).
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Interventionists entered prescription data into CFHH 
based on patient records and self- reported treatment 
regimen (#3). Occasionally, interventionists were slow 
to make monthly prescription checks when prompted 
by system alerts, resulting in apparent adherence levels 
of over 100%, traced to the use of alternating treatment 
regimens64 (Implementation Log, 1 December 2016, 
TMG minutes 10 January 2017). Nebulisers with data 
recording and transfer capability (#4), 2net Hubs (#5), 
the CFHH website and mobile application (#6), were 
made available (emails to project manager 20 May 2016, 
23 June 2016). The Capability Opportunity Motivation- 
Beliefs about Medicines Questionnaire (COM- BMQ—see 
online supplemental file 02)54 questionnaire data (#7) 
was collected in CFHH (online supplemental file 06, 
tables 1–22 and figures 1–9).
Interventionists were complimentary about the inter-
vention manual (#8) and highly satisfied with training, 
but suggested that future courses involved a case study 
approach, following a patient through the intervention 
to illustrate its different aspects (#9, online supplemental 
file 04). A member of the research team (MH) acted as an 
intervention mentor to interventionists (#10). Interviews 
(SD) and observations (MH, HC) identified differences 
in the way site investigators interacted with intervention-
ists, with one giving more intensive practical support, 
through weekly meetings and problem solving (not 
prescribed by the intervention), than the other. Fidelity 
data were collected on all three interventionists and the 
fidelity assessment instrument was modified before use 
in the full RCT (#11). During interviews, interventionists 
were enthusiastic about intervention processes (#12). As 
sites struggled to find space or time for consent/inter-
vention encounters in clinic, the study team requested 
an increase in the number of home visits (Implementa-
tion log 19 October 2016). As a result of initial problems 
in contacting participants and the need for flexibility in 
arranging meetings out of usual clinic hours, the study 
team requested flexible working in which the team 
worked 12:00 to 20:00 2 days a week (interviews & TMG 
minutes 29 November 2016).
Engagement
Interviews and click analytics showed that MDT members 
did not access adherence data (#13), aside from in the 
form of bar charts brought to MDT meetings by interven-
tionists. It is important to note that extending the use of 
CFHH to the MDT was not an objective of the trial and no 
training was given in this regard. Click analytics showed 
that interventionists tracked adherence (#14). Of 14 case 
study participants, 3 did not contribute complete adher-
ence data: R02/42 and R02/02 withdrew, while R02/03 
was lost to follow- up. In other participants, flatlines in 
adherence data caused concern (online supplemental file 
01). Flatlines at the beginning of the study (eg, R01/39, 
R01/48) indicated technical problems with pairing nebu-
lisers and hubs. Flatlines at the end of the study period 
(eg, R01/42, R01/44, R02/12) were confirmed as the 
genuine recording of non- adherence through the use 
of adherence data beyond the end of the study period, 
interview data, self- report subjective adherence and the 
Medication Adherence Data-3 (online supplemental file 
03, table F).
Click analytics showed the median number of partici-
pant CFHH sessions was three (#15, online supplemental 
file 03, table C). Of those with low usage, initial technical 
problems (R01/02, R01/48) and initial lack of availability 
of a mobile application (#6) were potential contributing 
factors. Some case study participants showed moderate 
(R02/52, R01/54 and R01/40: 9–13 sessions) or high use 
(R02/12 and R01/42:>40 sessions). Push notifications—
user- defined messages from the server which give partic-
ipants congratulations or reminders about adherence 
behaviour—were not available in the pilot trial (#16).
Based on fidelity assessment of intervention session 
recordings, the content fidelity of face- to- face interactions, 
was excellent (100%)—with all aspects delivered as per the 
manual (#17). Delivery quality fidelity was more variable 
(60%–92%). The generation of goals and action plans 
was sometimes too directive rather than negotiated and 
supportive. Interviews demonstrated that assessing the 
true level of motivation to adhere to treatment was chal-
lenging; sometimes those with insufficient intrinsic moti-
vation (eg, R01/48, R01/54 and R02/03) were assessed as 
having sufficient motivation and inappropriately tasked 
with setting and reviewing goals, making action plans and 
problem solving (see below #23–#26). These individuals 
were variably motivated by wanting to prove themselves 
to MDT members, who had doubted their adherence 
(R01/49 and R01/54, online supplemental file 05), or by 
helping the research:
I made that special effort ‘cause I was taking part in 
this trial…I didn’t see how it was going to make me 
better. (R01/48)
Interaction with these individuals should have been 
confined to relationship- building and trust- building. 
Fidelity assessment of recordings identified that, in inter-
actions with the adequately motivated, the focus was 
not always on the most active ingredients—goal- setting, 
action planning (habit formation) and problem solving/
coping planning. Participant run charts (online supple-
mental file 01) revealed a disparity in whether and when 
review visits happened (#18).
Activities
In interviews, CF team clinicians (as distinct from the 
interventionists) confirmed they were not monitoring 
adherence as part of usual care (#19). Participant R01/02 
complained that the research focus on adherence was 
‘parallel rather than integrated’ with mainstream clinical 
management. However, the intervention was designed to 
be interventionist delivered allowing individual rando-
misation in a system without contamination of controls 
rather than an intervention aimed at achieving system 
change which would have required a cluster trial design. 
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Participants’ clicks (median 11) on the CFHH ‘How 
am I doing?’ (run charts) page sometimes related to a 
limited number of sessions. In interviews, one moderately 
frequent user (R01/54) only accessed this page to check 
their data were uploading. Other moderate/frequent 
users described this page as important for adherence self- 
monitoring (#20), even when their grasp of their own 
adherence was poor (R01/49).
In interviews with participants, for tailored education 
about treatment (#21), participants accessed particular 
education pages for specific issues, such as nebuliser 
malfunction, which was viewed as, ‘more down to earth’ 
than technical manuals. In particular a video about the 
treatment action of Dornase alfa, was often praised, as 
a means of educating others about CF; ‘Talking heads’ 
videos (in these videos people with CF described strate-
gies for successful nebuliser use, #22) divided opinion: for 
some, the opportunity for social comparison65 provided 
relief and reassurance; those who were less appreciative 
were those who found comparisons with people healthier 
than themselves could make them feel as though they 
were not doing well and comparisons with those less 
healthy could make them fearful of the future.
Other activities (#23–#26 on the logic model) required 
participants to have adequate levels of motivation. Inter-
ventionists classified all but one case study participant 
(R01/44) as having adequate motivation (online supple-
mental file 03, table B) and therefore eligible for further 
tailored intervention. But, as detailed above (see #17 in 
the engagement section), this was sometimes based on 
inadequate discussion with the participants. In inter-
views, participants generally reported setting goals (#23), 
but fidelity assessment showed that goals were sometimes 
formulated by interventionists rather than by partic-
ipants (see #17). The mean number of review sessions 
(#24) over 5 months was 1 (online supplemental file 03, 
table E); this was fewer than intended, likely reflecting a 
failure of the study team to set appropriate expectations 
and a lack of time created by the high pace of recruit-
ment (problem log entries: 31 January 2017; 13 February 
2017). Two individuals (R01/39 and R01/40) received 
their first face- to- face session with an interventionist over 
halfway through the study period (online supplemental 
file 01). CFHH action plan (#25), problem solving and 
coping plan (#26) pages were accessed a median of two, 
three and one times, respectively (online supplemental 
file 03, table E). Interviews data suggest action/coping 
plans were completed during intervention visits but not 
accessed by participants otherwise. In interviews, some 
participants said they were reassured by the presence of, 
and sometimes reported insights from, problem- solving 
modules, such as what to do when going on holiday. 
However, the use of action plans was disliked by some 
participants who found writing down the action plans like 
‘going back to school’. This dislike at least partly reflected 
the generation of action and coping plans by interven-
tionists rather than by the participants themselves (see 
#17).
Immediate outcomes
The pilot was not designed to disseminate the interven-
tion across the centre and with minimal monitoring by 
professionals within the wider CF team (see #19) routine 
medical care was not informed by adherence (#27). 
Unsurprisingly, given the lower than expected face- to- face 
contact (#18, #24), intervention arm group averages for 
immediate (process) outcomes (#28–33) changed little 
over 5 months, with the exception that there was a mean 
reduction of 1.84 (SD 3.44) barriers to adherence per 
person (#33), which could be the outcome of problem 
solving and education about treatment processes (online 
supplemental file 03, table F). Frequent use of CFHH 
and self- monitoring in particular (see above, #20) did not 
necessarily mean that self- reported subjective adherence 
and electronically captured objective adherence were 
well aligned (#28, online supplemental file 03, tables F 
and G). A post hoc paired comparison of subjective and 
objective adherence at 5 (±1) months (figure 3) suggests 
that higher adherers were more uniformly accurate in 
their understanding of their own adherence, whereas low 
adherers could be overly optimistic.
Intermediate outcomes
Item #34 of the logic model, treatment optimisation, is 
defined by NICE as, ‘a person- centred approach to safe 
and effective medicines use’ to ensure best outcomes.66 
Treatment optimisation is a service- level objective, which 
was beyond the scope of our patient- focused intervention 
but is the subject of related ongoing research (see Discus-
sion section). During interviews, RCT participants in the 
intervention arm described behaviours that would affect 
treatment optimisation, for instance taking holidays from 
their treatment. Levels of CF treatment adherence (#35) 
Figure 3 Objective versus subjective adherence at 5 (±1) 
months stratified by adherence.
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were 10% (95% CI: −5.2 to 25.2) higher in the interven-
tion arm (online supplemental file 06). We developed a 
number of theories about why some intervention patients 
did or did not increase their adherence (#35) during 
the analysis. In some cases the run charts illustrated, 
inline with Control Theory, the goal- directed nature of 
behaviour and how it is regulated by feedback control 
processes.67 For example, R01/39 and R01/49 seemed 
to show improvement shortly before planned face- to- face 
visits from interventionists (online supplemental file 01). 
R01/39, who seemed intrinsically motivated when inter-
viewed, sustained improvement in adherence beyond the 
trial period through what they described as positive inter-
action with the interventionist. Others, who seemed more 
extrinsically motivated in interviews (R01/49, R01/54, 
R01/48: see #17), did not sustain adherence, with charts 
suggesting an effortful, ‘all- or- nothing’ pattern. At base-
line, R02/07 had no well- established routine (CHAOS 
score of 10: online supplemental file 01), implying 
substantial self- regulatory effort to achieve higher adher-
ence. In their interview, this participant reported finding 
habit formation parts, such as goal- setting, helpful which 
may have enabled him to maintain high adherence with 
reduced effort, as measured by increased habit and 
reduced life chaos and barriers (change scores −5 and −3, 
respectively: online supplemental file 03, table F). Finally, 
it is important to understand that individual- level adher-
ence can be unstable over time (online supplemental 
file 01, see especially, R01/54, R01/48) highlighting 
the problem of assessing adherence as a ‘snapshot’ in 
a pretest/post- test analysis, rather than in a continuous 
assessment over time.
Several participants with low baseline adherence 
appeared to have responded well to the intervention. 
R01/40 had high motivation (online supplemental files 
01 and 03, table B), possibly due to the salience of a recent 
hospitalisation for IVAB treatment of an exacerbation. 
Click analytic data showed high engagement, with inde-
pendent access of the website and use of problem- solving 
tools. However, in other patients, case study run charts 
(online supplemental file 01) showed that measuring 
change in average objective adherence between baseline 
and 5 months sometimes masked periods of success in 
between (eg, R01/02, and R02/12). Without looking at 
adherence graphs, and only measuring objective adher-
ence at baseline and 5 months, this would have been 
missed (see Discussion section). Interview data offered 
some reasons for improved adherence. While R01/49 
had not made an action plan and their subjective adher-
ence was optimistic (online supplemental file 03, table 
F), their objective adherence increased from low to 
moderate over the trial period (online supplemental file 
01); their motivation also increased and self- reported 
barriers decreased (online supplemental file 03, table 
F), potentially through their high use of problem- solving 
modules and self- monitoring (online supplemental file 
03, table D). R01/02’s run chart also showed a period of 
improvement, ending after the last review visit (online 
supplemental file 01); nonetheless, reduced life chaos 
(online supplemental file 03, Table F) and interview data 
suggested an established routine and reduced barriers 
associated with intensive face- to- face therapist interaction 
and action/coping plans (online supplemental file 03, 
table D). The tailing off of adherence after the end of 
the trial in some case study participants may indicate that 
adherence remained effortful or participation in the trial 
was motivated by altruism not help- seeking (see quota-
tion from R01/48, above).
Modifications to the intervention
Online supplemental file 07 documents 14 technical 
changes that will be made for the full- scale RCT, based 
on the process evaluation findings, to CFHH (n=5), IT 
infrastructure (n=1) and to the interventionist training, 
manual and procedures (n=8). To prevent adherence 
data flatlines, nebulisers (#4) and 2net Hubs (#5) will be 
paired at the factory. Three changes to CFHH (#6) will 
make it easier for interventionists to view/edit prescrip-
tion data and to handle alternating treatment regimens 
(#3). Other changes to CFHH will include making 
graphs more easily interpretable and, based on interview 
data and PPI feedback, adding descriptions to videos. 
Changes to the interventionist manual (#8) will increase 
the emphasis on ‘active ingredients’, introduce interven-
tion triggers for reduced adherence or exacerbations and 
introduce new habit formation sessions. The need for 
increased numbers of protocolised intervention review 
sessions arose because, in the feasibility study, a focus 
on RCT recruitment targets gave interventionists inade-
quate time to deliver review visits (#18, #24), critical for 
updating personalised action plans (#25) and updating 
coping plans (#26). Training (#9) in the full- scale trial 
will be delivered as an intensive 1- week course, with more 
explicit focus on intervention fidelity, supported by new 
case study data and role plays to ensure baseline compe-
tency (#17).
DISCUSSION
The process evaluation identified elements of the inter-
vention which could be improved and 14 changes were 
documented. The complex intervention was developed 
using mixed- methods research with an interdisciplinary, 
person- centred and iterative approach.68–74 The mere 
usage of a digital behaviour change intervention may not 
indicate engagement or lead to desired outcomes;68 73 75–78 
there is no simple dose–response relationship.79 In fact, for 
those with low motivation and low confidence, evidence 
of non- adherence can be threatening.80 81 With different 
baseline motivation and life chaos, a population- level 
definition of ‘effective engagement’70 may be infeasible, 
but contextual and motivational data may still explain 
patterns observed in run charts.82 What may matter more 
than defining engagement is the correct assessment 
and tailoring of management to different psychosocial 
barriers.69 83–91 Our study suggests that digital systems 
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cannot replace, only complement, face- to- face interaction 
between health professionals and patients,92–95 potentially 
creating a sense of ‘accountability’ consistent with control 
theory.46 96 However, it is important to recognise that in 
the absence of objective adherence data, clinicians and 
patients will find it difficult to even begin to engage with 
behaviour change.
Chronic disease self- management is a complex and 
multifactorial problem and, we were unable to cover all 
of the analyses that many would consider relevant. For 
instance, although the intervention is meant to increase 
health literacy through education, we cannot rule out that 
baseline socioeconomic status, known to affect health 
literacy, outcomes and self- management,97–99 was not a 
factor. Another limitation of this study is that we inter-
viewed just over only one quarter of the pilot trial sample. 
Given a relatively homogeneous population, narrow, 
exploratory study aims and the use of established theory, 
14 interviews should be adequate to discern common 
perceptions and experiences.100 101 In the full- scale eval-
uation of this intervention (see last paragraph of this 
section), the process evaluation will involve a user accept-
ability survey of ~250 intervention users from 19 centres 
and face- to- face interviews with over 50 intervention users, 
interventionists and clinicians. As in many other process 
evaluations, we will use maximum variation sampling on 
sociodemographic characteristics and baseline adher-
ence, alongside triangulation, to minimise the risk of 
bias.102 Additionally, readers should be aware that small- 
scale feasibility work does not generalise in every regard 
when scaled up in larger scale studies.103 104 Finally, early 
health economic modelling of the cost- effectiveness,105 
was not updated as part of this feasibility work, but will be 
revisited in 2021 as part of the full- scale evaluation.
Our use of objective adherence measurement over-
comes the limitations of previous studies106 and confirms 
that subjective and objective adherence are poorly 
aligned.23 This process evaluation has succeeded in 
demonstrating that delivery of this intervention is possible 
in busy clinical settings; participant uptake was high and, 
with further development on the basis of these findings, 
the process of gathering objective adherence data and 
implementing it alongside a behavioural intervention is 
both possible and effective.
Given the known difficulties with nebuliser use among 
PWCF, interventions that can make it less effortful are 
important.107 In particular, healthy behaviours are better 
predicted by a patient’s level of automatic behavioural 
repetition than their beliefs or experiences, meaning 
a focus on increasing habit strength is critical for 
chronic disease self- management.108 Through delivery 
of intervention components designed to promote habit 
formation, we intend to reduce effort with the CFHH 
intervention. We are limited in drawing conclusions as to 
the impact of habit formation components of the inter-
vention from this analysis; this is mostly due to the limited 
time constraints of the feasibility study leaving insufficient 
opportunity for habit formation.109 However, there was 
some indication that habit components were useful and 
we have elsewhere demonstrated the importance of habit 
in high adherence.110 111 It has also been indicated that 
adherence interventions focusing on habit formation are 
the most effective.112
Successful habit formation will reduce burden by 
making sustained self- care automatic. The CFHH inter-
vention aims to deliver the fall in burden highlighted 
by the Lind alliance prioritisation exercise as the most 
important goal of CF research.
To date, there is little previous research showing the 
effects of giving patients access to their data, with respect 
to health outcomes and cost- effectiveness. Amidst the 
evidence that does exist, the research is generally poor 
and lacks information about context and implementa-
tion.113 114 Following modifications made to our complex 
intervention, the full- scale RCT across 19 UK centres 
(ISRCTN55504164) will provide high- quality evidence, 
indicating the impact of adherence data on sustained 
self- care. The full- scale RCT will include a further process 
evaluation and health- economic modelling. Further-
more, the CFHH Data Observatory (ISRCTN14464661) 
following on from the RCT will address the issue of how 
to embed the use of adherence data in routine practice 
for healthcare professionals.115–119 The sites involved in 
the reported pilot study have now transitioned into the 
Data Observatory, eventually to be joined by sites involved 
in the full- scale RCT. Data collected in the Data Obser-
vatory quality improvement project will be used in the 
development of generalisable theory and practical guid-
ance about the collaborative use of adherence data,120–122 
with a focus on optimising the use of healthcare resources 
and improving patient care.66 123 The Observatory will act 
as a platform for efficient trials,124 125 providing an oppor-
tunity to share processes and improvement activities to 
enable participating CF clinical research teams to meet 
the demands of future research.126
CONCLUSIONS
We have developed a theory- based complex intervention 
to help PWCF adhere to their medication and form habits 
of sustained self- care. The process evaluation identified 
potential sources of intervention failure and modifica-
tions have been made accordingly. With improved inter-
vention processes, it is feasible and acceptable to support 
sustained self- care via medication adherence through 
the application of behaviour change theory delivered 
through digital and human components.
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1. Lay summary 
Cystic Fibrosis (CF) is an inherited disease affecting 10000 people in the UK with an average 
age at death of 28 years in 2012. The lungs of people with CF (PWCF) are prone to 
infections. Daily physiotherapy and inhaled medications are needed to stay healthy. Around 
£30 million is spent annually on inhaled therapy but average adherence has been shown to be 
only 36%. Data suggest that adherence is better in younger children (71% in under 12s, falling 
to 50% in teenagers) but of the 10000 UK PWCF almost 6000 are now adults. PWCF who 
collect <50% of their medication cost the healthcare system significantly more than PWCF 
who collect more than 80% and most of the additional cost results from unscheduled 
emergency care and hospital admission. This unscheduled emergency care is distressing for 
PWCF and their families. 
 
We have designed an intervention to help adult PWCF see how much treatment they use. We 
use dose-counting nebulisers to collect data and send it to a website where it can be displayed. 
We have worked with PWCF to make the information easy to understand. The website has 
modules which teach PWCF how to build successful treatment habits. We have developed a 
toolkit to help PWCF and a health professional (interventionist) work together to form habits 
of adherence to treatment. 
 
The NHS should not fund this intervention without its effectiveness and value for money 
being evaluated in a Randomised Controlled Trial (RCT). However, there is currently 
insufficient information to effectively plan or justify funding a RCT on the scale required. 
This feasibility study is an essential preliminary to the full scale RCT. The purpose of this 
feasibility study is to see whether the proposed procedures for the full scale RCT are feasible 
and acceptable to PWCF. It will also tell us whether the intervention can be delivered by 
health professionals and is acceptable to PWCF, outside the NHS trust where it was 
developed. 
 
We will recruit PWCF for four months at two CF units. We hope we will recruit 64 PWCF 
overall, but will deem the full scale RCT feasible if we recruit 48. A computer will decide 
whether people who consent to be in the study will receive usual care alone or also receive the 
intervention. Both groups have a short period of two to four weeks when data is collected 
through their nebulisers and fed back to the website. It is only after that period that those 
allocated to the intervention are allowed to use the website and receive enhanced care from 
the interventionist. After that point, all participants are followed up for 5 (+/-) months. 
Participants will complete a series of questionnaires at the outset and at 5 (+/-) months. 
 
With appropriate consent, the interventionist or member of the multidisciplinary team (MDT) 
will audio record consultations between themselves and PWCF who are receiving the 
intervention or usual care. Qualitative researchers will  conduct: 20-24 interviews with PWCF 
receiving the intervention; 20-24 interviews with PWCF receiving usual care; eight interviews 
with the four health professionals who are delivering the intervention; and eight semi-
structured interviews with members of the wider MDT. These interviews are intended to help 
the team understand and mitigate potential sources of failure in the intervention and the 
proposed full-scale trial. 
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Cystic Fibrosis (CF) is a long term condition (LTC) in which poor adherence to high cost 
drugs shortens lives and increases NHS costs. CF is a LTC affecting 10,000 people in the UK 
with PWCF typically dying from lung damage at a median age of 28 years [1]. Randomised 
controlled trials show that preventative medications reduce exacerbations and/or preserve 
lung function, [2–8] however adherence is poor. A recent review of objective measures of 
adherence using medicine possession ratios (MPR: prescriptions collected over prescriptions 
issued) and instrumented medication monitors showed adherence ranging from 67% for oral 
antibiotics, 31-53% for inhaled antibiotics, 53-79% for mucolytics agents and 41-72% for 
hypertonic saline [9]. Accumulating evidence suggests poor adherence is associated with poor 
outcomes. PWCF collecting four or more courses of alternate month nebulised tobramycin per 
year were 60% less likely to be admitted to hospital than PWCF collecting one or less [10]. 
Lower composite MPR predicted exacerbations requiring intravenous antibiotics (IVAB) [9]  
and over a 12 month period PWCF with an MPR of 80% had significantly lower total 
healthcare costs than PWCF with an MPR <50% with a cost difference $14,211 per patient 
and most excess costs related to hospital care [11] . Rescue therapy with IVAB can cause 
renal failure [12]. The total 2012 UK spend for CF was estimated to be £100 million of which 
£30 million was spent on inhaled antibiotics and mucolytics [13]. Although patient self-
reported adherence to inhaled therapy was 80%, objective measurement showed median 
adherence was only 36% and the clinicians were unable to predict which PWCF were able to 
successfully adhere [14]  making adherence support difficult. In 2012, the UK CF population 
received 171,907 days of IVAB with the 93,455 of these that occurred in hospital costing an 
estimated £27 million [15] . It is recommended that adherence interventions should be 
targeted where adherence really matters  [16] and targeting support towards the high cost 
inhaled preventative drugs in CF (median adherence 36%) has the potential to impact on the 




The National Institute for Health Research have commissioned a Programme Grant for 
Applied Research to systematically develop and evaluate an adherence intervention for 
PWCF. The Programme Grant has three work packages 
 
Work package 1: Build IT infrastructure to capture adherence data from nebulisers. Co-
produce a web-portal, ‘CFHealthHub’, with PWCF and clinicians, in order to display 
routinely collected adherence data for the use of both groups.  
 
Work package 2: Develop a toolkit based on psychological theory that can support PWCF to 
adhere to treatment. This will include feedback of measured adherence data and personalised 
interventions to increase adherence delivered through CFHealthHub. Manualise a Behaviour 
Change Intervention (BCI) for use by health professionals and PWCF.  
All four work packages have received a favourable opinion from an NHS REC: 
 
 Work package 2.1A: A study of the views of people with cystic fibrosis about their 
condition and treatments (Hampshire A REC: 14/SC/1455; IRAS: 171049); 
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 Work package 2.1C: A study to produce videos for the CFHealthHub website 
(Camden & Kings Cross REC: 15/LO/0944; IRAS: 182367); 
 
 Work package 2.2B: A  study to develop a Behaviour Change Intervention (BCI) to 
help patients with CF manage treatment adherence ((South Yorkshire REC: 
15/YH/0332; IRAS: 184477); and, 
 
 Work package 2.2B(1): A study to understand how to use the eTrack and Bi-neb 
nebuliser to help people with CF to manage their inhalation treatments (West of 
Scotland REC 5: 15/WS/0089; IRAS: 177900). 
 
Work package 3: Evaluate the toolkit developed in work package 2. The planned definitive 
evaluation will take place in a large-scale, multi-centre Randomised Controlled Trial (RCT). 
The definitive evaluation will compare usual care plus staff training in the importance of 
knowledge, skills and confidence building for adherence versus the same plus the structured 
behaviour change in intervention (CFHealthHub plus manual). 
 
There is too little information available to effectively plan or justify funding a full scale RCT. 
We wish to conduct feasibility study comprising of: 
 
 an ‘external pilot RCT’ to establish the feasibility of recruitment to a larger, definitive 
study; and, 
 
 a ‘process evaluation’ which will help us understand the strengths and weaknesses of 
both the intervention and research protocols, and ways of addressing any weaknesses. 
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3. Aim and objectives 
3.1 Aims 
The principal aims of this feasibility study are to assess the feasibility and acceptability of: 
 
 a complex intervention, when delivered outside the team which conceived and 
developed it; and, 
 
 procedures for a full-scale RCT. 
 
3.2 Objectives 
1. An external pilot randomised controlled trial to determine feasibility of a randomised 
controlled trial based on objective stop-go criteria (Section 7.1) related to: 
 
(a) participant recruitment; 
 
(b) participant retention; and, 
 
(c) quality of primary outcome data at 5(+/- 1) month. 
 
 
2. A process evaluation, relating quantitative and qualitative data on procedures to outcomes, 
in order to understand and mitigate potential sources of failure in:  
 
(a) the intervention; and,  
 
(b) the full trial. 
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4. Design 
Mixed-methods study comprising of: 
 




 Qualitative component: analysis of audio-recorded consultations and interviews. 
 
Quantitative and qualitative data will contribute to the process evaluation. 
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5. Participants and study settings 
5.1 Settings and locations where the data will be collected 
Nebuliser adherence data and information derived from CFHealthHub will be automatically 
uploaded by participants nebulisers in their own home. Data collection involving patient notes 
and patient reported outcome measures will take place in two specialist CF units which have 
not been involved in the development of the intervention. Exacerbation data will be collected 
by the ACtiF trial interventionist and clinicians at sites from participant notes.  
 
5.2 Eligibility 
5.2.1 Inclusion criteria for participants 
1. Diagnosed with CF and with data within the CF registry  
2. Aged 16 years and above 
3. Taking inhaled mucolytics or antibiotics via a chipped nebuliser (e.g. eTrack or Bi-
Neb) or able and willing to take via eTrack or Bi-Neb. 
  
5.2.2 Exclusion criteria for participants 
1. Post-lung transplant 
2. People on the active lung transplant list 
3. Patients receiving palliative care, Lacking in capacity to give informed consent 
4. Using dry powder devices to take antibiotics or mucolytics 
 
 
5.2.3 Eligibility criteria for study centres 
1. Adult CF Centre; 
2. Recognised by commissioners 
3. Receiving year-of-care funding 
 
5.2.4 Eligibility criteria for interventionists 
1. Health care professional  e.g. registered nurse, physiotherapist or other appropriately 
skilled individual such as a psychology graduate able to work at NHS Agenda for 
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In the external pilot RCT, we will test procedures for a full trial. This involves allocation of 
PWCF to either a complex intervention or usual care. A ‘complex intervention’ is defined as 
one with several interacting components [17]. The complex intervention under evaluation has 
three broad categories of components (Figure 1):  
 
(a) a microchipped device (nebuliser) for delivering inhaled medications, which are routinely 
prescribed for the control of cystic fibrosis (Section 6.2);  
 
(b) information technology infrastructure to capture and store adherence data from the 
nebulisers and display it to PWCF and the CF team (Section 6.3); and, 
 
(c) the behaviour change intervention, comprising a software platform (‘CFHealthHub’ 
mobile apps and website) offering adherence feedback and tailored modules of content and 
tools used by the health professional in interactions with PWCF (Section 6.4) and accessed 
independently by PWCF via CFHealthHub 
 
Services received as usual care described in Section 6.5. 
 












Person With Cystic Fibrosis
Interventionist and CF team  
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6.2 Microchipped devices 
Depending on treatment strategies at different centres the participant may use an eTrack 
nebuliser system (Section 6.2.1), an Bi-neb AAD System from (Section 6.2.2). 
6.2.1 The eTrack nebuliser system (Pari GmbH) 
The eTrack controller is a modified version of the eBase controller and can be used to operate 
both the eFlow rapid nebulizer or Altera nebulizer. Compared to the eBase controller the 
eTrack is equipped with a Bluetooth chip and  has a monitoring function to allow the capture 
of inhalation adherence data. The eFlow rapid nebuliser with eTrack controller is a CE 
marked medical device to be used for inhalation therapy. The device allows medications 
(approved for inhalation) to be transported deep into the lungs. 
6.2.2 The Bi-neb AAD System from (Philips Healthcare) 
The Bi-neb AAD system is a CE marked medical device which is intended for use to deliver 
aerosolised liquid medications for participants with cystic fibrosis.  The drug delivery device 
is small and battery powered designed to deliver a precise dose of drug into patient’s lungs. 
The Bi-neb AAD system is designed to deliver liquid medications that are specifically 
approved for use with the Bi-neb AAD System. 
 
6.3 Information technology infrastructure 
The information technology infrastructure for the complex intervention comprises: 
 
i. The Qualcomm hub (Section 6.3.1) 
ii. CFHealthHub (Section 6.3.2). 
iii. The Bi-Neb data transfer system (6.3.3) 
 
6.3.1 The Qualcomm hub 
The Qualcomm hub (Qualcomm; Cambridge, UK) is a wireless device which acquires data 
from the chipped device and transmits it to a cloud-based data centre. It is a Class I MDD and 
CE registered in Europe. It is designed, developed and manufactured in accordance with a 
quality system compliant with ISO13485 standards, meaning it aligns with the quality 
requirements of international regulatory agencies in the health care industry. 
 
6.3.2 CFHealthHub 
CFHealthHub is a web-portal which displays adherence data and provides resources and tools 
to people with cystic fibrosis and health professionals in order to support improved nebuliser 
adherence. It is available on-line via computers, tablets or mobile phones. 
 
A qualitative study (WP 2.1A) to identify the barriers and facilitators of nebuliser use in 
PWCF informed the development of an intervention designed to increase nebuliser adherence. 
Analysis of the interview data was conducted using the COM-B framework, and these 
findings were used to inform the development of a complex intervention centred around the 
feedback of objective adherence data. The intervention was further developed and refined in 
consultation with PWCF and clinicians. An iterative study in which prototype versions of the 
intervention were delivered to and reviewed by PWCF was conducted. In that iterative study 
we interviewed PWCF and interventionists about the usability and tailoring of the 
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intervention, and made improvements to the process and materials based on this feedback. 
The system has been developed to ensure it meets the requirements of the Data Protection Act 
1998. It is intended that data on maintenance and relapse will be generated during the full 
scale trial. 
 
CFHealthHub has a number of modules addressing barriers to adherence based on the COM-
B system described in greater detail in Section 6.4.1. The objectives of the modules as 
mapped to the COM-B are outlined in Table 1 below. 
 
 
Table 1. Learning objectives of the CFHealthHub modules  
 
 
COM-B model component Objectives 
Physical capability  - Have the skills to be able to use the nebuliser correctly 
 
Psychological capability  - Understand the importance of nebuliser use in CF 
treatment 
- Be able to remember to use nebuliser 
- Be able to self-monitor nebuliser use 
- Be aware of a need to improve nebuliser use 
 
Physical opportunity  - Have a realistic medication plan 
- Have a working/functioning nebuliser 
- Have a suitable place to use nebuliser 
- Have the time to use nebuliser 
 
Social opportunity  
 
- Be/feel supported by others to use nebuliser 
Reflective motivation  - Perceive benefits of nebuliser use 
- Perceive few/no concerns about nebuliser use 
- Understand the health consequences of use/non-use 
- Feel confident about nebuliser use 
- Intend to use nebuliser 
 
Automatic motivation - Have an established routine for nebuliser use 
- Have a habit to use nebuliser 
 
 
6.3.3 The Bi-Neb data transfer system 
The Bi-Neb Bluetooth data transfer system is intended to automatically extract breathing 
device use (adherence data) from the device (Bi-Neb) via a Smartphone hub and a secure data 
server onto CFHealthHub. Providing the Bi-Neb is within the Bluetooth range within the 
patient's house, the system can retrieve this data once a day.  
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6.4 The Behaviour Change Intervention (BCI) 
6.4.1 Rationale and theory 
The rationale of the BCI is to help CF patients to self-manage their condition and to form 
habits that will improve adherence to their medication, thereby extending life and 
improving quality of life. The MRC framework for developing and evaluating complex 
interventions recommends that intervention development should be informed by a suitable 
theoretical framework and evidence base [17]. The theoretical model adopted is the COM-
B model [18] which describes a ‘behaviour system’ of the essential and interacting 
conditions of Capability, Opportunity, and Motivation [18] . The model posits that non-
adherence is either non-intentional (a problem of capability or opportunity or intentional (a 
problem of motivation). The model has been adapted to nebuliser adherence on the basis of 
evidence about the factors influencing nebuliser adherence in PWCF [19–32], input from 
expert clinicians currently delivering services to PWCF, as well as from the PPI panel and 
exploratory research conducted in Sheffield. It is important that interventions are tailored 
to individual needs and use a multi-modal approach [33]. Each of the conditions of 
Capability, Opportunity and Motivation has been considered in turn in the development of 
our intervention. The primary component of the intervention is adherence feedback 
delivered via the CFHealthHub. Evidence suggests that while personalised feedback can 
have an effect size of up to 20% in increasing adherence [34, 35], feedback is most 
effective when combined with additional behaviour change techniques [34].  
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Figure 4. Interplay between COM-B components during habit formation 
 
 
 A= Automatic, R= Reflective, C= Capability, O=Opportunity 
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The identification and choice of appropriate behaviour change techniques has been driven by 
the Behaviour Change Wheel framework for the development of interventions [Michie, S. F., 
Atkins, L., & West, R. (2015). The behaviour change wheel: a guide to designing 
interventions.] which outlines a process of intervention design using the COM-B model 
"through the systematic evaluation of theory and evidence" (p. 13). In brief, the process 
involved the following steps: 
 
1. In depth identification and analysis of the factors influencing nebuliser adherence in 
PWCF through an examination of the existing literature, and a qualitative study in 
which participants viewed charts of their objective nebuliser adherence data within an 
interview about factors affecting their motivation, capability and opportunity to adhere 
to their nebuliser treatment (study 2.1).  The Theoretical Domains Framework (TDF; 
[36]) which analyses Capability, Opportunity and Motivation in greater detail was 
used as a framework to guide the analysis. 
2. Identification and evaluation of potential intervention functions (e.g. education, 
persuasion, enablement, environmental restructuring, modelling) to address the 
identified factors influencing nebuliser adherence in consultation with the research 
team, clinicians and PPI.  
3. Development of intervention modules to include specific Behaviour Change 
Techniques  to deliver intervention functions, selection of mode of delivery, and 
mechanism for tailoring of BCI delivery to meet individual needs with regard to 
Capability, Opportunity and Motivation. The module contents have been discussed 
and refined as a result of discussions with clinicians and PPI. 
4. Identification of potential mediators of behaviour change, and identification of tools to 
measure each mediator. 
 
 
The intervention arrived at through this process is described in Table 2. 
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Table 2: Intervention modules  
Module COM-B Intervention 
functions 
Behaviour Change Techniques Mode of Delivery 










 Self-monitoring of behaviour 
 Adding objects to the environment 
(CFHealthHub) 
 
 Charts of objective adherence data 
presented within CFHealthHub 








 Goal setting (behaviour) 
 Feedback on behaviour 
 Discrepancy between current 
behaviour and goal 
 Review behavioural goals 
 Graded tasks 
 Social reward 
 
 Discussion and agreement of goal 
with interventionist 
 Review of goal  
 Feedback on progress (through 
CFHealthHub and interventionist) 




















 Action planning 
 Habit formation 
 Prompts/cues (tailored) 
 
 Action planning tool within 
CFHealthHub 





Persuasion  Focus on past success  
 
 
 Interventionist encouraging focus 
on periods of higher adherence on 
charts 
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Module COM-B Intervention 
functions 
Behaviour Change Techniques Mode of Delivery 
Tailored parts of the intervention (based on baseline COM beliefs and barriers questionnaire (COM-BMQ)
1
 and consultation with interventionist) 
 







 Information about health 
consequences 
 Credible source 
 Salience of consequences 
 Demonstration of the behaviour 




 Q&A linked to information within 
CFHealthHub (tailored by baseline 
beliefs and prescription data) 
 Presentation though text, patient 
stories, 'talking heads' and 
animation 
 Credible sources including 
clinicians, PWCF and 
interventionist 
 Interventionist eliciting self-talk 
through focus on why motivation is 









 Demonstration of behaviour  
 
 'Talking heads' videos of coping 














 Instruction on how to perform the 
behaviour 
 Demonstration of the behaviour 
 Behavioural practice/rehearsal 
 Problem solving 
 Restructure the physical environment 
 self-talk 
 social support (practical) 
 
 Tailored problem solving guided by 
interventionist 
 Solution bank within CFHealthHub. 
 Construction of if-then coping plans  
 Videos demonstrating correct use of 
nebulisers within CFHealthHub 
                                                 
1
  Incorporating the Beliefs about Medicines Questionnaire (BMQ-specific nebuliser treatment) Horne, 2010 
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6.4.2 Intervention providers 
 
Interventionists may already be working at, or be new to participating organisations or be the 
ACtiF interventionist employed to deliver the trial locally at the site. Externally appointed 
staff will be recruited through a formal job interview. Suitable individuals will include 
registered nurses or other member of the multidisciplinary team or a ; graduate in a suitable 
subject such as  psychology or, other relevant profession who holds relevant skills / 
experience. Candidates for the post will ideally have a minimum of two years postgraduate 
experience which might include delivering a research project to time and target. They will be 
employed on the Project to work to NHS Agenda for Change Band 4 or above. They must 
have access to a car for work purposes e.g. participant home visits.  
 
Interventionists will be supported in the delivery of the intervention by members of the 
Multidisciplinary team (MDT) at the site in which they are based. MDTs will receive training 
about the approach of the intervention, and the way in which they can support its delivery (see 
page 28). 
 
Training for interventionists in how to deliver the intervention according to the specifications 
of the behaviour change manual will be provided by Marlene Hutchings with oversight 
provided by Madelynne Arden and/or Judy Bradley.  A comprehensive training manual and 
training programme  will be developed to facilitate this. A certificate of competence will be 
provided prior to the interventionist being able to use CFHealthHub with participants. 
 
An additional trained regional interventionist will offer support to trial sites. This on occasion 
will involve input to patients (face to face or telephone contact), and assisting with problem 
solving via liaising with the nebuliser company. They will be named on the local site 
delegation log.  
6.4.3 Materials 
 
The BCI contains two broad categories of components: 
 
i. CFHealthHub behaviour change modules including adherence feedback used by 
PWCF and health professionals 
 
ii. The behaviour change manual and toolkit used by the interventionist in interactions 
with PWCF in order to understand the specific barriers to adherence for that 





The BCI will be delivered over a 4 to 6 month period through a combination of face-to-face 
sessions and contact via telephone with an interventionist, and through participant interaction 
with different modules of content available on CFHealthHub. The interventionist will discuss 
participant data with members of the MDT to ensure that care is informed by objective 
adherence data. If any concerns become apparent as the interventionists collect data and work 
with participants, these concerns will be passed onto the clinical team. The clinical team will 
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follow their standard procedures in relation to any concerns raised. The intervention content 
and delivery flow are outlined in Figure 5 and described below: 
6.4.4.1 Consent Visit (all participants) 
At the consent visit participants will be given a chipped nebuliser (eTrack) and Qualcom hub 
or the participants will receive a visit from a clinical trainer who will convert the participant’s 
I-neb to a Bi-neb by adding a Bluetooth chip and providing a Smartphone hub. The clinical 
trainer may set up the Bi-neb in the patient’s home or at hospital either during the main 
consent visit or at a separate visit after consent has been obtained. Both the eTrack and Bi-neb 
will connect to CFHealthHub  which will enable adherence data be collected. The 
interventionist will input the participant's prescription details into CFHealthHub.  Together 
these will allow the system to generate adherence charts for that participant. At this visit 
participants will complete a range of baseline measures (see Table 3) including the COM 
beliefs and barriers questionnaire (COM-BMQ) which will be entered into CFHealthHub.  
The responses to this questionnaire will be used to populate the 'My toolkit' section of 
CFHealthHub with specific tailored elements from the 'My treatment' modules prior to the 
Initial Intervention Visit. The participant’s pseudomonas status will be clarified at baseline 
and confirmed by the PI with the opportunity to compare the participant’s prescription with 
the pseudomonas status. 
 
6.4.4.2 Initial Intervention Visit (intervention arm only) 
Participants will be introduced to CFHealthHub.  They will be asked to complete an online 
consent form on behalf of their NHS trust in which they will specify what additional data they 
would be willing for CFHealthHub to record and display (e.g. name, and uploaded 
photographs) and what functional options they would like access to (e.g. push notifications). 
Permissions may be changed at any time. The participant will have the option to upload their 
own “patient story” into CFHealthHub after completion of the online consent form.    
The interventionist will discuss their motivation to adhere to their nebuliser treatment, will 
address beliefs associated with poor adherence and will refer back to answers on the COM-
BMQ to elicit the participants beliefs associated with adherence. Participants will be shown 
'My toolkit' which will have been prepopulated with tailored motivational content (see 
consent visit).   
 
The interventionist and participant will look at and discuss the adherence charts on 
CFHealthHub with a focus on period of higher adherence. The interventionist will note any 
barriers raised by participants during this discussion.   
The interventionist will support the participant to identify where and when additional 
nebuliser treatments could be fitted into their schedule and support them to make an action 
plan using the online tool available on CFHealthHub.  This action plan will be saved to the 
'My toolkit' zone. The interventionist will then agree a % adherence goal for the next four to 
six weeks based on the number of additional treatments that have been planned. This will be 
recorded on CFHealthHub and will be represented by a target line on the adherence charts. 
If motivation is so low that participants are reluctant to set an action plan/goal then the 
interventionist will spend further time discussing motivation and will skip to confidence 
building (see below). 
 
The interventionist will encourage participants to focus on likely problems or issues that 
might disrupt the achievement of the adherence goal and will use the Problem-solving module 
on CFHealthHub to address each of these anticipated problems.  The Problem-solving module 
includes solutions based on educational content, practical support (e.g. model letters to 
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employers) and interactive tools.  Relevant solutions will be saved to the 'My Toolkit' zone of 
CFHealthHub. 
The interventionist will discuss the participant's confidence to meet their goal and will 
identify 2-3 'talking heads' videos showing other people with CF addressing and overcoming 
similar barriers to nebuliser adherence. 
The visit will conclude with a review of the goal and the tailored and personalised contents 
saved to the 'My toolkit' zone of CFHealthHub.  The interventionist will encourage a learning 
mindset, emphasising that even if adherence doesn’t increase starting to think about adherence 
will produce learning that will make subsequent attempts to change easier.   
 
6.4.4.3 Participant Independent access to CFHealthHub (intervention arm) 
Participants will have independent access to CFHealthHub at all times following the Baseline 
visit.  They can, at any time, access their adherence charts, 'My toolkit' contents, and can 
browse the other areas of content as they wish.  Frequency of access to each area of 
CFHealthHub will be monitored and recorded. 
Adherence charts will provide colour -coded feedback about participant achievement towards 
their adherence goal so that they are provided with immediate, easy to recognise information 
about their achievements.  Subject to consent, participants will be sent encouraging messages 
via push notifications, or alternatively when they access CFHealthHub, to match the progress 
made e.g. congratulations on achieving their goal, congratulations on having made progress 
towards their goal, encouragement to remember their action plan. 
 
6.4.4.4 Review visit (Visit 3 - intervention arm) 
At the review visit, the interventionist and participant will look at and discuss the adherence 
charts on CFHealthHub and goal achievement with a focus on progress made and periods of 
higher adherence.  
 
If the adherence goal was met then the participant will be encouraged to set a new higher 
adherence goal or to a goal to maintain their current level of adherence which will be recorded 
on CFHealthHub. Following this the participant and interventionist will review the contents of 
'My toolkit' and revise action plans, problems/solutions as required. If issues of motivation are 
still a concern the interventionist may recommend additional/alternate elements of content 
from 'My treatment' or 'Talking heads' to go into 'My toolkit'. 
If the adherence goal was not met then the interventionist and participants will discuss the 
barriers to goal achievement (motivation, capability, opportunity). The interventionist will 
address beliefs associated with poor adherence and will add/revise the elements of content 
from 'My treatment' or 'Confidence building' to go into 'My toolkit'. 
If no goal was previously set then the interventionist will review motivation and confidence 
and then will consider if the participant is ready to action plan and set a goal.  If not they will 
spend more time reviewing motivation and confidence. 
The participant will be encouraged to set a realistic % adherence goal for the next four to six 
weeks and this will be recorded on CFHealthHub. The interventionist will support the 
participant to revise their action plan as needed and save this to the 'My toolkit' zone. Based 
on the earlier discussion about the barriers that prevented goal achievement the Problem-
solving module on CFHealthHub will be used to address each of the problems encountered, 
and any that are anticipated.  Relevant solutions will be saved to the 'My Toolkit' zone of 
CFHealthHub. 
 
The visit will conclude with a review of the goal and the tailored and personalised contents 
saved to the 'My toolkit' zone of CFHealthHub.  The interventionist will re-emphasise a 
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learning mindset, emphasising that the participant cannot fail, but can learn from the process 
so that they can work together on the adherence challenge.  
 
Participating centres will provide participants with contact details, typically telephone 
numbers, but other methods may be volunteered by centres. Contact details will be provided 
so that participants can contact the centre if they have queries or problems regarding 
CFHealthHub between visits. The interventionist will be able to feedback any information 
from the intervention delivery after the baseline intervention visit to members of the wider 
CF team.  This may include adherence data from sessions with the participant’s clinician and 
MDT particularly if the participant raises any concerns or issues e.g. side effects of a drug to 
allow their usual clinician to discuss this with them at their next clinic visit. 
6.4.4.5 Subsequent Review (intervention arm) 
Following these two sessions the amount of interaction which each PWCF has with the 
interventionist will be tailored to their needs and requirements although it is anticipated that 
these will normally marry with routine clinic visits:  They may have additional face-to-face 
sessions or contact via telephone or e-mail. No more than one monthly face-to-face session 
will be conducted because of the research protocol; if the participant requests additional 
support, the centre may accommodate this at their discretion. Review meetings will take 30 
minutes and be conducted over the 5month (+/- 1 month) of the follow-up period. The 





6.4.4.6 Final research visit (5 months +/- 1 month from consent) 
 
All participants will complete a final research visit 4-6 months from the date of consent. At 
this visit the interventionist will collect the primary and secondary outcome data (see table 3) 
including demography data, health care resource use and the participant completed 
questionnaires. At this final research visit the interventionist will re-check that all adherence 
data has been transferred  to CFHealthHub. The eTrack can store approximately 6 months of 
treatment data, ensuring all the data is transferred at this visit should help to prevent missing 
data.   
 
Following the final 4-6 month post-consent research visit, we will continue to collect: 
adherence data from CFHealthHub; exacerbations; FEV1 and ask participants the subjective 
adherence question until, 30th April 2017. At this point the study closes and the involvement 
of all participants ceases.  After the trial ends (30/4/17), the aspiration is to allow participants  
in the control to have access to the intervention for which negotiations are ongoing. Currently 
funding is in place for the trial interventionists at study sites to deliver the intervention only 
over a 12-month period i.e. up to 30/4/17. It is anticipated that CFHealthHub used outside the 
trial would be delivered within the existing resources of the MDT so using CFHealthHub 
outside the trial should not need the trust to employ any additional staff members. As this is a 
pilot feasibility study where we are testing the intervention in participants, there is an 
expectation that further iteration of CFHealthHub may occur.
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Figure 5. Behaviour change intervention flow chart
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6.5 Usual care 
Patients in both arms will receive usual care. Usual care is heterogeneous within and between centres, based 
on the needs of patients and the skills and interests of CF Unit staff. To better understand the configuration 
of usual care at participating centres a survey tool will be administered by the CTRU to the lead clinician at 
the centre. This will identify the spectrum of clinical and behaviour change interventions that are in use in 
the management and self-management of CF. 
 
A minor component of the intervention is to train all members of the MDT in awareness of patient activation 
so that they are open to addressing issues raised for PWCF in the intervention arm. In addition, a staff 
member in the MDT will help to deliver the intervention. There is the possibility that the awareness of 
patient activation will have some effect on PWCF in both the intervention and control arms, and of leakage 
of the learning from the behaviour change component of the intervention to controls. We will investigate this 
possibility during the process evaluation. 
 
Members of the MDT at each centre will receive one half-day, on-site, face-to-face training about the 
importance of objective nebuliser adherence data in the management of CF, and awareness of the importance 
of building patients' knowledge, skills and confidence to enable them to self-manage their treatment. This 
will include training in the interpretation of graphs and charts of objective adherence data produced by 
CFHealthHub, and the rationale for reducing target adherence in poor adherers in order to increase 
confidence. This will be delivered by designated members of the ACtiF research team. 
 
Participants in the control arm will use a microchipped nebulizer but will not be able to access adherence 
data or other content and tools through CFHealthHub, neither will they receive the structured CFHealthHub 
intervention as described in the intervention manual.  Control arm participants using Bi-neb nebulizers might 
have access to their data as part of routine care but this will not be in the user friendly format provided by the 
intervention. 
 
One function of the qualitative research interviews with staff and control participants  (see Section 8 below) 
is to understand the extent to which the patient activation awareness training has affected staff behaviour and 
whether control arm participants have received some aspects of the behaviour change intervention. 
 
6.6 Criteria for discontinuing or modifying allocated interventions  
There are no criteria for discontinuing treatment. Participants will be made aware that their participation is 
voluntary and they may discontinue study interventions, should they wish, at any time.  
 
If a participant wishes to withdraw from treatment they will be able to speak to a member of the site study 
team i.e. ACtiF interventionist. This will be documented on a participant withdrawal form, within the Case 
Report Form. Any data already collected during the course of the trial up to the point of withdrawal will be 
used in the final analysis. We will ask the participants for their permission to continue to collect the primary 
outcome data i.e. CF exacerbations. The participant or clinician can make the decision to discontinue the 
allocated study intervention for any reason.   
 
Participants will have the following options if they wish to withdraw: 
1. Withdraw from the intervention i.e. intervention delivery visits only but will remain in the study. 
Patients can continue to use CFHealthHub. All study data would continue to be collected at 
subsequent follow up time points as per protocol. 
2. Withdrawal from the study. Unless the patient objects, any data collected up to this point would be 
retained and used in the study analysis. The local interventionist would ask the participant if they 
agree to the collection of primary outcome data as defined in the protocol and or adherence data If 
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they agree to collection of adherence data, CTRU and or interventionist will continue to follow up 
participants for adherence data. 
 
3. Withdrawal from the trial entirely. Unless the patient objects, any data collected up to this point 
would be retained and used in the study analysis. If the patient does not wish to be contacted with 
regard to primary outcome data or adherence data, no further contact with regard to the study will be 
made. If the participant does specifically request for all their data to be removed information 
regarding the participant will be retained at site, as part of the patient notes, along with their 
withdrawal form and request to delete the data. 
 
A participant would be classed as complete if they have continued in the study until the last protocol defined 
visit, however there may be missing visits and / or data.         
 
 
Loss to Follow-Up 
A participant would be classed as lost to follow up if the participant has 1) not completed the study or 2) 
been withdrawn despite attempts for further contact, as per protocol, having been made. Unless the 
participant withdraws from the study entirely we will continue to collect the primary outcome data when 
possible (i.e. from medical notes).   
 
This withdrawal section has been developed in accordance with the CTRU Participant Discontinuation and 
Withdrawal of Consent Standard Operating Procedure (SSU003).  
 
6.7 Strategies to improve adherence to intervention protocols 
6.7.1 For health professionals 
The intervention protocols will be described in detail in an intervention manual. Interventionists will be 
trained to deliver the intervention according to the manual protocols.  Interventionist training (as a form of 
behaviour change) will focus on Capability, Opportunity and Motivation.  It will utilise evidence about the 
importance and likely effectiveness of the intervention and will challenge common misconceptions about 
adherence.  Skills training and an introduction to the tools available on CFHealthHub will increase staff 
capability, and we will work with clinics and clinicians to ensure that the practical requirements for 
intervention delivery are in place: space, time etc (opportunity).  
CFHealthHub will record interventionist access to the site.  It will also automatize some of the tailoring of 
the intervention according to the COM-BMQ which will be completed online.  The contents of 'My Toolkit' 
will be recorded for each participant so that we will have records of what content they have been 
recommended. Interventionists will also be required to complete session records each time that they deliver 
the intervention to record the decisions made and the reasons for these, 
 
6.7.2 For patients 
Where participants provide consent we will send optional push notifications to encourage engagement with 
CFHealthHub.  For example, we will send congratulatory messages when adherence improves, encouraging 
messages to remind participants to engage with the content. Face-to-face visits will, where possible be 
arranged to coincide with clinic visits as per usual care, therefore minimising the additional burden on 
participants. 
 
6.8 Relevant permitted / prohibited concomitant care 
No concomitant care will be denied based on the research protocol. 
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7. Outcomes 
7.1 Feasibility outcomes (‘stop-go’ or ‘success’ criteria for RCT)  
In line with proposed CONSORT extension for pilot studies [37], in this section, we state the criteria for 
success of the external pilot trial. The criteria are based on the primary feasibility objectives, which provide 
the basis for interpreting the results of the external pilot and for determining the feasibility of proceeding to 
the full-scale study scheduled for months 31 to 60 of the project. Depending on the funder’s perspectives, the 
outcome of the external pilot might be: 
 
(i) “Stop - main study not feasible”; 
(ii) “Continue, but modify protocol - feasible with modifications”;  
(iii) “Continue without modifications, but monitor closely - feasible with close monitoring”; or, 
(iv) “Continue without modifications - feasible as is.”[37] 
 
We anticipate that modifications to the research protocol will be necessary as the feasibility study 
progresses. Some of the qualitative research will be undertaken early in the pilot trial and lessons learned 
about the trial procedures will be identified and acted on during the pilot trial. There are three objective stop-
go criteria:  
 
1. Feasibility of recruitment to RCT 
Defined as recruitment of no fewer than 48 participants randomised at two centres over four months, 75% of 
the rate required in the main trial; 
 
2. Feasibility of retaining participants in the RCT 




If these are met the full trial will go ahead. If these are not met overall, but are met in the last half of the pilot 
trial after trial procedures have been improved based on lessons learned from the early stage of the pilot trial, 
then the full trial will go ahead. 
 
7.2 Process data relating to the implementation of the trial 
1. Number and characteristics of eligible patients approached for the study 
Collected by centres in screening logs and transferred to Prospect database 
 
2. Reasons for refused consent 
Collected by centres in screening logs and transferred to Prospect database. 
 
3. Reach 
How many participants are consented into the study, sub-grouped by socio-economic status (from CF 
Registry), as a proportion of:  
 
 Those approached, expressed quantitatively, based on ‘pre-screening’ logs completed by ACtiF 
interventionist; 
 
 Those known to be eligible, expressed quantitatively based on CF Registry. 
 
4. Participant attrition rate 
Collected by centres in screening logs and transferred to Prospect database. 
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5. Reasons for attrition 
Collected by centres in screening logs and transferred to Prospect database. 
 
6. Maintenance: 
The processes by which participants are kept involved in the collection of key secondary outcome data 
research data: 
- The extent to which adherence data is successfully uploaded from the chipped nebulisers , 
described quantitatively using CFHealthHub (Intervention arm only). 
 
7. Number of missing values/incomplete cases 
Assessed by data management team, based on data in Prospect database. 
 
8. Participant,/interventionist and members of MDT  views on research protocols  
Assessed through qualitative interviews and to include: 
 Barriers to recruitment, problems encountered in reaching participants [38];  
 Perceived problems with trial procedures such as recruitment, informed consent etc. 
 Acceptability 
 Perceived utility and burden of outcome assessments. 
 
9. A survey on the content of usual care at participating centres 
A CTRU staff member will complete this survey with the principal investigator, a senior medic or delegate 
working at the participating centre. 
 
7.3 Process data relating to the implementation of the intervention 
1. Context 
Definitions of ‘context’ tend to cluster around setting, roles, interactions and relationships [39]. It is 
important that context is understood as diachronic and emergent rather than synchronic and static [40, 41]. 
Frameworks for process evaluation have defined ‘context’ as: 
 
 “aspects of the larger social, political, and economic environment that may influence intervention 
implementation” [42]; 
 
 “factors external to the intervention which may influence its implementation, or whether its 
mechanisms of impact act as intended” [43]. 
 
The context, and its interaction with implementation, mechanisms of impact, outcomes, the description of 
the intervention and its causal assumptions [43] will be described using qualitative data from research 
interviews, field notes, study management logs, minutes and e-mails. The focus will be how the context of 
individual CF Units affects implementation of the intervention and its potential outcomes. 
 
2. Implementation 
Definitions of ‘implementation’ tend to cluster around the processes or stages of adoption, the methods, 
means or social organisation of bringing innovative practices into use [39]. One way of describing the 
process of getting research into practice is to use a process model [44]. To structure our narrative of how the 




Based on e-mails and minutes we will describe in narrative terms, the procedures used to approach and 
attract to the project NHS Trusts and interventionists [42]. 
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4. Training: 
The comprehensiveness of the training component of the intervention for the health professionals delivering 
the intervention will be assessed by a combination of audio recordings of consultations and by interview.  
 
5. Fidelity 
“The extent to which the intervention was delivered as planned. It represents the quality and integrity of the 
intervention as conceived by the developers. Fidelity is a function of the intervention providers.”[42] 
 
 Interaction with participant along lines recommended by manual, determined by audio recordings of 
consultations between the interventionist and PwCF in the intervention arm. 
 
 Recommendation of appropriate CFHealthHub tasks by interventionist, determined by  audio 
recordings and by data from CFHealthHub; 
 
The fidelity assessment will be developed and based on a tool used by Borelli et al [46]. 
 
6. Use [38] / dose received [42] of intervention 
Use of CFHealthHub by participant, as proposed by interventionist, determined by data capture by 
CFHealthHub, including the online activities started and completed, minutes spent on recommended pages 
and which parts the participant has picked out and put in a “my favourites” page. The number of times, 
frequency over time and duration with which users log on to CFHealthHub, as well as the activities they 
perform while logged in, described quantitatively using data from CFHealthHub.  
A record of the discussion between the interventionist and the MDT will be kept. This will include who was 
there, brief notes of what was discussed and any agreement of treatment goals made. 
 
7. Acceptability 
The acceptability of the intervention to hospital staff and PWCF assessed through semi-structured 
interviews. 
 
8. Perceived benefits and harms 
Assessed through semi-structured interviews with health professionals and PWCF. 
 
9. Leakage of intervention to controls 
Assessed through audio recordings of consultations between the MDT, interventionist, and PwCF in the 
control arm, and semi-structured interviews with PwCF in the control arm. 
 
7.4 Clinical outcomes and covariates 
The time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits 
for participants can be found in Table 3 and Table 4 below.  
7.4.1 Primary clinical outcome 
The primary clinical outcome is the number of pulmonary exacerbations in 5 (+/-1) month post-baseline 
follow-up period, defined according to the Fuchs criteria [47]. An exacerbation of respiratory symptoms will 
be said to have occurred when a patient was treated with parenteral antibiotics for any one of the following 
12 signs or symptoms [48]: 
 
1. change in sputum;  
2. new or increased hemoptysis;  
3. increased cough;  
4. increased dyspnea;  
5. malaise, fatigue, or lethargy;  
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6. temperature above 38 °C;  
7. anorexia or weight loss;  
8. sinus pain or tenderness; 
9. change in sinus discharge. 
10. change in physical examination of the chest, derived from notes by site staff. 
11. decrease in pulmonary function by 10 percent or more from a previously recorded value, derived 
from notes by site staff; or,  
12. radiographic changes indicative of pulmonary infection, derived from notes by site staff. 
 
The trial interventionist or prescribing clinician/nurse will collect data on the “exacerbations” form at the 
point of a participant starting a course of IV antibiotics.   
 
7.4.2 Secondary clinical outcomes 
1. Body Mass Index (BMI). 
 
2. Forced expiratory volume in 1 second (FEV1): standardised spirometry as a measure of condition 
severity [49]. 
 
3. EuroQol EQ-5D-5L: generic health status measure for health economic analysis [50]. 
 
4. The Patient Activation Measure (PAM-13) (Health Style Assessment): assessment of patient 
knowledge, skill, and confidence for self-management [51]. *PAM-13 was labelled as “Health Style 
Assessment” following a request from the licence owners to ensure the purpose of the questionnaire 
is clear for participants.  
 
5. Assessment of routine : measure of life chaos [52]. 
 
6. Self-Report Behavioural Automaticity Index (SRBAI): automaticity-specific subscale of the Self 
Report Habit index to capture habit-based behaviour patterns [53]. 
 
7. Cystic Fibrosis Questionnaire-Revised (CFQ-R): disease specific health-related quality of life 
instrument [54]. 
 
8. The Patient Health Questionnaire depression scale (PHQ-8): severity measure for depressive 
disorders [55]. 
9. MAD (Medication Adherence Data-3 items) : medication adherence measure 
 
10. The General Anxiety Disorder 7-item anxiety scale (GAD-7): severity measure for anxiety [56]. 
 
11. The Capability Opportunity Motivation Behaviour Beliefs Questionnaire (COM-BMQ): This 
questionnaire incorporates: 
 
a. The Beliefs about Medicines Questionnaire - specific (Nebuliser adherence) (BMQ 21-
item): a validated self-report tool[57], customised by the author to identify perceived 
necessities and concerns for nebuliser treatment.   
b. The following project-specific items: one additional belief item, one intention item, one 
confidence item, and a list of barriers.  These will serve as a tailoring tool for the intervention 
and also as a secondary outcome measure.  
 
12. Subjective adherence single question: self-report estimate of adherence as a percentage. Self-
reported problems: identification of capability and opportunity barriers to nebuliser adherence 
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13. Concomitant medications: bespoke instrument, designed for this research project. 
 
14. Resource use form: interventionist collects data from a combination of hospital notes and  the NHS 
patient electronic system to determine 1) inpatient IV days 2) Routine clinic visits 3) Unscheduled 
outpatient contacts 3) unscheduled inpatient stays.  
 
15. Exploratory analysis of habit formation: analyses with the objective nebuliser data will be 
performed to explore the process of habit formation with the delivery of the adherence intervention 
 
16. Prescription: a monthly prescription check  to both check for data transfer to CFHealthHub and 
review for an indication that the prescription has  changed or indication of microorganism e.g. 
pseudomonas (please see table 2 and 3 and refer to section 10.1.1). 
 
17. Adherence to prescribed medication (see 7.4.3) 
 
18. Any treatment with IV antibiotics 
 
7.4.3 Adherence to prescribed medication 
 
Adherence to prescribed medication will be defined in several ways including: 
 
1. Unadjusted adherence 
2. Simple normative adherence (without numerator adjustment) 
3. Sophisticated  normative adherence (without  numerator adjustment) 
4. Simple normative adherence (with numerator adjustment) 
5. Sophisticated  normative adherence (with  numerator adjustment) 
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Table 3. Individual-level data derived from PWCF and sites 
 
+ Pseudomonas (or other microorganism) status will be checked together with the monthly prescription  




















































































































Enrolment          
Pre-screening form (before 1st visit) Prospct Site - - - - - -  
Confirmation of eligibility form Prospct Site  - - - - -  
Informed consent Prospct Site  - - - - -  
Intravenous days in last registry year Prospct Site  - - - - -  
Pseudomonas status + Prospct Site  - - - - -  
Primary outcome          
Exacerbations form including: Prospct Site  - -     
 Parenteral antibiotics          
 Change in sputum*          
 New or increased hemoptysis*          
 Increased cough*          
 Increased dyspnea*          
 Malaise, fatigue, or lethargy*          
 Temperature above 38 °C*          
 Anorexia or weight loss*          
 Sinus pain or tenderness*          
 Change: sinus discharge*          
 Change: phys. exam. chest*          
 Decrease: pulmonary function *          
 Indicative radiographic changes*          
Secondary outcomes          
BMI (height and weight) Prospct Site  - - -  -  
FEV1
 Prospct Site  -  -    
EQ-5D-5L** Prospct PWCF  - -   -  
PAM-13(Health Style Assessment) Prospct PWCF  - - -  -  
Assessment of Routine Prospct PWCF  - - -  -  
SRBAI Prospct PWCF  - - -  -  
CFQ-R Prospct PWCF  - - -  -  
PHQ-8 Prospct PWCF  - - -  -  
GAD-7 Prospct PWCF  - - -  -  
MAD-3 (Medication Adherence Data-3 items) Prospct PWCF  - - -  -  
COM-BMQ Prospct PWCF  - - -  -  
Objective adherence CFHH CFHH  -  -  -  
Subjective adherence single question Prospct PWCF  -  -    
Concomitant medications Prospct Site  - - -  -  
Other SAEs Prospct Site - -  -  -  
Resource use Prospct Site - - - -  -  
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** EQ5D-5L collected at the start and end of every exacerbation episode 
 





























































































































Clinician metrics        
Adherence data* PWCF       
Recommendation of modules by interventionist Interventionist   -  - x 
Feed back to participant their adherence data screens (data 
click) 
Interventionist 
  -  - x 
Check prescription with participant Interventionist   -  - x 
Order of clicks CFHH   -  - x 
Interventionist responds to patient changing prescription Interventionist  -     x 
 Monthly check on prescription + 
Interventionist
/ CTRU      
x 
Time in and out preparation 
Interventionist
/CFHH   
- -  x 
Time in and out with patient 
Interventionist
/CFHH 
  - -  x 
Time in and out review 
Interventionist
/CFHH   
- -  x 
Patient metrics        
Adherence (number of nebulized doses taken per day.) 1
 
PWCF      x 
Duration of inhalation Nebuliser   - - - x 
Accessing CFHealthHub – look at adherence data PWCF   - - - x 
Accessing CFHealthHub – look at ‘My Toolkit’ PWCF   - - - x 
Accessing CFHealthHub problem solving / education / 
talking heads pages outside of ‘My Toolkit’ 
PWCF 
  - - - x 
Accessing CF HealthHub – first to last click in a session PWCF   - - - x 
*Adherence data collected for both research and control arms 
+ Monthly prescription checked by CTRU centrally to alert local interventionists to any potential changes in control arm and potentially also  
intervention arm 
X data continued to be collected in CFHealthHub and interventionist responds for those participants who have “opted in” to receive intervention 
till 30/4/17 
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Figure 6. Participant timeline for the external pilot RCT  
 
*When I-nebs are converted to Bi-nebs a representative from the company (Philips) will do this between the consent visit and first 
intervention visit.  
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The study recognises that flexibility in accommodating participant schedules may cause time windows to 
change but this will allow us to adapt the intervention for the main RCT. 
8. Sampling 
8.1 Quantitative components 
8.1.1 Sites 
Two large specialist CF centres have been screened for their ability to recruit participants based on the 
number of participants they have on their CF registry and their motivation to participate in the pilot trial.  
 
8.1.2 Sample size 
The sample size for a feasibility study should be adequate to estimate the uncertain critical parameters 
(standard deviations for continuous outcomes; consent rates, event rates, attrition rates for binary outcomes) 
needed to inform the design of the full RCT with sufficient precision [37, 58–60]. For the main RCT, the 
target sample size is 688 participants (344 per arm). We are proposing that 15 CF units recruit on average 46 
patients in six months, a recruitment rate of approximately eight patients per centre per month.  
 
To assess whether this recruitment rate is feasible the external pilot RCT will open in two CF units for 12 
months, with four months recruitment, one months ‘run-in’ period (the period between the consent and 
baseline visit), and 5 (+/-1) months follow up. To match the proposed recruitment rate of the main RCT, the 
target sample over the four months for which the pilot RCT is open, will be 32 per centre (64 in total from 
the two pilot centres). We propose to recruit to time, that is for a fixed period of four months rather than to a 
fixed sample size. We would want to see a minimum of 75% of the recruitment target to be confident of the 
trial viability i.e. at least 48 patients in total consented and randomized in four months’ of recruitment from 
two centres. 
 
8.1.3 Approach, non-participation and recruitment  
Approach: Health professionals involved in approaching and screening PWCF and collecting data will be 
trained in the study protocol and procedures. Additionally those taking consent will have up-to-date training 
in Good Clinical Practice (GCP). All study personnel will be named on the study delegation log. Health 
professionals working with the CF team will identify a sample of PWCF registered at the centre via the CF 
registry database locally. All inclusion and exclusion criteria will be assessable via patient records and they 
will exclude any patients who do not fit the eligibility criteria.  
 
A member of the participant’s direct clinical team will send the potential participant a PIS and introductory 
letter by post or give the written information during a routine clinic visit. A sticker with a website address 
and Quick Response code will be placed in the envelope both of which will link to a video of the researcher 
explaining the study.  If information is provided in a routine clinic visit, the clinical care team will seek 
permission for the ACtiF Interventionist to follow up with a phone call in order to answer any further 
questions and discuss involvement. Written informed consent may be conducted at this visit where the 
participant is happy to take part as this is a low risk trial. 
 
Telephone call: Up to a week after posting out the information, the ACtiF Interventionist will telephone the 
PWCF to discuss the study over the phone and answer any questions. If the potential participant is happy to 
take part, the ACtiF Interventionist will arrange an appointment to gather written informed consent. 
 
Non-participation: Spontaneously offered reasons for non-participation in the trial will be recorded.  
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8.2 Qualitative components 
 
At each of the two pilot sites we will undertake: 
 
 Audio-recordings of all 16 initial assessments for PWCF in the intervention arm and 10-12 
consultations between the senior interventionist from the MDT (or other MDT member) and PWCF 
in the control arm. Numbers will depend on numbers of PWCF giving written consent for this.    
  
 10-12 semi-structured face-to-face (or telephone or skype) interviews with PWCF receiving the 
intervention and 10-12 semi-structured face-to-face interviews with PWCF in the control arm (total 
n~40-48 PWCF; n~40-48 interviews); 
 
 two semi-structured face-to-face (or telephone or skype) interviews with each of the two 
interventionists in each centre (total n=4 interventionists; n=8 interviews); and, 
 
 two semi-structured (face to face, telephone or skype) interviews with two members of the MDT 
(total n=4 staff; n=8 interviews). 
 
Written informed consent will be obtained from both the interventionist and the PWCF participating in the 
audio recording when they consent to be in the study. Separate consent will be sought from PWCF and 
interventionists or members of the wider CF team for semi-structured interviews. 
 
9. Assignment of interventions 
9.1 Sequence generation 
Participants will be allocated in equal proportions to one of the two groups using a computer generated 
pseudo-random list, stratified by centre and the number of days participants have been on IV antibiotics in 
the previous 12 month period as collected at consent visit, with random permuted blocks of varying sizes. 
The two categories for stratification within the number of IV days will be (i) less than or equal to 14 days 
and (ii) greater than 14 days. 
9.2 Allocation concealment 
The allocation sequence will be hosted by the Sheffield CTRU in accordance with their standard operating 
procedures and will be held on a secure server. Access to the allocation sequence will be restricted to those 
with authorisation. The sequence will be concealed until recruitment, data collection, and analyses are 
complete. 
9.3 Implementation 
The allocation sequence will be created by a Sheffield CTRU statistician who is not otherwise associated 
with the trial. At the consent visit, a health professional who is named on the delegation log, will go over the 
patient information sheet again with the study candidate and answer any questions. If the PWCF is still 
willing to enter the trial, they obtain full written consent and complete the eligibility form. If the participant 
is eligible, then baseline assessments will be taken. The recruiting health professional will log into the 
remote, secure Internet-based randomisation system and enter basic demographic information, after which 
the allocation will be revealed.  
 
9.4 Blinding 
After revelation of the allocation, only the statisticians will be blinded to allocation as per CTRU SOPs 
(ST001 and ST005) 
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10. Data collection, management and analysis 
10.1 Quantitative data 
10.1.1 Data collection methods 
Data handling and record keeping. The Sheffield CTRU will oversee data collection, management and 
analysis and ensure the trial is undertaken according to Good Clinical Practice Guidelines and CTRU 
standard operating procedures. Data will be collected and retained in accordance with the Data Protection 
Act 1998. Patients will be reassured that all data which are collected during the course of the research will be 
kept strictly confidential.  
 
The study team will train those collecting data in the study procedures before the trial begins. Data will 
either be collected directly from the participants, carers, interventionist, CFHealthHub or from source 
documents (e.g. patient notes) and input onto the CRF or Sheffield CTRU’s electronic web-based data 
capture system (Prospect). The Data Monitoring and Management Plan for the study will provide further 
guidance on the types and levels of data and how these will be monitored and verified. Some essential 
documents may be posted to the central team to facilitate this e.g. participant consent forms in which case 
this will be detailed in the appropriate participant PIS and consent forms.  
 
The CTRU will perform checks with the participant via monthly phone calls to ensure data is being captured 
and alert the local interventionist if there is an indication of a prescription change and a need to check 
pseudomonas (or other microorganism) status. This is required for the correct denominator to assess 
“normative adherence”. Data will be extracted from the CF registry to understand exacerbations in the 
preceding 12 months since prior exacerbations can have a bearing on the optimum target regimen. 
 
 
Plans to promote participant retention and complete follow-up. 
Participant retention will be ensured by the following procedure: 
1. At each point of contact, the interventionist will check with the participant that the Qualcomm hub or 
Smartphone hub is plugged in and turned on. A member of CTRU who is performing data and 
prescription checks may alert the interventionist. They will remind the participant of the proximity 
required for data transfer (10 metres) 
2. In the event of no data being displayed in CFHealthHub for a period of at least a week (and the 
participant is not known to be on holiday) the interventionist will make contact with the participant 
(Email/Text/Telephone call) to check that the following 
 That the Qualcomm or Smartphone hub is plugged in 
 That the Qualcomm hub is working (showing solid green and yellow lights on the display) 
 That they have been within range of the Qualcomm hub sufficient to facilitate data transfer 
(10 metres) 
 That the Smartphone hub is switched on (showing the locked ‘password’ screen when any 
button is pressed) 
 That the Bi-neb and Smartphone hub have been kept in the same room, or at least have been 
in close proximity at some point during the day. 
 
Any participants using the Bi-neb who are still experiencing issues after following the steps above, may 
receive a face to face or telephone support (at home or hospital) from the clinical trainer to resolve any 
outstanding issues.   
 
Troubleshooting: 
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Data capture will be monitored both by interventionist at the site and centrally by the CTRU. In the event of 
data not being uploaded patients will be contacted to trouble shoot problems. Patients will be offered support 
to suit their circumstances including home visits (conducted by the members of the site research team) where 
necessary. 
 
10.1.2 Data Management 
Anonymised trial data will be entered onto a validated database system designed to an agreed specification 
between the Chief Investigator and Sheffield CTRU. The research staff at sites (mainly the ACtiF 
interventionist) will be responsible for data entry locally. The Sheffield CTRU Trial Manager, research 
assistant and the Data Management Team will work with sites to ensure the quality of data provided. The 
study manager, research assistant, data manager, PI’s, any research nurses and  site interventionist will have 
access to the anonymised data on the database through the use of usernames and encrypted passwords.  The 
system has a full electronic audit trail and will be regularly backed up. The secure data management system 
will incorporate quality control procedures to validate the study data. Error reports will be generated where 
data clarification is needed. Output for analysis will be generated in a format and at intervals to be agreed 
between Sheffield CTRU and the Chief Investigator.  
 
Trial documents will be retained in a secure location during and after the trial has finished. The study will 
use the CTRU’s in-house data management system (Prospect) for the capture and storage of participant data. 
Prospect stores all data in a PostgreSQL database on virtual servers hosted by Corporate Information and 
Computing Services (CiCS) at the University of Sheffield. Prospect uses industry standard techniques to 
provide security, including password authentication and encryption using SSL/TLS. Access to Prospect is 
controlled by usernames and encrypted passwords, and a comprehensive privilege management feature can 
be used to ensure that users have access to only the minimum amount of data required to complete their 
tasks. This can be used to restrict access to personal identifiable data. 
 
Participants who give consent to the qualitative part of this study will also give consent to their name and 
address to be given to the University of Sheffield qualitative research staff in order to be contactable.   
10.1.3 Data quality assurance 
Prospect provides a full electronic audit trail, as well as validation and verification features which will be 
used to monitor study data quality, in line with CTRU SOPs and the Data Management Plan (DMP). Error 
reports will be generated where data clarification is required. Rates of missing data and data points which are 
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10.2 Qualitative data 
10.2.1 Audio recordings of consultations  
 
All initial assessments will be audio recorded with permission (n=16 in each site). Findings 
from early assessments will be fed back to the interventionist so that changes can be made to 
the intervention delivery before subsequent assessments. Consultations between the senior 
interventionist and PWCF in the control arm will be audio recorded with permission (n=10-
12 in each site). Encrypted digital recorders will be used and recordings sent securely to the 
research team for analysis. 
10.2.2 Semi-structured interviews: participants 
In each site we will interview 3-4 PWCF receiving the intervention who are recruited at the 
beginning of the pilot. We will interview them around one month into the intervention to 
seek views of the most intensive part of the intervention. This will identify any problems 
early and be fed back to the intervention development team, staff delivering the intervention, 
and trial staff. We will interview 5-6 PWCF around four to six months into the intervention. 
These PWCF will have experienced more independent use of the CFHealthHub and we can 
explore how to keep PWCF engaged with the intervention in the longer term. We will 
interview 2-3 PWCF who drop out of the intervention to explore why this occurred. We will 
interview 10-12 PWCF in the control arm around four to six months into the trial to explore 
whether they have experienced aspects of patient activation and leakage of the intervention.   
 
10.2.3 Semi-structured interviews: professionals 
The first interviews with the interventionist and senior interventionist in each site will take 
place after they have undertaken assessments with the first few PWCF to identify teething 
problems with the intervention or the trial and the comprehensiveness of  the training 
sessions they received. The findings will be fed back to the team to consider whether 
changes are needed to the intervention or trial protocol. The second interviews will take 
place when the first few PWCF have completed the intervention to allow the interventionist 
to reflect back over the whole process. The interventionists may have different lengths of 
experience of working with CF, nebulisers or behaviour change and we will consider the 
influence of differences in backgrounds on their ability to implement the intervention.  
 
We will also undertake interviews with two members of the MDT at each centre when the 
first few PWCF have received 2-3 months of the intervention and then again towards the end 
of the feasibility study when all PWCF have been recruited and received around 3 months of 
the intervention.  
 
10.2.4 Undertaking the interviews 
 
For the interviews we have developed topic guides based on our research questions and 
these are attached to the application. Topic guides develop throughout any qualitative 
interview study and our topic guides may  change as the study progresses. We will audio 
record all interviews after receiving written permission to do so. We will use an encrypted 
digital recorder. Reflexive notes will be made during and after the interviews. We expect 
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interviews to last around one hour. We do not expect data saturation in pilot studies; the aim 
is to identify any learning that can be addressed in preparation for the full trial.   
 
11. Data analysis 
11.1 Quantitative analysis 
The analysis will be performed after data lock by a CTRU statistician under the supervision 
of the senior study statistician. As the trial is a pragmatic parallel group RCT data will be 
reported and presented according to the CONSORT 2010 statement [61] with reference to 
proposed extension for pilot / feasibility studies [37]. As a pilot/feasibility study the main 
analysis will be mainly descriptive and focus on confidence interval estimation and not 
formal hypothesis testing [58].  We will report rates of consent, recruitment and follow-up 
by centre and by randomized group. 
 
Clinical outcome measures will be summarised overall and by randomized group. Baseline 
demographic (age, gender), physical measurements (e.g. weight, height, BMI), and patient 
reported outcome measures (EQ-5D, PAM-13, Assessment of Routine, MAD-3, SRBAI, 
CFQ-R, GAD-7, COM-BMQ, PHQ-8), and clinical measurements (e.g. FEV1, IV days in 
last registry year ) will be described and summarised overall and for both treatment groups. 
 
The primary outcome is the number of pulmonary exacerbations treated with IV antibiotics 
over the 6 month post-randomisation follow-up period. We will also include, as part of the 
feasibility analysis, estimation of the effect size for the 6-month pulmonary exacerbations 
outcome with 95% confidence interval estimates to check that the likely effect is within a 
clinically relevant range (as confirmation that it is worth progressing with the full trial). For 
this we will use a Poisson generalised linear model (GLM). Secondary continuous outcomes 
such as six-month post randomisation FEV1, BMI  EQ-5D, PAM-13, Assessment of 
Routine, MAD-3, SRBAI, CFQ-R, GAD-7, COM-BMQ, PHQ-8) will be analysed with a 
multiple linear regression model with the baseline value of the outcome and randomised 
group as covariates. The treatment group coefficient and its associated 95% confidence 
interval will be reported from the various multiple linear regression models. The mean level 
of adherence (to prescribed medication) between the intervention and control groups over 
the 6 month post-randomisation follow-up period will also be reported and compared 
between the groups and a 95% confidence interval (CI) for the mean difference in this 
parameter between the randomised groups will also be calculated. 
 
 
Further analyses with the objective nebuliser data will be performed to explore the process 
of habit formation with the delivery of the adherence intervention. The analyses will 
include: 
(a) generating objective habit scores by taking into account time of nebuliser use 
(b) using statistical process control to identify when periods of stability is achieved 
(c) other time-series methods, including cross-correlation between habit scores and 
adherence. 
 
Adverse events will be based on serious adverse events (SAE) case report forms.  A serious 
adverse event is defined as any adverse event or adverse reaction that results in death, is life-
threatening, requires hospitalisation or prolongation of existing hospitalisation, results in 
persistent or significant disability or incapacity, or is a congenital anomaly or birth defect.  
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The following summaries will be presented as overall rates and stratified by AE 
classification:  
 
 the number and percentages of patients reported as having Serious Adverse Events 
(SAE) in each treatment arm; and, 
 
 the number and percentages recorded as having all forms of Adverse Events (AE) in 
each arm. 
 
This information along with the acceptability of the study design and protocol to 
patients/GPs; the safety of the intervention; patient recruitment and attrition/retention rates 
will enable us to determine whether or not the definitive RCT is feasible within a 
satisfactory timescale and cost envelope using UK centres alone. 
 
11.2 Qualitative analysis 
Transcripts will be coded using the latest version of NVivo (QSR International). The 
analysis will use the National Centre for Social Research ‘Framework’ approach [62]. AO’C 
and SD will undertake the following stages of the analysis of patient transcripts: 
familiarisation; identifying a thematic framework; indexing; charting; and, mapping and 
interpretation. The theoretical framework for understanding intervention adherence is the  
Necessities-Concerns framework [63] within the COM-B system [18]. This will be used 
within the thematic framework. We will use the process evaluation functions of context, 
mechanisms and implementation to frame the analysis [43]. Within mechanisms we will use 
the COM-B system as stated above and consider the use of the Theoretical Domains 
Framework [36]. We will compare and contrast findings from each site because the different 
backgrounds of the interventionists, and the different contexts in which care is provided in 
each CF unit, may affect implementation and acceptability of the intervention.  
 
 
Figure 7. Assumptions of the MRC Guidance on Process Evaluation  
 
[39, 64]  
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Context
Settings, roles, interactions and relationships (Pfadenhauer LM et al, ZEFQ 2015;109(2):103-114)
Contextual factors that shape theories of how the intervention works
Contextual factors that affect (and may be affeected by) implementation, intervention mechanisms and outcomes
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What is delivered
    Fidelity
    Dose
    Adaptations
    Reach
Mechanisms of impact
Participant responses to and








This qualitative research will: 
 
 Inform the refinement of the intervention (e.g. CFHealthHub, training of 
interventionists, initial assessments, manualised instructions) and its implementation (e.g. 
introduction within a CF Unit) for use in the full trial. 
 Inform refinement to trial procedures for the full trial. 
 Inform the selection of the final secondary measures used in the full trial to ensure 
they address the perceived benefits of the intervention.  
 Help to understand the extent of any leakage of the intervention to controls. 
 
 
11.3 Combining data and findings from the different components 
 
We will use Farmer’s triangulation protocol to display the findings from each component 
of the study together and discuss as a team the extent to which findings converge, 
complement each other or contradict each other [65, 66]. For example, we will display all 
findings about recruitment together to consider the feasibility of recruitment for the full 
trial and the actions required to ensure feasibility.  We will also display in a matrix the 
qualitative and quantitative data for individual PWCF who have received the intervention 
and been interviewed [66]. We will use this to consider the extent to which our secondary 
outcome measures identify issues raised by PWCF in the interviews.         
12. Monitoring 
12.1 Oversight  
The CTRU SOP GOV003 Data Monitoring and Ethics Committee states “A DMEC does 
not need convening in studies that carry low risk to patients”. This project involves 
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delivering a behaviour change intervention through the website CFHealthHub and would 
therefore be classified as low risk.  
 
The overall responsibility for the study will be with Sheffield Teaching Hospitals NHS 
Trust who will act as sponsors for the study.  The local Principal Investigator (PI)  will be 
responsible for the study at each participating site and it will be registered and approved 
with each local R&D department. The study will be conducted in accordance with the 
protocol, GCP and Sheffield CTRU Standard Operating Procedures. The two committees 
which will govern the conduct of the study are: 
 
1. Programme Steering Committee (PSC) 
2. Project Management Group (PMG) 
 
The PSC will be responsible for the overall conduct of the trial and consists of an 
independent chair and four other independent members including a statistician and PPI 
representative. The committee will meet every 6 months to monitor the study. 
 
The PMG will comprise of the trial manager and the core research team . The PMG will 
meet on a monthly basis to monitor the day-to-day running of the trial. The Trial Manager 
will be jointly supervised by the CI and the Assistant Director of CTRU via the form of 
regular meetings (face to face and telephone calls). The Trial Manager will be responsible 
for liaising with the whole project team. Trial monitoring procedures will be assessed 
based on the level of risk of the study. The Site Monitoring Plan will outline the types and 
frequency of site monitoring activities for the study and this will be agreed with the 
Sponsor prior to the start of the study. 
 
12.2 Description of any interim analyses and stopping guidelines 
There are no planned interim analyses or stopping guidelines for this study. 
 
12.3 Harms (safety assessments) 
12.3.1 Serious Adverse Events 
Trial sites are to report Serious Adverse Events (SAEs) in conjunction with the CTRU 
standard operating procedure PM004 (Adverse events and serious adverse events). The 
definition of an SAE is as follows: 
 results in death; 
 is life-threatening* (subject at immediate risk of death); 
 requires in-patient hospitalisation or prolongation of existing hospitalisation;** 
 results in persistent or significant disability or incapacity;  
 consists of a congenital anomaly or birth defect; or, 
 is another important medical event that may jeopardise the subject.*** 
 
* ‘life-threatening’ refers to an event in which the patient was at risk of death at the time of 
the event; it does not refer to an event which hypothetically might have caused death if it 
were more severe. 
**Hospitalisation is defined as an inpatient admission, regardless of length of stay, even if 
the hospitalisation is a precautionary measure for continued observation. Hospitalisations 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-039089:e039089. 10 2020;BMJ Open, et al. Hind D
46 
ACtiF Pliot Protocol 
 v3.1 16Nov16 
for a pre-existing condition, including elective procedures that have not worsened, do not 
constitute an SAE. 
***Other important medical events that may not result in death, be life-threatening, or 
require hospitalisation may be considered a serious adverse event/experience when, based 
upon appropriate medical judgment, they may jeopardise the subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition. 
 
It is not anticipated that there will be many SAEs related to the behaviour change 
intervention. We will report any SAEs which are deemed related to the trial intervention 
and unexpected to the Sponsor within the specified timeframes below (12.3.4). 
 
12.3.2 Adverse events we require reporting: 
We do require that sites report any new diagnosis of depression which requires treatment 
with medication or psychological therapy e.g. Cognitive Behavioural Therapy (CBT).  
12.3.3 Expected SAEs and adverse events 
Certain adverse events are common to CF and associated medications. Expected SAEs 
must be reported in the annual safety report. Hospitalisation as a result of an exacerbation 
will be recorded in the study database and not be reported as an SAE. 
 
Expected AEs in relation to medications or common in patients with CF  
1. Acute FEV1 drop >15% after 1st dose of medication 
2. Increased  productive cough 
3. Nasal congestion or stuffy nose 
4.  Chest congestion 
5. Wheezing 
6. Chest pain or chest discomfort 
7. Voice alteration/change 
8. Dysponea (breathlessness) 




13. Crackles in lung 





18.  Indigestion / reflux 
19. Tonsillitis 
20. Joint pain 
21. Decreased appetite 
22. Fatigue 
23. Headache 
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24. Distal intestinal obstructive syndrome 
25. Fever 
26. Otitis media or ear infection 
27. Conjunctivitis 
28. Pneumothorax 
29. Decreased exercise tolerance 
30. Pyrexia 
31. Abdominal pain 
32. Influenza 






Adverse events and SAEs can be reported for participants at any stage of their trial 
participation. A member of the site study team (interventionist, clinician or other) will 
enquire about any adverse events at routine clinic appointments. These will be record on 
the adverse event section of the paper CRF and database. The event will be assessed by the 
local Principal Investigator and the form will be kept in the site file.  Serious adverse 
events will be reported in the periodic safety reports to the research ethics committee and 
Trial Steering committee. 
 
All adverse events (serious or other based on the definitions above) will be recorded on the 
case report form and details will be entered on the study database within 1 week of 
completing the paper form. Any SAEs which are deemed related to the trial intervention, 
the site will complete the paper CRF and fax details this form to the CTRU within 24 
hours of becoming aware of the event in order for the CTRU to report this event to the 
Sponsor and the main REC within the required timeframes (15 days). 
 
In participants using the Bi-Neb, any Adverse or SAEs relating to the use of Promixin via 
this device will be reported to the Patient Support team (PSP) at Phillips as per their 
standard practice. 
 
12.4 Auditing  
The sponsor will permit monitoring and audits by the relevant authorities, including the 
Research Ethics Committee. The investigator will also allow monitoring and audits by 
these bodies and the sponsor, and they will provide direct access to source data and 
documents. 
 
12.5 Finance and indemnity 
The trial has been financed by the NIHR and details have been drawn up in a separate 
agreement. This is an NHS sponsored study.  If there is negligent harm during the clinical 
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trial when the NHS body owes a duty of care to the person harmed, NHS Indemnity will 
cover NHS staff, medical academic staff with honorary contracts and those conducting the 
trial.  NHS Indemnity does not offer no-fault compensation and is unable to agree in 
advance to pay compensation for non-negligent harm. Ex-gratia payments may be 
considered in the case of a claim.  
 
13. Ethics and dissemination 
13.1 Approvals 
The trial will be conducted subject to Research Ethics Committee favourable opinion 
including any provisions for site specific assessment.  The application will be submitted 
through the IRAS central allocation system. The approval letter from the ethics committee 
and copy of approved patient information leaflets, consent forms and any ethically 
approved questionnaires will be present in the site files before initiation of the study and 
patient recruitment. Local research governance approvals will be sought from all 
participating research sites. This clinical trial will be conducted in accordance with Good 
Clinical Practice Guidelines and CTRU standard operating procedures. MHRA approval is 
not required for this study. 
 
13.2 Protocol amendments 
The investigator will be updated following an amendment to the protocol or study 
documents. The new documents, REC approval, R&D approval, HRA assessment letter 
and any other appropriate documentation surrounding the amendment will be sent to the 
site via a “site file update”. The sites will receive the documents with a site file update 
sheet, detailing where to file the amended documents and which documents to supersede. 
If there are any significant changes to the study procedures or eligibility criteria sites will 
be notified by a combination of email, telephone, newsletters or additional project training 
when required. 
 
In relation to informing REC, if any study documents require amending, the changes will 
be discussed with the sponsor and either a substantial (via IRAS and HRA) or minor 
amendment (notification via email) will be submitted to REC and HRA. Following REC 
acknowledgment and approval (when applicable) other appropriate approvals will be 
obtained i.e. HRA and R&D approval.  
   
If a protocol amendment requires participants to be re-consented they will be informed of 
the amendment by an updated participant information sheet and will be asked to re-consent 
to the study. Trial registries, journals and regulators will be updated regarding protocol 
amendments when appropriate. 
 
13.3 Consent 
Consent for the main trial: 
The ACtiF trial interventionist or local PI at the site will be responsible for taking informed 
consent from potentially eligible trial participants face to face at home or in clinic. Any 
researcher or clinical member of the team taking informed consent will be trained in study 
procedures and GCP.  Participants will have the option to specify whether they are 
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interested in being approached for the qualitative interviews and audio recordings.  
However, they do not have to consent to these to be involved in the main study.  
 
Consent for the interviews: 
Consent for interviews (participant, interventionist or MDT member) will separately be 
taken by the qualitative researcher. Participants can participate in the main trial but choose 
to not take part in the qualitative research. 
13.4 Confidentiality 
Participant confidentiality will be respected at all times. Participant names and contact 
details will be collected and entered on the prospect database. Access to these personal 
details will be restricted to users with appropriate privileges only. All users who do not 
require access to identifiable data will only identify data by participant ID number, and no 
patient identifiable data will be transferred from the database to the statistician. 
 
Trial documents (paper and electronic) will be retained in a secure location during and 
after the trial has finished.  All source documents will be retained for a period of 5 years 
following the end of the trial.  Where trial related information is documented in the 
medical records – those records will be retained for 5 years after the last patient last visit. 
Each site is responsible for ensuring records are archived and the information supplied to 
the Chief Investigator. 
 
Any participant data held within CFHealthHub  will be stored on a secure server at the 
University of Manchester.  CFHealthHub complies with the Data Protection Act and 
follows best practice guidelines on security and information governance.  Encrypted 
channels are used to transfer any data to and from the web and mobile application 
platforms. All user interaction with the CFHealthHub server and each action performed by 
a user will be logged. An audit log contains the username of the user performing the action, 
the date & time of the action, short description of the action performed. All users are 
authenticated via a secure password a with access to the system restricted on a role basis.  
 
13.5 Declaration of Interests 
Martin Wildman has received funding from Zambon who market the Ineb to carry out 
research to understand the performance of the Ineb and in the past we received funding 
from Zambon to carry out work to understand barriers to adherence. 
 
13.6 Access to data 
The central ACtiF study team alone will have access to the final dataset details of which 
will be outlined in the study DMP. 
 
13.7 Ancilliary and post-trial care 
Centres will be able to continue to use CFHealthHub if they wish to do so after the end of 
the pilot and feasibility study. If so, participants in the control arm will be able to cross 
over to use the intervention at this stage. 
13.8 Dissemination policy  
As this is a feasibility study its main interest will be to potential researchers and funding 
bodies. Data will be reported according to the revised CONSORT statement (Schultz, 
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2010). The findings of this research will be available to NIHR, patient groups and other 
interested bodies. It will also be offered for presentation at medical meetings and will be 
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Appendix 1.  W.H.O. Trial Registration Data Set 
 
DATA CATEGORY  INFORMATION 
Primary registry and trial identifying number To be added 
Date of registration in primary registry To be added 
Secondary identifying  numbers NIHR: RP-PG-1212-20015 
Sponsor (STH): STH19213 
Source(s) of monetary or material support National Institute for Health Research 
(NIHR) Programme Grants for Applied 
Research programme. 
Primary sponsor Sheffield Teaching Hospitals NHS 
Foundation Trust. 
Secondary sponsor(s) none 
Contact for public queries Chin Maguire 
Trial Manager 
Clinical Trials Research Unit  
University of Sheffield 
Regent Court  
30 Regent Street  
Sheffield  
S1 4DA   
Tel: (+44) (0)114 222 0717  
Fax: (+44) (0)114 222 0870 
email : c.maguire@sheffield.ac.uk 
Contact for scientific queries Dr Martin Wildman 
Adult CF Centre 




Tel: (0114) 2715212 
Fax: (0114) 222 0870 
email : Martin.Wildman@sth.nhs.uk 
Public title Adherence to treatment in adults with Cystic 
Fibrosis (ACtiF) 
Scientific title Development and evaluation of an 
intervention to support Adherence to 
treatment in adults with Cystic Fibrosis : a 
feasibility study comprised of an external 
pilot randomised controlled trial and process 
evaluation 
Countries of recruitment United Kingdom 
Health condition(s) or problem(s) studied Cystic Fibrosis 
Intervention(s) Usual care plus a microchipped nebuliser 
with or without a complex intervention. The 
complex intervention consists of: 
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- A software platform, CFHealthHub 
mobile apps and website, which 
allows access to medication 
adherence data and education 
modules intended to remove barriers 
to adherence 
- A manual containing a ‘behaviour 
change toolkit’ to guide interactions 
between health 
Key inclusion and exclusion criteria Inclusion criteria for participants 
1.Diagnosed with CF and with data within 
the CF registry  
2.Aged 16 years and above 
3.Taking inhaled mucolytics or antibiotics 
via a chipped nebuliser (e.g. eTrack or Bi-
Neb) or able and willing to take via eTrack 
or Bi-Neb. 
  
Exclusion criteria for participants 
1.Post-lung transplant 
2.People on the active lung transplant list 
3.Patients receiving palliative care, 
4.Lacking in capacity to give informed 
consent 
5.Using dry powder devices to take 
antibiotics or mucolytics 
Study type Feasibility study comprised of an external 
pilot randomised controlled trial and process 
evaluation 
Date of first enrolment Anticipated: 02/05/2016 
Target sample size We propose to recruit to time, that is for a 
fixed period of four months rather than to a 
fixed sample size. To match the proposed 
recruitment rate of the main RCT, the target 
sample over the four months for which the 
pilot RCT is open, will be n=64. 
Recruitment status Not yet open. 
Primary outcome(s) Exacerbations of cystic fibrosis as defined by 
the Fuchs criteria (N Engl J Med 1994, 
331:637–42.) 
Key secondary outcomes None. 
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-039089:e039089. 10 2020;BMJ Open, et al. Hind D
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-039089:e039089. 10 2020;BMJ Open, et al. Hind D
Pilot – ACtiF Control Patient Topic guide: v1 2Feb16 
 
6. How could the care you received for helping you to use your nebuliser as prescribed be 
improved? 
 
7.  Overall how happy are you with the care you received for your nebuliser? [Prompts: what 
could be done better?] 
 
Now I want to ask you about specific kinds of things that might have changed since the trial 
started: 
 
8. Since you joined the trial has the care that you receive in the unit / hospital changed at all? 
[Prompts: Has anybody done anything different? What have they done?] 
 
9.  Since you joined the trial has anyone asked you to change how you use your nebuliser? If so, 
what have they suggested you do? [Prompt: capability skills / knowledge including beliefs / 
where has the change come from?] 
 
10.  Since you joined the trial has anyone suggested ways to help you use your nebuliser as much 
as possible? If so what? [Prompt: opportunity finding time to use nebuliser / making plans / 
setting goals / where has the change come from?] 
 
11.  Since you joined the trial has anyone helped you have more confidence to use your 
nebuliser as prescribed? [Prompt: where has the change come from? what have they done?] 
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Now I’d like to talk to you about the CFHealthHub website / app.  
6. What was good about the website? [Prompts: my plan, how am I doing, tool kit, graphs, my 
treatment] 
 
7. What needs to be improved? [Prompts: my plan, how am I doing, tool kit, graphs, my 
treatment] 
 
8.  Do you think you’ve had any benefit from using the website?  
If yes, what benefit and what about the website helped you to get this?  
If no, what has stopped you gaining benefit? 
 
9.  Have the website and/or meetings helped you to improve how often you use your 
nebuliser?  
If yes, how has it helped you to do this?  
If not, why not? 
 
10.  How do the CFHealthHub website and the meetings work together?  
 
11.  Has using CFHealthHub helped you to be able to use your nebuliser any better? Why / Why 
not? [Prompt: capability skills / knowledge including beliefs] 
 
12.  Has using CFHealthHub helped you to find the time to use your nebuliser more? Why / why 
not? [Prompt: opportunity / making plans] 
 
13.  Has using CFHealthHub made you want to use your nebuliser more? Why / why not? 
[Prompt: motivation and confidence] 
 
14.  How does the CFHealthHub service (website and meetings) fit with the care you were 
already receiving at the unit/hospital? 
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15.  Do you think you would continue using CFHealthHub? [Prompt: during the study / after the 
study] 
 
16.  Is CFHealthHub a good thing to use in general for people with CF? Why? / Why not? 
 
17.  How have you found being part of the study? 
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d) session 2? [Prompts: reviewing adherence data, introducing CFHH, explaining 
modules, setting goals, action planning, identifying suitable tailored content, technical 
issues, anything else] 
 
e) session 3? [Prompts: reviewing goals, reviewing adherence plans, motivation, 
problem solving, anything else] 
 
3. What works or could be improved about the training manuals and training sessions? 
  
4. What works or could be improved about the support available from the research 
team? [Prompts: timing, availability, problem solving].  
[Specific prompt for MDT senior interventionist: do you think the training has 
equipped you to deliver this intervention in your centre yourself after the trial ends? If 
no, what further training would be needed?] 
 
5. How has the CFHH intervention been received by the rest of the team? [Prompt: how 
has your communication been with the rest of the team about CFHH?] 
 
6. What sort of follow-up did participants request? How will you handle this? 
 
7.  How has the CFHH intervention helped your participants to know how to use their 
nebuliser? [Prompt: capability / skills, knowledge and beliefs] 
 
8.  How has the CFHH intervention helped your participants find ways to use their 
nebuliser more? [Prompt: opportunity] 
 
9.  How has the CFHH intervention helped to motivate your participants to use their 





10. How engaged did participants seem with CFHH? [Prompt: What feedback if any have 
you had from participants about CFHH?] 
 
11. How useful do you think CFHH is for your participants?  
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12. How easy / difficult has it been to get your participants to use CFHH? 
 
13. Have you seen any changes to the ways in which your participants use their 
nebulisers since starting CFHH? 
 
14. What have you learnt from using CFHH with your participants? 
 
15. What if any are the benefits to you and / or to your participants of using CFHH?  
 
16. How do you think CFHH fits with the other care offered by the centre? 
 
17. How have you found being part of the trial? 
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10. How does the CFHealthHub intervention help to motivate your patients to use their nebuliser? 
[Prompts: How / Why doesn’t it help?] 
  
11. Do you think CFHealthHub is helping your intervention patients to improve their adherence? If 
yes, what key things have helped this? If no, what if anything could be done to help this? 
 
12. Has the CFHealthHub intervention changed anything about the way in which you and/or your 
team approach adherence in your centre?  
i) for patients receiving the intervention?          
ii) for patients not receiving the intervention? 
[Prompts: MDT discussions / differences between control and intervention patients] 
  
13. Which patient groups are most likely to benefit from CFHealthHub? Why? 
 
14. Which patient groups are least likely to benefit from CFHealthHub? Why? 
 
15. Would you consider continuing to use CFHealthHub in the future? Why? Why not? 
 
16. How has it been for you / your centre taking part in the trial? [Prompt: recruitment to the study] 
 
17. How able do you feel to go on delivering care related to improving adherence after the study 
ends? [Prompt: has the study changed the way you will go about this?] 
 
18. Are there any aspects of the research that we haven’t talked about that you’d like to comment 
on? 
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Additional File 03 - Quantitative results from process evaluation 
Table a. Key dates in process evaluation by participant 
 
 
Study ID Interview Date Baseline date 5 month follow 
up date 
Date of first 
intervention 
meeting 
Time in the trial 
at interview 
(days) 




Time in trial at 
follow up (days) 
R02/02  13/09/2016 06/07/2016 10/11/2016 05/08/2016 69 39 127 
R02/03  09/09/2016 08/07/2016 NA 05/08/2016 63 35 NA 
R02/42  12/10/2016 15/07/2016 21/12/2016 NA 89  NA 159 
R02/07  15/11/2016 12/07/2016 12/12/2016 09/09/2016 126 67 153 
R02/12  02/11/2016 14/07/2016 03/01/2017 05/10/2016 111 28 173 
R02/52  03/02/2017 04/07/2016 22/11/2016 05/10/2016 214 121 141 
R01/44  01/12/2016 07/07/2016 16/11/2016 08/11/2016 147 23 132 
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R01/48  17/01/2017 04/07/2016 15/11/2016 13/10/2016 197 96 134 
R01/49  30/01/2017 22/07/2016 07/12/2016 10/10/2016 192 112 138 
R01/54  21/03/2017 25/07/2016 13/12/2016 02/11/2016 239 139 141 
R01/39  27/02/2017 02/08/2016 21/12/2016 03/11/2016 209 116 141 
R01/02  06/12/2016 31/08/2016 25/01/2017 15/08/2016 97 113 147 
R01/40  05/12/2016 05/09/2016 17/02/2017 05/10/2016 91 61 165 
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 Table b. Interventionist-generated motivation data (intervention 
arm) R02/42, R02/49, R02/15 and R01/48 were all missing 
 
Participant ID Date Consent Visit 
Motivation Rating 
Was Participant motivation too low 
Answer Yes/No 
R02/39 05.08.16 7 No 
R02/40 23.08.16 4 No 
R02/02 05.08.16 7 No 
R02/03 03.08.16 1 No 
R02/43 12.08.16 7 No 
R02/05 22.08.16 5 No 
R02/45 18.08.16 7 No 
R02/07 09.08.16 7 No 
R02/48 05.10.16 7 No 
R02/10 14.09.16 7 No 
R02/11 28.09.16 7 No 
R02/50 26.09.16 7 No 
R02/12 05.10.16 7 No 
R02/52 03.10.16 7 No 
R01/39 03.11.16 7 Page missing from report 
R01/02 16.09.16 7 No 
R01/03 03.10.16 5 No 
R01/40 05.10.16 7 Page missing from report 
R01/42 15.08.16 5 Page missing from report 
R01/44 08.11.16 7 Page missing from report 
R01/47 10.10.16 5 Yes 
R01/06 10.10.16 7 Page missing from report 
R01/49 17.10.16 7 No 
R01/08 01.11.16 7 Page missing from report 
R01/50 Missing report     
R01/53 29.11.16 7 Not ticked  
R01/54 Missing report     
R01/10 10.11.16 2 Not ticked  
R01/57 31.10.16 0 Yes 
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collected (did not 
withdraw from data 








Overall (n=33) 29(88%) 3(1,8) 20(2.1,47.8) 
    
Qualitative case studies    
High adherence at end    
R01/39 Yes 1 0 
R02/07 Yes 2 96.7 
R01/40 Yes 9 43.1 
R02/52 Yes 13 96.6 
Moderate adherence at end    
R01/49 Yes 4 13.2 
Low adherence at end    
R01/54 Yes 11 44.8 
R01/02 Yes 1 30.2 
R01/48 Yes 3 1.8 
R02/12 Yes 44 10.2 
R02/03 No 3 5.4 
R01/44 Yes 1 19.5 
Withdrawn    
R01/42 Yes 41 21.1  
R02/02 No 3 92.5 
R02/42 No 0 4.2 
 
Note: R02/42, R02/02 withdrew from adherence data collection and from the intervention 
and R02/03 was lost to follow-up. R01/42 did not withdraw from data collection until the end 
of the study; they did not contribute sufficient data for the 150-180 day period.
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(IQR) overall (n=33) 11( 5 , 30 )* 3( 0 , 7 )* 2( 1 , 3 )* 2( 1 , 7 )* 3( 0 , 8 )* 1( 0 , 3 )* 1(0.5)† 
Qualitative case studies        
High adherence at end        
R01/39 8 3 1 1 0 1 1 
R02/07 5 1 1 1 2 0 1 
R01/40 52 0 1 1 3 0 1 
R02/52 70 5 3 1 17 1 1 
Medium adherence at end        
R01/49 30 2 1 0 1 0 1 
Low adherence at end        
R01/54 24 4 5 3 4 2 1 
R01/02 3 0 1 2 0 1 2 
R01/48 38 6 2 7 7 1 1 
R02/12 98 12 10 13 14 8 1 
R02/03 15 12 1 25 1 14 1 
R01/44 11 0 2 4 8 3 1 
Withdrawn        
R01/42 69 18 9 16 20 3 2  
R02/02 3 7 1 8 8 7 1 
R02/42 0 0 0 0 0 0 0 
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Table e. Activities: highly motivated participants  








































High motivation Mean 
(SD)†/Median* (IQR) 
overall (n=17) 
16 (5  33)* 5  (2 ,12)* 3 (1 , 4)* 4 (2 , 12)* 4(2 , 11)* 1(1 , 7)* 1.12(0.33)† 
        
Qualitative case studies 
(high motivation)        
R02/07 5 1 1 1 2 0 1 
R02/52 70 5 3 1 17 1 1 
R01/49 30 2 1 0 1 0 1 
R01/02 3 0 1 2 0 1 2 
  
R02/12 98 12 10 13 14 8 1 
R02/03 15 12 1 25 1 14 1 
R02/02 3 7 1 8 8 7 1 
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Increased Motivation Increased necessity and 
















Change in BMQ question 
'I want to do all my 
prescribed medications in 









Change in BMQ 
question 'I am 
confident I can do 
all my prescribed 
medications in the 















n Overall 30 31 31 31 31 31 31 31 31 
Mean 
(SD) 
overall 2.07(27.87) -0.1(1.27) 0.26(0.58) -0.19(0.31) 0.06(1.79) 
-
2.38(14.01) 0.32(3.92) 0.1(2.75) -1.84(3.44) 
Qualitative case studies         
 
 baseline(change) % baseline (change)   baseline (change)     
High adherence at end 
R01/39  85(14) 7(0) 0.5 -0.4 7(0) -5.9 -2 2 -4 
R02/07  100(-2) 7(0) 0.2 -0.2 7(0) 0 1 -5 -3 
R01/40  92(8) 7(0) 0.6 -0.2 5(1) 7.2 -9 0 1 
R02/52  95(-25) 7(0) 0.3 -0.2 7(0) 4.9 3 -1 1 
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R01/49  100(0) 7(0) -0.8 -0.7 7(0) 9.9 -1 0 -4 
Low adherence at end 
R01/54  60(-10) 7(-1) -0.3 0.4 6(0) -7.9 1 -1 6 
R01/02  55(16) 7(0) 0.8 -0.2 2(3) 0 -1 -1 -2 
R01/48  0(100) 7(0) 0.9 -0.8 6(0) 0 0 0 -2 
R02/12  NA 7(0) -0.1 -0.7 4(0) 14.6 -3 -2 -5 
R02/03  50(NA) 1(NA) NA NA 2(NA) NA NA NA NA 
R01/44  0(0) 7(0) 1.4 0.2 5(-4) -16.6 0 -1 -5 
Withdrawn 
R01/42  0(0) 5(-1) -0.3 -0.1 4(0) -5 -1 5 -6 
  
R02/02  80(10) 7(0) 0.1 -0.5 7(0) 9.2 2 -1 1 
R02/42  100(0) 7(0) 0.9 0 7(0) -12.1 1 7 -1 
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Table g. Intermediate Outcomes 
  
End of trial adherence 
(day 150-180)✦ 





exacerbations in 6 
months 
Mean (SD)⁺/ Median (IQR)* 
overall (n=33) 
34.7 ( 0.4 ,78 )*  1.25( -5.8 , 36.3 )* 0.1(0.51)⁺ 1( 0 , 2 )* 
         
Qualitative case studies     
High adherence at end     
R01/39 95.2 95.16 -0.02 1 
R02/07 93.5 -3.12 NA 0 
R01/40 88.2 45.07 0.22 0 
R02/52 83.9 -12.68 -0.13 0 
Medium adherence at end     
R01/49 68.3 55.06 -0.12 3 
Low adherence at end     
R01/54 29 -15.8 -0.03 2 
R01/02 29 -1.14 0 0 
R01/48 5.2 3.34 1.07 0 
R02/12 0 -10.23 -0.21 0 
R02/03 0 -5.42 NA NA 
R01/44 0 -19.54 0.9 1 
Withdrawn     
R01/42 NA NA 0 0 
R02/02 NA NA -0.04 3 
R02/42 NA NA 0.35 1 
 ✦Normative numerator adjusted adherence 
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Additional File 04: Joint display table (data sources in bold) 
# Logic model column / 
construct 
Quantitative Qualitative Convergence 
code 
 INPUTS    
1 MDT introduction to 
CFHealthHub  
- Chief investigator reported: introducing MDT 
to concept behind and application of CFHH. 
- 
2 CF Clinicians aware of the 
importance of monitoring 
adherence 
- Chief investigator reported: briefing 
collaborating MDTs. Reported change agents at 
centres internalised idea; some residual 
scepticism among senior physicians. 
- 
3 Prescription data Study team found adherence levels of over 100% 
(Implementation log, 01 Dec 16) 
Late identification of prescription changes found 
to be responsible. (Minutes, Trial 
Management Group Meeting 10 Jan 17) 
Expansion  
4 Chipped nebuliser - Devices ordered centrally by CTRU were 
delivered to sites on 20th May 2016 and 
processed for distribution on 23rd June 2016. 
(Project manager emails) 
- 
5 Qualcom-Hub (docking & 
upload) 
- Devices ordered centrally by CTRU were 
delivered to sites on 20th May2016 and 
processed for distribution on 23rd June 2016 
(Project manager emails) 
- 
6 CFHealthHub website/app - Available, but under development through trial 
(Additional File 01) 
- 
7 COM-BMQ questionnaire COM-BMQ questionnaire data was collected at 
baseline for all consenting participants 
- - 
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responses (Additional File 04 - Table 8) 
8 Intervention manual - High levels of interventionist satisfaction with 
manual. R01 Interventionist 1 remarked that, 
“all the stuff in the manuals was really good.”  
- 
9 Interventionist training 
programme 
Structured questionnaire on interventionist 
confidence after training programme: 
Interventionists (n=5) all averaged >8 for 
confidence across 11 questions. Isolated scores of 
<8 occurred three times: viewing charts/tables, 
completing report forms and understanding online 
training/assessment. 
In interviews, interventionists reported high 
levels of satisfaction; one requested for more 
integration of research and intervention 
procedures. R01 Interventionist 1 remarked 
“You had the manual but I was missing bits”. 
She wanted more case studies and mock patients 
in the training to compensate for this. An 
interventionist (R01 MDT member 1), who was 
a social worker by background, found the 
training very good, indicating that it the training 
had acceptability beyond physiotherapists. 
Expansion 
10 Interventionist support - Research team member (MH) reported giving 
mentorship and that one site/trust received more 
support from the PI than the other. The main 
interventionist at the other site received support 
from the part-time interventionist who was a 




Structured instrument for the assessment of 
interventionist competence: Digital recordings 
were made and assessed for fidelity by MA, MH 
and JB. Fidelity assessment instrument modified 
after discussion, in advance of use on full-scale 
RCT. 
- - 
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12 Motivated and effective 
interventionists 
- In interviews, interventionists reported that 




   
13 Clinicians accessing 
adherence data* 
Clinicians did not access CFHH. (CFHH Click 
analytics) 
In interviews, interventionists talked about run 
charts occasionally being viewed when brought 
to MDT meetings by interventionists.  
Confirmation  
14 Adherence data tracking  CFHH click analytics showed interventionists 
accessing data before meetings 
This was confirmed in interviews. Confirmation 
15 Participant accessing 
CFHealthHub 
Click analytics: The median number of sessions 
over 5 (+/- 1) months was 3 (interquartile range 1 
to 8, range 1-44, Additional File 05 - Table c), 
with a mean duration of 36.1 (SD=23.9) minutes. 
The mean total duration of interaction time across 
the study was 49.3 (SD 44.8) minutes. The mean 
length of an interaction was 12.4 (SD=9.6) 
minutes. The median number of days in the trial 
with interactions was 2 (IQR=1,7). 
Lack of usability was explained in interviews 
by initially difficult login procedures and the 
lack of a mobile app for most of the pilot trial, 
leading participants to access an unsatisfactory 
desktop version on their mobile. 
Expansion 
16 Push notifications/reminders 
each week* 
- Programmer reported that automated push 
notifications not available during pilot trial. In 
interviews, one participant and one 
interventionist, reported the spontaneous 
development of informal push notifications in 
which the interventionist was ringing up and 
praising the participant for accomplishments, 
thereby building the relationship. 
- 
17 CFHealthHub Intervention 
sessions delivered according 
Collected via project-specific structured fidelity 
assessment instrument (#11). After discussion 
Fidelity observations indicated: limited 
discussion of motivations; communication style 
Expansion 
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to Manual (Fidelity) between MA, MH and JB summary scores were 
agreed for delivery of content 100% and quality of 
delivery: 60-92%. Co-author Judy Bradley is 
intending to publish this work elsewhere. 
sometimes paternalistic rather than autonomy-
enabling; insufficient attention to most active 
ingredients. 
18 Initial session, and then 
review at each clinic visit 
Collected via click analytics. Patient run charts 
reveal a disparity in when and whether these 




   
19 Clinicians monitor 
adherence 
- Clinician access to adherence data was sporadic 
(see #13) and staff interviews confirmed that it 
was not monitored. In an interview, participant 
R01/02 described the research intervention as 
“parallel rather than integrated” with 




for all participants 
   
20 Self-monitoring adherence Click analytics: 'How am I doing?' pages were 
the most frequently visited in terms of the total 
number of clicks during the trial. 30 (90.9%) 
participants clicked a median of 11 (range 5-30) 
times in 5 months, but sometimes in a single 
session (Additional File 05 – Table d). Access 
did not always result in good alignment between 
subjective and objective adherence (Additional 
File 05 – Tables f and g respectively). 
In interviews, moderate and frequent users said 
they mostly valued this page for self-
monitoring. 
Expansion 
21 Tailored education about 
treatment 
Click analytics: Toolkit clicked a median 3 
(range 0-7) times (Additional File 05 – Table d). 
In participant interviews, the DNASE video 
was popular. Other pages were accessed 
Expansion 
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infrequently or when issues arose, when the 
information was viewed as “more down to 
earth” (R02/07) than technical manuals.  
22 Tailored patient stories 
(videos) 
Click analytics: ‘Talking heads’ videos accessed 
a median 2 (range 1-3) times (Additional File 05 
– Table d). 
In participant interviews, these videos divided 
opinion. Some participants liked to know that 
they were not alone; others did not want to see 




for those with adequate 
motivation 
   
23 Personalised goal-setting Click analytics: Participants set target adherence 
levels in CFHH (Additional File 05 – Table 3). 
In interviews, participants reported goal-
setting, but it was not clear how much it came 
from patients and how much from 
interventionists. 
Expansion 
24 Goal review 
 
  
Click analytics: Mean (SD) review sessions 1 
(0.5) (Additional File 05 – Table e). 
- - 
25 Personalised action plan Click analytics: Action plan pages clicked on 
median 2 (inter-quartile range 1-7) times 
(Additional File 05 – Table e). 
Disliked by some participants who, the 
interventionist from centre R01 reported 
during an interview, found writing down 
action plans like “being at school” 
Expansion 
26 Tailored problem-solving Click analytics: Problem solving and coping plan 
pages clicked on median 3 (inter-quartile range 0-
8) and 1 (0-3) times respectively (Additional File 
05 – Table e). 
In interviews, one participant realised that 
when she goes to her friend’s house, rather than 
missing a treatment she could do it in the car or 
anywhere. One interventionist from centre R02 
thought it important that the information was 
Expansion 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-039089:e039089. 10 2020;BMJ Open, et al. Hind D




   
27 Medical care informed by 
adherence 
- Interviews with PIs found that the trial and 
intervention ran alongside usual care rather than 
being informed by it (see also #13, #19). 
- 
 
For all participants 
   
28 Acute awareness of 
adherence / increased 
Motivation 
Answers to the subjective adherence question 
(Additional File 05 – Table f) were well aligned 
with run charts (Additional File 07) in those 
with high adherence. Alignment was more 
variable in those with moderate and poor 
adherence. 
In interviews, some with high adherence  used 
the CFHH “How am I doing page” (run charts) 
as a check (R02/07, R01/40); other high 
adherers did not (R01/49). Some felt that it 
increased their adherence, acknowledging that 
monitoring meant that they had, “…better make 
an effort here”. 
Expansion 
29 Increased necessity and 
decreased concern  
No change in the group averages for the COM-
BMQ (incorporating Beliefs about Medicines 
Questionnaire - specific (Nebuliser adherence) 21-
item validated self-report tool[1]) or Patient 
Activation Measure (PAM-13) (Health Style 
Assessment) assessment of patient knowledge, 
skill, and confidence for self-management[2]. 
(Additional File 05 – Table f) 
- - 
30 Increased self-efficacy / 
Motivation 
No change in the group averages for a single 
question about confidence to adhere or the PAM-
13. (Additional File 05 – Table f) 
- - 
 
For those with adequate 
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motivation 
31 Increased self-efficacy/ 
Motivation 
No change in the group averages for a single 
question about confidence to adhere or the PAM-
13. (Additional File 05 – Table f) 
- - 
32 Increased habit / Reduced 
CHAOS 
No change in the group averages for Self-Report 
Behavioural Automaticity Index (SRBAI) 
automaticity-specific subscale of the Self Report 
Habit index to capture habit-based behaviour 
patterns[3] or in the assessment of routine 
measure of life chaos[4]. (Additional File 05 – 
Table f)  
- - 
33 Reduced barriers No change in the group averages for The Beliefs 
about Medicines Questionnaire - specific 
(Nebuliser adherence) (BMQ 21-item) 
(Additional File 05 – Table f) 
The tailored problem-solving modules (#26) 
were not widely used but, in interviews, party 
plans and nebuliser guides were cited as having 
removed barriers by those who did use this 
content. For instance, one participant was able 
to find the technical name for a part of a 






   
34 Treatment optimisation - Interview data revealed patients to be behaving 
in unexpected ways, for instance taking holidays 
from their treatment or not taking medication as 
prescribed. 
- 
35 Increased adherence Nebuliser data via CFHH: Mean adherence 
across all participants was 10 (95% CI: -5.2 to 
25.2) percent higher in the intervention than in the 
- - 
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control arm. Within the case study participants (all 
intervention), an increase of 7.5% (95% CI: -8.2-
23.1) in simple normative adherence with 
numerator adjustment can be observed in the 
intervention arm. Following month 1, adherence is 
consistently higher in the intervention arm with 
the greatest difference observed in month 5 (mean 
difference: 10.8, 95% CI: -11.44, 22.9). These 
differences would indicate a potentially clinically 
important difference between the intervention and 
usual care arms.  
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Additional File 05 - Case-ordered descriptive matrix for fourteen case studies 
Qualitative findings in italics. Otherwise, motivation, confidence, necessities, concerns, life chaos and subjective adherence (baselines and process outcomes) 
from self-report instruments (see Methods and Additional File 04). Engagement, activities and data captured by CFHealthHub. 
Case / baselines / context Engagement Activities Process outcomes Intermediate outcomes 
High adherence (average 
>80%) in last month of trial 
    
R01/39. High motivation, 
confidence and necessities, 
medium concerns, quite high 
chaos. They got a lot of 
information about CF from other 
websites. 
Used CFHH once. Very 
engaged with interventionist 
and trial. 
Didn't make plans – felt it 
was her responsibility to 
adapt her life; found others 
monitoring helpful. Didn't 
like videos or social aspects 
of website because of the 
reminder of her mortality. 
Knowledge that 
clinicians could access 
treatment adherence 
information provided 
extra motivation to 
adhere. 
End of trial adherence 95% 
(95% improvement). 
R02/07. High motivation, and 
confidence, medium-high 
necessity, medium concerns and 
chaos. Existing high adherer, sees 
treatment as a “plan for 
longevity” rather than a “chore”. 
Used CFHH twice. Didn't 
find it useful or like the 
videos (doesn't want to see 
negative side of CF). 
Made action plan, accessed 
some modules once. Found 
goal-setting with 
interventionist helpful. 
Little change as already, 
motivated. Reduced 
CHAOS and barriers. 
End of trial adherence 93% 
(3% decline). 
R01/40. High motivation, 
medium confidence and 
necessities, low concerns, 
medium-to-low chaos. Was 
recruited soon after exacerbation. 
Had nine CFHH sessions. 
"I've been logging on to track 
my progress... every two 
weeks to a month". Finds 
others monitoring him 
helpful. 
Frequent self-monitoring. 
Compensates for slippages 
by planning to do the rest 
of his doses. 
Motivation already high, 
but habit lacking. 
Intervention has made 
him think about 
adherence more than he 
did before. 
End of trial adherence 88% 
(45% improvement). 
Variance over trial, but 
trajectory. 
R02/52. High motivation, 
confidence and necessity, low 
concerns, low-medium chaos. 
Existing good adherer; wanted 
something like a fitness tracker 
with feedback - messages on 
performance. 
13 CFHH sessions. Liked the 
more portable nebuliser, 
could take it away on work. 
CFHH session that precedes 
interventionist visit explained 
by interventionist testing 
login details. 
Frequent self-monitoring, 
regular use of tailored 
education and problem 
solving (fixing nebuliser 
problems) and some use of 
videos. Wanted it 
expanding to physical 
activity. 
Motivation already high. 
Increased habit. 
End of trial adherence 83% 
(12% decline). 
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Case / baselines / context Engagement Activities Process outcomes Intermediate outcomes 
Moderate adherence (average 
50-80%) in last month of trial 
    
R01/49. High motivation, 
confidence, medium-high 
necessity and concerns low 
chaos. Participated to ‘prove’ 
themselves to their 
physiotherapist; poor awareness 
of own adherence not improved 
over course of trial. 
4 CFHH sessions Used problem-solving 
modules and self-




End of trial adherence 68% 
(55% improvement). An 
important improvement 
from low adherence, but 
subjective adherence still 
poorly ‘calibrated’ with 
objective adherence. 
Poor adherence (>50%) in last 
month of trial 
    
R01/54. Professed high 
motivation and confidence, 
medium necessity, low 
concerns, medium to low chaos. 
Wants the doctor “to notice” 
that they are adherent to their 
treatment, demotivated by the 
fact they don't. 
44 CFHH sessions. 
Appreciative of extrinsic 
motivation from face-to-
face contact with 
interventionist. 
Frequent self-monitoring; 
initially high use of action 
plans and problem solving. 
Dislikes ‘talking heads’ 
videos. 
More barriers by the end of 
the trial. 
End of trial adherence 29% 
(16% decline), but run chart 
shows huge variance week 
by week. 
R01/02. High motivation, low 
confidence, medium necessity 
and concerns, high chaos. 
Dissatisfaction at service 
reconfiguration: moved across 
from Poole to Southampton 
during trial. Upset that wider 
team isn’t noticing their 
adherence. 
Used CFHH once but had 
technical problems. 
Appreciative of 
interventionist: "Having a 
personal contact and 
someone to guide you 
through it is really useful" 
Wider team not talking 
about adherence: "parallel 
rather than integrated". 
Two review sessions with 
interventionist.  
Reduced CHAOS and 
barriers; increased self-
efficacy 
Lack of pre-post change not 
contradicted by the run 
chart which shows 
improvement.  
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Case / baselines / context Engagement Activities Process outcomes Intermediate outcomes 
R01/48. professed high 
motivation and confidence, 
medium-high necessities and 
concerns; medium chaos. This 
69-year old doesn't like 
nebulising; “can't teach an old 
dog new tricks”. No belief in 
benefit of nebulised medication. 
Poor awareness of own 
adherence. Altruistic trial 
participant. 
Used CFHH three times. 
Access problems 
(passwords, etc) - gave up. 
Some engagement with 
toolkit, action plans and 
problem-solving, didn't like 
the videos. Engagement 
drops off as soon as the last 
meeting over. 
No change in process 
outcomes. 
End of trial adherence 5% 
(3% improvement). Said 
was making an effort for the 
trial. In line with this, 
objective adherence was 
high (~80%) for weeks 6-21 
R02/12. High motivation, 
medium to low confidence, 
medium to high necessity and 
concerns, medium chaos. 
Started off engaged, lots of 
CFHH use and two 
intervention sessions in first 
100 days, nothing 
thereafter. 
Made plans, liked website, 
checked graphs. Liked face-
to-face interaction with 
interventionist. 
Decreased chaos and 
barriers but also decreased 
habit. 
Initial improvement in 
adherence (up to 100% 
between weeks seven and 
nine after first intervention 
not sustained over time. 
Review stimulates brief 
improvement at week 15, 
again not sustained. 
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Case / baselines / context Engagement Activities Process outcomes Intermediate outcomes 
R02/03. Low motivation and 
confidence, medium necessities, 
concerns and chaos. Treatment 
is something that he has to do 
but doesn’t want to do it, or 
think about CF. Forgets about 
treatment because of busy 
lifestyle. Prioritises other things 
above health. Knows that this 
doesn't end well, but no 
readiness to change. 
Minimal short-term 
engagement with CFHH. 
Interventionist notes that 
participant has always been 
difficult to get hold of. 
Made action and coping 
plans, checked graphs. 
No process data at follow-
up. 
Withdrew from treatment 
early. 
R01/44. High motivation, 
medium confidence, necessities, 
low concerns, high chaos ("I 
can't seem to get into a 
routine"). Recruited during 
exacerbation: baseline 
artificially high. Intervention 1 
visit didn't happen until Week 
17. Participant describes self as 
"uncompliant" except around 
inpatient stays.  
One CFHH session (at 
intervention visit 1). 
Interventionist appears not 
to have done correct 
preparation. Only 
participant rated by an 
interventionist as having 
inadequate motivation. 
Participant confirms that he 
made action plan, coping 
plan and checked graphs 
with interventionist but 
chaotic lifestyle and low 
motivation prevented 
further use. Admits only has 
a routine in hospital. 
No change in process 
variables. 
Initial spikes of 
adherence not sustained 
over time. 
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Withdrawn     
Case / baselines / context Engagement Activities Process outcomes Intermediate outcomes 
R01/42. Medium motivation, 
low confidence, medium-high 
necessity, medium concerns, 
low chaos. Originally an i-neb 
user. Does not think nebulising 
three times a day is achievable. 
Moved house during study. No 
broadband – so didn’t do 
nebulisations. 
Loved the website and 
shared it. 41 CFHH 
sessions. Intervention visit 
1 reported to be chaotic. 
Made action plan. Little change in process 
variables. 
Interview might have 
triggered brief increase in 
nebuliser use, when 
participant realised 
nebulisations were being 
logged even when he wasn't 
plugging it in. 
R02/02. High motivation and 
confidence, medium-high 
necessity low concerns and 
chaos. Interview shows them to 
be motivated by interventionist 
visit and qualitative interview 
(Hawthorne effect). Subjective 
adherence poorly aligned to 
objective adherence. 
Limited engagement. Three 
CFHH Sessions all on the 
same day. 
Made an action plan but 
reported that she didn't set 
goals because she thought 
she her adherence was 
already good. 
Little change in process 
variables. 
Adherence run chart starts 
off high, but drops off 
quickly. Interview might 
have triggered brief 
increase in nebuliser use. 
Withdrew from collection 
of nebuliser data collection. 
R02/42. High motivation and 
confidence, medium to high 
necessity, low concerns, 
medium chaos 
Withdrew - didn't like the 
eTrac nebuliser - delivering 
the drug too quickly made 
them cough. Interventionist 
encouraged 
discontinuation. 
Didn't look at the website. No change in process 
outcomes 
Assumed no change in 
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The primary objective of this study was to determine the feasibility of proceeding to a definitive 
trial. An external pilot randomised controlled trial to determine feasibility of a randomised 
controlled trial based on objective stop-go criteria related to: 
(a) participant recruitment; 
(b) participant retention; and, 
(c) quality of primary outcome data at 5 (+/- 1) months post randomisation. 
These were assessed by 
i. The number of screened, eligible and recruited participants per month, per centre and 
overall; 
ii. The number and percentage of participants who complete their 5(+/-1) month post 
randomisation follow up; 
iii. The number of Fuchs criteria by exacerbation. 
Clinical outcomes 
The primary clinical outcome measure was the number of pulmonary exacerbations in the 5 (+/-1) month 
post-baseline follow-up period, defined according to a modified version of the Fuchs criteria. The original 
Fuchs criteria was 4 out of 16 symptoms leading to IV antibiotic treatment. An exacerbation of 
respiratory symptoms will be said to have occurred when a participant was treated with parenteral 
antibiotics for any one of the following 12 signs or symptoms: 
1. change in sputum; 
2. new or increased hemoptysis; 
3. increased cough; 
4. increased dyspnea; 
5. malaise, fatigue, or lethargy; 
6. temperature above 38 °C; 
7. anorexia or weight loss; 
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8. sinus pain or tenderness; 
9. change in sinus discharge. 
10. change in physical examination of the chest, derived from notes by site staff. 
11. decrease in pulmonary function by 10 percent or more from a previously recorded value, derived 
from notes by site staff; or, 
12. radiographic changes indicative of pulmonary infection, derived from notes by site staff. 
The trial interventionist or prescribing clinician/nurse will collect data on the "exacerbations" form at the 
point of a participant starting a course of IV antibiotics. 
The following secondary outcomes were also collected at baseline and 5 (+/-1) month follow up: 
1. Body Mass Index (BMI). 
2. Forced expiratory volume in 1 second (FEV1): standardised spirometry as a measure of condition 
severity. 
3. EuroQol EQ-5D-5L: generic health status measure for health economic analysis. 
4. The Patient Activation Measure (PAM-13): assessment of patient knowledge, skill, and confidence 
for self-management. 
5. Confusion, Hubbub, and Order Scale (CHAOS 6-item): measure of life chaos. 
6. Medication Adherence Data-3 items (MAD-3) 
7. Self-Report Behavioural Automaticity Index (SRBAI) 
8. Cystic Fibrosis Questionnaire-Revised (CFQ-R): disease specific health-related quality of life 
instrument. 
9. The Patient Health Questionnaire depression scale (PHQ-8): severity measure for depressive 
disorders. 
10. The General Anxiety Disorder 7-item anxiety scale (GAD-7): severity measure for anxiety. 
11. The Capability Opportunity Motivation Behaviour Beliefs Questionnaire (COM- BMQ): This 
questionnaire incorporates: 
a. The Beliefs about Medicines Questionnaire - specific (Nebuliser adherence) (BMQ 21-item): a 
validated self-report tool, customised by the author to identify perceived necessities and concerns 
for nebuliser treatment. 
b. The following project-specific items: one additional belief item, one intention item, one confidence 
item, and a list of barriers. These will serve as a tailoring tool for the intervention and also as a 
secondary outcome measure. 12.Subjective adherence single question: self-report estimate of 
adherence as a percentage. Self-reported problems: identification of capability and opportunity 
barriers to nebuliser adherence 
13. Concomitant medications: bespoke instrument, designed for this research project. 
14. Resource use form: interventionist collects data from a combination of hospital notes and the NHS 
patient electronic system to determine 1) inpatient IV days 2) Routine clinic visits 3) Unscheduled 
outpatient contacts 3) unscheduled inpatient stays. 
15. Prescription: a monthly prescription check to both check for data transfer to CFHealthHub and 
review for an indication that the prescription has changed or indication of microorganism e.g. 
16. Adherence to prescribed medication 
17. Any treatment with IV antibiotics 
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Sample Size 
Sample size calculation was based on estimating parameters within a certain amount of precision 
rather than hypothesis testing. The sample size for a feasibility study should be adequate to 
estimate the uncertain critical parameters (standard deviations for continuous outcomes; consent 
rates, event rates, attrition rates for binary outcomes) needed to inform the design of the full RCT 
with sufficient precision. 
To assess recruitment rate, the external pilot RCT ran in two CF units for 12 months, with four 
months recruitment, one months 'run-in' period (the period between the consent and baseline 
visit), and 5 (+/-1) months follow up. To match the proposed recruitment rate of the main RCT, 
the target sample over the four months for which the pilot RCT was open, was 32 per centre (64 
in total from the two pilot centres). We aimed to see a minimum of 75% of the recruitment target 
to be confident of the trial viability i.e. at least 48 patients in total consented and randomized in 
four months' of recruitment from two centres. 
Randomisation 
Randomisation was conducted using a computer generated pseudo-random list with random 
permuted blocks of varying sizes, created and hosted by the Sheffield CTRU in accordance with 
their Standard Operating Procedures (SOPs) and was held on a secure server. ACtiF participants 
will be randomised in a 1:1 ratio, intervention to control arms, stratified by: 
• Site; 
• Number of IV days in previous 12 months as collected at consent visit (two categories will 
be (i) less than or equal to 14 days and (ii) greater than 14 days). 
Study researchers accessed the allocation for each participant by logging in to the remote, secure 
internet-based randomisation system. Once a participant had consented to the study, the 
researcher logged into the randomisation system and entered basic demographic information. 
After this information had been entered the allocation for that participant was then revealed to 
the researcher. 
Block randomisation with randomly varying block size of 2, 4 and 6 was used so that the 
sequence of allocation could not be predicted. The block sizes were determined by the trial 
statistician and block size was not revealed to any other member of the study team. 
Blinding 
The trial statisticians remained blind until data freeze, at which point unblinded data was 
presented to them so checks could be carried out. 
Statistical Methods 
All statistical analyses were performed in R version 3.3.1. 
Analysis Populations 
The ITT population includes all participants for whom consent was obtained and who were 
randomised to treatment, regardless of whether they received the intervention or not. This is the 
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primary analysis set and endpoints were summarised for the ITT population unless otherwise 
stated. 
Participant Flow 
A CONSORT flow diagram was used to display data completeness and patient flow from first 
contact to final follow up. 
The number of participants recruited at each centre each month was presented. The number of 
participants who withdrew consent from the trial, withdrew from the intervention, withdrew from 
collection of the primary outcome, withdrew consent from adherence data collection and who 
were lost to follow up were presented overall, by treatment arm and site. The reasons for 
attrition, where given, were presented. 
Patient reported outcome measures (PROMS) 
The following PROMS were completed at baseline and 5 (+/-1) month follow up visit. For 
detailed methods of how these questionnaires were scored, please see the appendix. 
Data completeness 
A CONSORT flow diagram was used to display data completeness and patient throughput from 
first contact to final follow up. 
Baseline characteristics 
Participants' demographics (age, sex, ethnicity, IMD decile), physical measurements (weight, 
height, BMI), clinical measurements (FEV1, IV days in last registry year, Pseudomonas status, 
Adherence in first 2 weeks, Subjective adherence, Medication, Treatment burden) patient 
reported outcomes (EQ-5D-5L, PAM-13, CHAOS, MAD-3,SRBAI, CFQ-R, GAD-7, 
COMBMQ, PHQ-8). Imbalance between treatment arms was not tested statistically but were 
reported descriptively. 
Primary effectiveness analysis of clinical outcomes 
The primary endpoint of the study is the number of exacerbations in a 5 (+/- 1) month period. 
Exacerbations were defined as being treated with IV antibiotics and meeting at least 1 Fuchs 
criteria. 
The number of exacerbations by participant were presented. The number and percentage of 
exacerbations with each Fuchs criteria were presented. The length of IV course was summarised 
by intervention arm for all exacerbations and for participants experiencing exacerbations. 
The primary effectiveness analysis used a negative binomial model and included all 
exacerbations in a 6 month follow up period. Participants who were not followed for this length 
were excluded. An adjusted model included IV days in the previous 12 months as a covariate. 
Although not prespecified, a further sensitivity analysis was carried out. This model included the 
number of days followed up as an offset. This allowed all consenting participants to be included. 
An adjusted offset model included IV days in the previous 12 months as a covariate. 
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Secondary effectiveness analysis of clinical outcomes 
Patient reported outcome measures 
Secondary outcomes were measured at baseline and 5 (+/-1) months post randomisation. The 
mean difference between treatment arms was calculated for each of the secondary outcomes, 
along with 95% confidence intervals using a multiple linear regression model. Adjustment for 
baseline and site was carried out and both unadjusted and adjusted results were presented. 
Adherence to medication 
The time of inhalations of medication was recorded via chipped nebulisers. This data along with 
prescription data was used to calculate a number of different adherence measures. Adherence in 
people with CF is of key importance. For this reason, it was decided that 7 separate measures of 
adherence to prescribed medication were to be presented: 
1. Total doses; 
2. Unadjusted adherence; 
3. Simple normative adherence (without numerator adjustment); 
4. Sophisticated normative adherence (without numerator adjustment); 
5. Simple normative adherence (with numerator adjustment); 
6. Sophisticated normative adherence (with numerator adjustment); 
7. Subjective single adherence. 
Measures 1-6 are calculated daily based on the chipped nebuliser data and the dose prescribed 
that day. Means can be calculated for set periods, e.g. weekly. 
The specific calculations of these adherence measured are described below. 
Total doses taken 
As a basic, unadjusted measure of adherence, the total number of doses taken for the time period 
will be calculated. 
Unadjusted adherence 
Adherence is typically calculated as the dose taken divided by the dose described per day. 
Simple normative adherence (without numerator adjustment) 
Quality of adherence reporting is dependent on the PWCF being prescribed the appropriate 
medications. Adjusting the denominator of the adherence calculation controls for treatment 
rationalisation to try reduce treatment burden, which is an approach often seen in people in CF. 
The simple normative adherence is calculated as follows: 
1. If the participant does not have pseudomonas 
• Minimum denominator is set at 1 treatment/day. 
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2. If the participant has chronic pseudomonas 
• Minimum denominator is set at 3 treatments/day 
3. The participant has chronic pseudomonas and intermittent inhaled antibiotic regimens 
• Minimum denominator is 3 treatments/day during 28 day 'on' period 
• Minimum denominator is 1 treatment/day during 28 day 'off' period 
4. The participant has intermittent pseudomonas 
• Minimum denominator is 3 treatments/day for 1 or 3 months depending on the eradication 
regime 
• Minimum denominator is 1 treatment/day for the rest of the time 
In calculating normative adherence an expected minimum prescription based on a patient's health 
state is needed. Most patients take a dose of a mucolytic, and patients meeting the criteria will 
take two doses of antibiotics. In adherence calculations, participants had their denominator 
amended to reflect their prescription. A complication arises in denominator adjustments when 
the antibiotic prescribed is one that is expected to be used in an alternating fashion (e.g. 28 days 
use, 28 days off). The antibiotic medications Aztreonam Lysine and Tobramycin are normally 
prescribed in this way; for patients with prescriptions for these medications with periods of more 
than 28 days without a prescription for an antibiotic, the denominator was adjusted to add in 2 
doses / day. After 28 days of substituted antibiotic use, a 28 'day off' cycle was programmed. 
This cycle was continued until such time as another antibiotic prescription was present. 
Sophisticated normative adherence (without numerator adjustment) 
The sophisticated normative adherence is calculated as follows: 
1. If someone has 'mild genotype', is pancreatic sufficient and has FEV1 > 90%, without 
Pseudomonas and used <= 14 days intravenous antibiotics in the past 1 year. 
• There is no minimum target. Denominator is determined by the agreed prescription between 
clinicians and participants. 
2. If someone is homozygous for class I-III CFTR mutation OR pancreatic insufficient OR 
FEV1 <= 90%, but without Pseudomonas and used <= 14 days intravenous antibiotics in 
the past 1 year. Minimum denominator is set at 1 treatment/day. 
3. If the person has chronic pseudomonas AND/OR 
• the person used > 14 days intravenous antibiotics in the previous year Minimum 
denominator is set at 3 treatments/day 
4. If the person has chronic pseudomonas AND/OR used > 14 days intravenous antibiotics in 
the previous year but is on intermittent inhaled antibiotic regimens 
• Minimum denominator is 3 treatments/day during 28 day 'on' period 
• Minimum denominator is 1 treatment/day during 28 day 'off' period 
5. If someone has intermittent pseudomonas but used <= 14 days intravenous antibiotics in the 
past 1 year 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-039089:e039089. 10 2020;BMJ Open, et al. Hind D
• Minimum denominator is 3 treatments/day for 1 or 3 months depending on the eradication 
regime 
• Minimum denominator is 1 treatment/day (or 0, i.e. no minimum target) depending on their 
genotype, pancreatic status and FEV1 for the rest of the time. 
Numerator adjustment in simple and sophisticated normative case 
Numerator adjustment occurs only if a daily adherence measure is greater than 100%, thus the 
maximum daily adherence is set at 100%. 
Subjective single adherence 
All participants will be asked to estimate their adherence as a percentage at baseline, clinic visits, 
5(+/-1) months and any further visits up to 30th April 2017. These subjective measures were 
presented separately. The question referred to the previous 2 weeks. 
Adherence summaries 
The mean and SD was calculated for each month of the trial by treatment arm. Weekly 
numerator adjusted normative adherence was calculated and a mean by treatment arm was 
calculated and presented as a line graph for the first 25 weeks from randomisation. 
Intervention adherence 
The intervention comprised of: 
(a) a chipped nebuliser to collect adherence data 
(b) access for participants and interventionist to the adherence data summaries 
(c) an online platform (CFHealthHub) offering summaries of adherence and tailored modules 
to be used by the health professional when interacting with the participant and 
independently by the participant. 
A number of metrics were collected from CFHealthHub including the timing and date of clicks 
and the page/module that was clicked on. Interactions with CFHH were defined as a series of 
clicks with no greater that 15 minute gaps between clicks. Length of each session was calculated 
and days with interactions were calculated by participant. 
The mean, standard deviation (SD), median and interquartile range (IQR) for the CFHH metrics 
were calculated and presented by participant. The same summary statistics were also presented 
for length of all sessions. The timing of CFHH interactions in days from randomisation was 
plotted by participant. The number of clicks per page category (Home, How am I doing?, 
Treatment etc) was plotted in a bar chart and also presented in a table by participant and by 
session. 
Date and time of sessions with the interventionist were also recorded. The number of sessions 
with an interventionist and the length of sessions by participant were summarised in a table. 
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Clinic visits 
The number of clinic visits completed by each participant excluding consent and 5 month follow 
up was recorded. Summary statistics were presented by treatment arm to assess whether 
ascertainment bias occurred in the intervention arm. 
Safety analysis 
The number of Adverse Events (AEs) and Serious Adverse Events (SAEs) was recorded and 
presented by treatment arm. These events were further categorised by the type of adverse event 
and whether they were related to the intervention. 
Protocol non compliances 
The number and type of protocol non compliances were presented descriptively. 
Summary of missing data 
The number of missing values or scores for each of the primary and secondary outcomes was 
presented by baseline and 5 (+/-1) months post randomisation and by treatment arm. 
Furthermore, the number and percentage of missing items was presented for each of these 
questionnaires. 
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Results 
Participant Flow 
Participants were recruited for 4 months across 2 sites. The CONSORT flow diagram (Fig.1) shows the 
flow of participants through the trial. 32 participants were randomised at each site. 33 participants were 
randomised to the intervention arm and 31 participants were randomised to usual care. A total of 59 
participants completed the 5 (+/- 1) month follow up visit (Intervention = 31, Usual care = 28). 
A total of 8 participants discontinued the trial before the follow up visit (Intervention = 4, Usual care = 4). 
Of these discontinuations, 5 no longer had their adherence data collected and the same 5 participants did 
not have their primary outcome collected. Of those who did not continue with primary outcome 
collection, 2 participants died, 1 withdrew consent and 2 were lost to follow up. 
Following the 5 (+/-1) month visit, adherence data and primary outcome data was collected. 2 participants 
withdrew from adherence data collection during this time (Intervention =1, Usual care =1). 59 
participants completed primary outcome data collection up to study completion on 30th April 2017 
(Intervention = 31, Usual care =28). 
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Recruitment by centre and month 
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CONSORT diagram
 
Figure 1: CONSORT flow diagram for ACtiF pilot study. 
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Table 1: Participants consented by centre and by month 
 
June 16 July 16 Aug 16 Sept 15 Total 
Site A 4 16 7 5 32 
Site B 2 17 5 8 32 
Attrition by Centre and Treatment arm 
Table 2: Attrition presented by treatment arm and site. 









Overall  64 1(17%) 2(33%) 2(40%) 5(7.8%) 
Treatment 
arm 
Intervention 33 0(0%) 0(0%) 2(40%) 2(6.1%) 
 Usual Care 31 1(20%) 2(40%) 0(0%) 3(9.7%) 
Site Site A 32 0(0%) 1(20%) 1(20%) 2(6.2%) 
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Baseline characteristics 
Table 4 shows the baseline characteristics of participants randomised by treatment arm. 33 
participants were randomised to the intervention and 31 were randomised to usual care. The 
average age of participants was 29.7 (SD=11.5). Participants in the intervention arm were 
slightly older (median=28, IQR=(21,37)) than those in the usual care arm (median=26, 
IQR=(20,34)). Table 5 shows the CF measures presented by treatment arm. Tables 6-7 show the 
baseline questionnaire scores presented by treatment arm. 
Baseline demographics 
Table 3: Baseline demographics by treatment arm 
 
Intervention Control Overall 
Age    
n 33 31 64 
Mean(SD) 31.6(13.3) 27.8(8.9) 29.7(11.5) 
Median(IQR) 28(21,37) 26(20,34) 27(21,36) 
Min,Max (16,69) (16,50) (16,69) 
Sex    
Male 18(54.5%) 18(58.1%) 36(56.2%) 
Female 15(45.5%) 13(41.9%) 28(43.8%) 
Socioeconomic Status    
Most deprived 6(18.2%) 1(3.2%) 7(10.9%) 
High deprivation 4(12.1%) 7(22.6%) 11(17.2%) 
Average 8(24.2%) 8(25.8%) 16(25%) 
Low deprivation 6(18.2%) 9(29%) 15(23.4%) 
Least deprived 9(27.3%) 6(19.4%) 15(23.4%) 
Weight (KG)    
n 33 31 64 
Mean(SD) 65.5(18) 63.7(15.6) 64.6(16.8) 
Median(IQR) 63(53,76) 62.9(49,74) 63(52.9,74.3) 
Min,Max (35,128) (35.6,103.7) (35,128) 
Height (cm)    
n 33 31 64 
Mean(SD) 168.6(10.5) 167.7(9.6) 168.2(10) 
Median(IQR) 170(162,177) 168(159,175) 168.5(160.5,175.5) 
Min,Max (147,193) (149,186) (147,193) 
BMI    
n 33 31 64 
Mean(SD) 22.8(5) 22.4(4.3) 22.6(4.6) 
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Median(IQR) 22.2(19.7,25.3) 22.1(19.1,25.4) 22.1(19.55,25.35) 
Min,Max (15.8,42.8) (16,33.9) (15.8,42.8) 
 
Table 4: Baseline CF measures by treatment arm 
 
Intervention Control Overall 
No. of IV days in previous 12 months    
n 33 31 64 
Mean(SD) 26.3(25.7) 26(22.1) 26.2(23.8) 
Median(IQR) 17(7,44) 28(0,44) 17(7,44) 
Min,Max (0,117) (0,70) (0,117) 
No. of participants requiring IV days    
in previous 12 months    
At least 1 IV day 26(78.8%) 23(74.2%) 49(76.6%) 
Days since last IV start date    
n 31 28 59 
Mean(SD) 168.7(245.2) 202.3(325.2) 184.6(283.9) 
Median(IQR) 75(45,194) 100(24.5,219.5) 91(39,213) 
Min,Max (6,1085) (7,1575) (6,1575) 
FEV1    
n 33 31 64 
Mean(SD) 2(0.8) 2.3(1) 2.1(0.9) 
Median(IQR) 1.9(1.4,2.4) 2.1(1.6,2.8) 1.9(1.5,2.7) 
Min,Max (0.8,4) (0.6,5) (0.6,5) 
FEV1 % Predicted    
n 33 31 64 
Mean(SD) 53.4(19.4) 61.4(22.7) 57.3(21.3) 
Median(IQR) 49.2(39.4,61.9) 53.4(43,80) 49.6(41.9,76.7) 
Min,Max (26,103) (23.2,100.7) (23.2,103) 
Clinician pseudomonas status    
Negative 15(45.5%) 8(26.7%) 23(36.5%) 
Intermittent 3(9.1%) 3(10%) 6(9.5%) 
Chronic 15(45.5%) 19(63.3%) 34(54%) 
Leeds Criteria pseudomonas status    
Negative 15(45.5%) 10(33.3%) 25(39.7%) 
Intermittent 4(12.1%) 4(13.3%) 8(12.7%) 
Chronic 14(42.4%) 16(53.3%) 30(47.6%) 
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Subjective adherence    
n 23 20 43 
Mean(SD) 65.6(40.1) 67.8(35.4) 66.6(37.6) 
Median(IQR) 90(20,99) 80(45,99.5) 90(35,99) 
Min,Max (0,100) (0,100) (0,100) 
Simple normative adherence (first 2 
weeks) 
   
n 33 31 64 
Mean(SD) 0.5(0) 0.5(0) 0.5(0) 
Median(IQR) 0.5(0.5,0.5) 0.5(0.5,0.5) 0.5(0.5,0.5) 
Min,Max (0.5,0.5) (0.5,0.5) (0.5,0.5) 
Treatment Burden    
Low 10(30.3%) 11(35.5%) 21(32.8%) 
Medium 16(48.5%) 12(38.7%) 28(43.8%) 
High 2(6.1%) 5(16.1%) 7(10.9%) 
Baseline outcome measures 
Table 5: Baseline outcome measures by treatment arm 
 
Intervention Control Overall 
EQ5D-5L    
n 33 31 64 
Mean(SD) 0.866(0.121) 0.822(0.151) 0.845(0.137) 
Median(IQR) 0.901(0.767,0.951) 0.825(0.737,0.942) 0.872(0.752,0.946) 
Min,Max (0.53,1) (0.486,1) (0.486,1) 
PAM-13    
n 33 31 64 
Mean(SD) 60.4(11.2) 60(13.2) 60.2(12.1) 
Median(IQR) 60.6(53.2,67.8) 58.1(48.9,67.8) 60.6(51,67.8) 
Min,Max (36.8,84.8) (38.1,90.7) (36.8,90.7) 
CHAOS    
n 33 31 64 
Mean(SD) 9.8(3.4) 10.1(4) 10(3.7) 
Median(IQR) 10(8,11) 10(7,12) 10(8,11) 
Min,Max (4,18) (4,20) (4,20) 
MAD-3    
n 32 30 62 
Mean(SD) 9.8(3.3) 9(3.4) 9.4(3.4) 
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Median(IQR) 9(8,12.5) 9.5(6,11) 9(8,12) 
Min,Max (3,15) (3,15) (3,15) 
SRBAI    
n 33 30 63 
Mean(SD) 11.5(4.9) 10.2(5.6) 10.9(5.2) 
Median(IQR) 12(8,16) 9(4,14) 10(7,15) 
Min,Max (4,20) (4,20) (4,20) 
GAD-7    
n 33 31 64 
Mean(SD) 4.1(4.5) 3.8(3.6) 3.9(4) 
Median(IQR) 3(0,5) 3(1,7) 3(0.5,5.5) 
Min,Max (0,15) (0,11) (0,15) 
PHQ-8    
n 33 31 64 
Mean(SD) 7(4.9) 6.5(5.2) 6.8(5) 
Median(IQR) 6(3,12) 6(3,8) 6(3,10.5) 
Min,Max (0,16) (0,18) (0,18) 
Table 6: Baseline CFQR domains by treatment arm 
 
Intervention Control Overall 
Physical Functioning    
n 33 31 64 
Mean(SD) 48.5(34.8) 49.2(30.8) 48.9(32.7) 
Median(IQR) 38(25,88) 42(17,83) 42(21,85.5) 
Min,Max (0,100) (0,100) (0,100) 
Emotional Functioning    
n 33 31 64 
Mean(SD) 70.2(21.1) 62.3(26.1) 66.4(23.8) 
Median(IQR) 67(53,93) 67(40,80) 67(53,87) 
Min,Max (27,100) (7,100) (7,100) 
Eating    
n 33 31 64 
Mean(SD) 79.9(24.8) 74.6(27.7) 77.3(26.2) 
Median(IQR) 89(67,100) 78(56,100) 89(61.5,100) 
Min,Max (0,100) (0,100) (0,100) 
Social Functioning    
n 33 31 64 
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Mean(SD) 65(20.3) 59.6(26.2) 62.4(23.3) 
Median(IQR) 67(50,78) 61(44,83) 67(44,83) 
Min,Max (17,100) (11,100) (11,100) 
Body Image    
n 33 31 64 
Mean(SD) 68.5(27.3) 64.9(31.7) 66.7(29.3) 
Median(IQR) 78(56,89) 67(44,100) 78(44,89) 
Min,Max (0,100) (0,100) (0,100) 
Treatment Burden    
n 33 31 64 
Mean(SD) 50.5(16.5) 51.6(25.9) 51(21.4) 
Median(IQR) 44(44,67) 56(33,67) 50(44,67) 
Min,Max (11,78) (0,100) (0,100) 
Respiratory    
n 33 31 64 
Mean(SD) 53.5(27.5) 54(27.3) 53.7(27.2) 
Median(IQR) 50(33,78) 56(33,78) 56(33,78) 
Min,Max (0,100) (6,100) (0,100) 
Digestion    
n 33 31 64 
Mean(SD) 77.9(16.9) 80.4(26.4) 79.1(21.9) 
Median(IQR) 78(67,89) 89(78,100) 89(67,100) 
Min,Max (44,100) (0,100) (0,100) 
Role Functioning    
n 33 31 64 
Mean(SD) 65.2(24.3) 64(25.9) 64.6(24.9) 
Median(IQR) 67(50,83) 67(42,83) 67(50,83) 
Min,Max (0,100) (8,100) (0,100) 
Vitality    
n 33 31 64 
Mean(SD) 37.8(22.8) 40.6(22) 39.2(22.3) 
Median(IQR) 33(17,50) 42(25,58) 42(25,58) 
Min,Max (8,92) (0,75) (0,92) 
Health Perceptions    
n 33 31 64 
Mean(SD) 47.8(27.7) 51.6(24.9) 49.6(26.3) 
Median(IQR) 44(22,67) 56(33,67) 44(33,67) 
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Min,Max (0,100) (0,100) (0,100) 
Weight    
n 33 31 64 
Mean(SD) 70.7(36.1) 63.4(39.8) 67.2(37.9) 
Median(IQR) 100(33,100) 67(33,100) 83.5(33,100) 
Min,Max (0,100) (0,100) (0,100) 
Table 7: Baseline COM-BMQ domains by treatment arm 
 
Intervention Control Overall 
COM BMQ Necessities    
n 33 31 64 
Mean(SD) 3.2(0.7) 3.4(0.8) 3.3(0.8) 
Median(IQR) 3.1(2.7,3.7) 3.3(2.9,4.1) 3.1(2.7,4) 
Min,Max (2,4.9) (2,4.7) (2,4.9) 
COM BMQ Concerns    
n 33 31 64 
Mean(SD) 2.1(0.6) 2.2(0.6) 2.1(0.6) 
Median(IQR) 2.1(1.5,2.6) 2.1(1.7,2.6) 2.1(1.6,2.6) 
Min,Max (1.2,3.4) (1.1,3.3) (1.1,3.4) 
Primary Analysis 
• In total, there were 79 exacerbations in participants followed up for at least 6 months 
• Of these, 60 exacerbations fitted our criteria to be included in the primary analysis 
– 18 were not treated with IV antibiotics 
– 1 did not meet any Fuchs criteria 
• A total of 60 participants had at least 6 months of exacerbation data (Intervention=32, 
Control =28) 
• 4 participants were excluded 
– 2 died (Control=2) 
– 1 withdrew consent (Control=1) 
– 1 lost to follow up before 6 months (Intervention=1) 
• 35 exacerbations occurred in Intervention participants, 25 occurred in Control participants 
• 33 participants experienced at least 1 exacerbation (Intervention= 19 (60%), Control= 14 
(50%)) 
The most frequently reported Fuchs criteria (Table 9) were 'Increased cough' (n=52) and 'Change 
in sputum (n=48). The median number of Fuchs criteria reported per exacerbation included in the 
primary analysis was 4 (IQR=4,6). 
The median IV course length of exacerbations included in the primary analysis was 14 days in 
both the intervention and usual care arm (Table 12). 
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As ACtiF was a pilot study, it was not powered to detect an intervention effect. However, 
differences between treatment arms and their 95% confidence intervals have been calculated 
(Table 13). The median number of exacerbations was 1 in the intervention arm and 0.5 in the 
usual care arm. Following adjustment for site and the number of IV days in the previous year, 
adjusted IRR was 1.12 (95% CI: 0.658-1.94). This demonstrates a small increase in 
exacerbations in the intervention arm, however the confidence intervals are relatively wide. The 
IRR from the offset model shows an IRR of 0.958 (95% CI: 0.615,1.5). Here, a small decrease in 
exacerbations can be observed. As with the previous model, the confidence interval is relatively 
wide. 
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Exacerbations summary 
Number of Exacerbations 
 
Figure 2:The number of exacerbations in participants by treatment arm in 6 months [n=60] 
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Fuchs Criteria 
Table 8:The number of each Fuchs criterion in the exacerbations used as the primary outcome 
  
n (%) for 
exacerbations in 6 
months after consent 
and meeting our 
criteria (primary 
outcome) 
n (%) for 
exacerbations 
treated with IV 
antibiotics and met at 
least one Fuchs 
criteria 
n (%) for any 
exacerbation 
during the study 
Change in sputum 48 ( 80 %) 63 ( 77.8 %) 69 ( 69 %) 
New or increased 
hemoptysis 
12 ( 20 %) 15 ( 18.5 %) 16 ( 16 %) 
Increased cough 52 ( 86.7 %) 70 ( 86.4 %) 77 ( 77 %) 
Increased dyspnea 43 ( 71.7 %) 56 ( 69.1 %) 61 ( 61 %) 
Malaise, fatigue, or 
lethargy 
48 ( 80 %) 66 ( 81.5 %) 69 ( 69 %) 
Temperature above 38 
°C 
13 ( 21.7 %) 18 ( 22.2 %) 20 ( 20 %) 
Anorexia or weight loss 20 ( 33.3 %) 30 ( 37 %) 31 ( 31 %) 
Sinus pain or 
tenderness 
13 ( 21.7 %) 19 ( 23.5 %) 21 ( 21 %) 
Change in sinus 
discharge 
13 ( 21.7 %) 21 ( 25.9 %) 22 ( 22 %) 
Change in physical 
examination of the 
chest, derived from 
notes by site staff. 
9 ( 15 %) 12 ( 14.8 %) 13 ( 13 %) 
Decrease in pulmonary 
function by 10 percent 
or more from a 
previously recorded 
value, derived from 
notes by site staff 
12 ( 20 %) 17 ( 21 %) 19 ( 19 %) 
Radiographic changes 
indicative of pulmonary 
infection, derived from 
notes by site staff) 
2 ( 3.3 %) 2 ( 2.5 %) 2 ( 2 %) 
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Table 9:Summary of Fuchs criteria for the exacerbations that were included in the primary 
outcome (IV days and at least 1 Fuchs criteria in 6 month follow up period 
Description 
 
Exacerbations included in primary analysis  
n (%) with IV and at least 1 Fuchs 60 ( 60 %) 
Mean (SD) number of Fuchs criteria 4.8 ( 2.1 ) 
Median (IQR) number of Fuchs criteria 4 ( 4 , 6 ) 
Min, max number of Fuchs criteria (1,10) 
n (%) of exacerbations with at least 2 Fuchs criteria 58 ( 96.7 %) 
n (%) of exacerbations with at least 3 Fuchs criteria 48 ( 80 %) 
n (%) of exacerbations with at least 4 Fuchs criteria 46 ( 76.7 %) 
n (%) of exacerbations with at least 5 Fuchs criteria 29 ( 48.3 %) 
n (%) of exacerbations with at least 6 Fuchs criteria 20 ( 33.3 %) 
n (%) of exacerbations with at least 7 Fuchs criteria 12 ( 20 %) 
n (%) of exacerbations with at least 8 Fuchs criteria 8 ( 13.3 %) 
n (%) of exacerbations with at least 9 Fuchs criteria 3 ( 5 %) 
n (%) of exacerbations with at least 10 Fuchs criteria 1 ( 1.7 %) 
 
Table 10:Summary of the exacerbations in the 6 month follow up period that were not included 
in the primary outcome (IV days and at least 1 Fuchs criteria) and the reasons for exclusion 
Exacerbations in 6 months not meeting criteria for primary outcome 
 
Total exacerbations excluded 19 ( 24 %) 
n (%) with IV days but no Fuchs criteria met 1 ( 1 %) 
n (%) with no IV but at least 1 Fuchs 7 ( 8 %) 
n (%) no IV days or Fuchs recorded (missing values) 11 ( 14 %) 
 
  
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-039089:e039089. 10 2020;BMJ Open, et al. Hind D
Length of IV course 
Table 11:Summary of IV length by exacerbation and participant 
 
Intervention Usual Care 
IV days per exacerbation in 6 months   
n 35 25 
Mean (SD) 13.6(4.2) 13.7(3.3) 
Median (IQR) 14(13,14) 14(13,15) 
Min, Max (2,30) (7,21) 
IV days per participant with exacerbations in 6 months   
n 19 14 
Mean (SD) 13.4(2.7) 13.6(3.2) 
Median (IQR) 14(11,14) 14(13,15) 
Min, Max (9,21.7) (8,20) 
IV days per exacerbation in whole study   
n 45 36 
Mean (SD) 13.7(4.1) 13.9(3.1) 
Median (IQR) 14(13,14) 14(13,15) 
Min, Max (2,30) (7,21) 
 
Figure 3:The length on IV courses by treatment arm 
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Analysis models 
6 month model 
Table 12:Analysis of the primary clinical outcome, the number of exacerbations treated with IV antibiotics with at least 1 Fuchs 
criteria in a 6 month period adjusted for site and the number of IV days in the previous year. 
 
Intervention n Mean (SD) Median (IQR) Control n Mean (SD) Median (IQR) IRR 95% CI 
Unadjusted 32 1.1 ( 1.1 ) 1 ( 0 , 2 ) 28 0.9 ( 1.1 ) 0.5 ( 0 , 2 ) 1.22 (0.686,2.21) 
Adjusted       1.12 (0.658,1.94) 
Offset model 
Table 13:A sensitivity analysis using all exacerbations treated with IV antibiotics with at least 1 Fuchs criteria that occurred during the 
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Secondary analysis 
Tables 15-16 show the results of the secondary analyses. As this is a pilot study, we have not powered to detect any effect. Key results 
are described below. 
• Adjusted mean difference of 5% (95% CI: -2-12%) in FEV % predicted. This is an encouraging difference in the intervention 
arm. 
• No notable differences in any of the other secondary outcomes but this is not of great concern as it is a pilot study. 
• Fewer participants had BMI recorded than other outcomes (Intervention=18, Control=15). 
• Small reduction in BMQ Concerns score in intervention arm (Mean difference=-0.21, 95% CI: -0.38,-0.048). 
Figure 4 shows the distribution of the secondary outcome measures at baseline and follow up by treatment arm. 
 
Table 14:Results of secondary effectiveness analysis 
 n 








Diff 95% CI 
FEV1 
Unadjusted 
30 1.8(1.17,2.83) 2(0.9) 27 1.9(1.46,2.83) 2.2(1) -0.21 (-0.73,0.3) 
FEV1 Adjusted       0.22 (-0.062,0.51) 
FEV1 % 
Unadjusted 
30 51.8(33.46,71.26) 54.2(21.1) 27 50.9(42.49,77.97) 59(23.9) -4.8 (-17,7.1) 
FEV1 % 
Adjusted 
      5 (-2,12) 
BMI Unadjusted 18 20.5(19.5,26) 22.1(4.2) 15 23.4(20.7,26.2) 23.8(3.5) -1.7 (-4.5,1.1) 
BMI Adjusted       -0.08 (-1,0.89) 
EQ5D-5L 
Unadjusted 






      -0.016 (-
0.087,0.055) 
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PAM-13 
Unadjusted 
31 63.1(51,67.8) 58.5(14.3) 28 58.1(51,63.1) 57.9(9.9) 0.56 (-5.9,7) 
PAM-13 
Adjusted 
      0.046 (-5.8,5.9) 
CHAOS 
Unadjusted 
31 9(7,13) 9.9(3.9) 28 9(7.5,11.5) 9.4(3.3) 0.55 (-1.4,2.4) 
CHAOS 
Adjusted 
      0.79 (-0.47,2.1) 
MAD-3 
Unadjusted 
31 12(9,13) 10.8(3.9) 26 9.5(7,13) 9.4(3.6) 1.4 (-0.58,3.4) 
MAD-3 
Adjusted 
      0.82 (-0.51,2.1) 
SRBAI 
Unadjusted 
31 13(8,16) 12.1(5.3) 28 10.5(6,15.5) 10.6(5) 1.4 (-1.3,4.1) 
SRBAI Adjusted       0.15 (-1.8,2.1) 
GAD-7 
Unadjusted 
31 3(1,6) 4.1(4.1) 28 2.5(0,7) 4.2(4.4) -0.05 (-2.3,2.2) 
GAD-7 
Adjusted 
      -0.31 (-1.9,1.3) 
PHQ-8 
Unadjusted 
31 7(4,12) 7.3(5.2) 28 4(1.5,7) 5.3(5.1) 2 (-0.68,4.7) 
PHQ-8 
Adjusted 













31 3.4(3,4) 3.5(0.6) 27 3.4(2.9,4) 3.5(0.7) 0.011 (-0.35,0.37) 
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      0.12 (-0.16,0.4) 














Diff 95% CI 
CFQ-R Physical 
Unadjusted 
31 54(25,88) 54.4(31.6) 28 62.5(33,92) 60.9(31.2) -6.4 (-23,10) 
CFQ-R Physical Adjusted       -2.6 (-13,7.4) 
CFQ-R Emotional State 
Unadjusted 
31 67(53,93) 68.3(23.4) 28 73(56.5,90) 72.3(22.7) -4 (-16,8) 
CFQ-R Emotional State 
Adjusted 
      -7.7 (-
16,0.55) 
CFQ-R Eating Unadjusted 31 89(67,100) 80.7(21.6) 28 83.5(67,100) 79.9(20.7) 0.85 (-10,12) 
CFQ-R Eating Adjusted       1.1 (-6.5,8.7) 
CFQ-R Social Unadjusted 31 67(56,78) 65.4(15.8) 28 64(50,83) 66.4(20.9) -1 (-11,8.6) 
CFQ-R Social Adjusted       -3.7 (-10,2.8) 
CFQ-R Body Image 
Unadjusted 
31 78(67,89) 73.3(23.8) 28 78(56,100) 73.1(25.5) 0.19 (-13,13) 
CFQ-R Body Image 
Adjusted 
      0.62 (-7.2,8.5) 
CFQ-R Treatment Burden 
Unadjusted 
31 56(44,67) 56.5(16.6) 28 56(44,67) 57.3(19.9) -0.83 (-10,8.7) 
CFQ-R Treatment Burden 
Adjusted 
      1.2 (-6.4,8.8) 
CFQ-R Respiratory 
Unadjusted 
31 67(44,78) 59.5(25.2) 27 67(50,83) 65.6(22.7) -6.1 (-19,6.6) 
CFQ-R Respiratory 
Adjusted 
      -4.4 (-14,4.8) 
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CFQ-R Digestion 
Unadjusted 
31 89(67,100) 81.1(18.4) 27 89(78,100) 84.4(23.5) -3.3 (-14,7.7) 
CFQ-R Digestion Adjusted       -2.3 (-11,6.2) 
CFQ-R Role Unadjusted 31 75(33,83) 64.8(26.1) 27 75(56,92) 70.3(21.5) -5.6 (-18,7.1) 
CFQ-R Role Adjusted       -8.2 (-17,0.4) 
CFQ-R Vital Unadjusted 31 42(25,42) 38.5(19.5) 28 50(33,62.5) 48.7(23) -10 (-
21,0.81) 
CFQ-R Vital Adjusted       -7 (-
15,0.99) 
CFQ-R Health Unadjusted 31 44(22,67) 45.5(25.4) 28 61.5(33,72.5) 56.8(27.6) -11 (-25,2.6) 
CFQ-R Health Adjusted       -6.5 (-16,2.8) 
CFQ-R Weight Unadjusted 31 89(67,100) 81.1(18.4) 27 89(78,100) 84.4(23.5) -3.3 (-14,7.7) 
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Figure 4:Box plots showing the distribution of secondary outcomes by treatment arm 
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Adherence to CF medication 
During the trial, 8 participants withdrew from adherence data collection (Intervention=4, Control=4). An exact date of withdrawal was 
not recorded but could be seen from inhalation data (last non zero number of daily inhalations). This has been improved for the main 
trial and date of adherence data collection withdrawal will be recorded. 
Participants who withdrew from adherence data collection were removed from summaries of adherence for 6 months as they did not 
have 6 months' worth of data. Where possible, inhalation data collected before withdrawal was included in the mean adherence by arm 
in the monthly table and the plot by week. The number included in each of these estimates can be seen in Table 18. 
Table 17 shows the mean adherence by treatment arm for the 6 months post randomisation. Adherence is greater in the intervention 
arm for each of the different adherence measures. A difference of 10% (95% CI: -5.2 to 25.2) in simple normative adherence with 
numerator adjustment can be observed in the intervention arm. Table 18 shows the difference in simple normative adherence with 
numerator adjustment by treatment arm for each individual month in the study. Adherence is greater in the Intervention arm in month 
1 (mean difference=2.6, 95% CI: -13.5,18.6). Following month 1, adherence is consistently higher in the intervention arm with the 
greatest difference observed in month 5 (mean difference: 13%, 95% CI: -4.8, 30.8). These differences would indicate a potentially 
clinically important difference between the intervention and usual care arms. 
The difference in adherence has been presented by weeks post randomisation in Figure 5. There is a difference in numerator adjusted 
normative adherence with greater adherence observed in the intervention arm. This difference becomes clear after week 4 which 
coincides with use of the intervention around week 2-3. 
 










Mean Difference (95% 
CI) 
Baseline (first 2 weeks) 29 25.9(31.4) 26 23.2(29) 2.6(-13.9,19.2) 
Total doses 29 222.4(233.1) 26 245.7(238.6) -23.3(-151.2,104.6) 
Unadjusted adherence 29 47.7(33.8) 26 37.7(27.1) 10(-6.5,26.4) 
Simple normative 29 45.5(32.8) 26 34.7(27) 10.8(-5.4,27) 
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Sophisticated normative 29 41.6(33.4) 26 34.2(27.1) 7.5(-8.9,23.9) 
Simple normative with numerator 
adjustment 
29 43.6(30.4) 26 33.6(25.9) 10(-5.2,25.2) 
Sophisticated normative with numerator 
adjustment 
29 39.9(30.9) 26 33.2(25.9) 6.8(-8.6,22.2) 













32 29.7(34.5) 28 27.2(27.5) 2.6(-13.5,18.6) 
Month 
2 
31 42.1(33.1) 28 33.7(31.5) 8.4(-8.5,25.2) 
Month 
3 
30 42.3(33.7) 28 33.3(34.8) 9(-9,27.1) 
Month 
4 
29 42.7(34.7) 27 34.5(30.5) 8.2(-9.3,25.7) 
Month 
5 
29 42.8(36.2) 27 29.8(30.1) 13(-4.8,30.8) 
Month 
6 
29 41.3(36.5) 27 32.9(28.5) 8.4(-9.1,25.9) 
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Figure 5:Mean weekly adherence by treatment arm 
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Intervention adherence (Participants) 
Table 19 shows the median number of CFHH interactions was 3 (IQR: 1-8). 3 participants had 
no interactions with CFHH and the maximum number of interactions was 44. The mean total 
duration of interaction time across the study was 49.3 (SD= 44.8) minutes. The mean length of 
an interaction by participant was 12.4 (SD=9.6) minutes and the mean length of all interactions 
was 6.6 (SD=11) minutes. The median number of days in the trial with interactions was 2 
(IQR=1,7) by participant. Figure 6 shows the wide range of values across participants, 
particularly for the total duration of interactions. 
Figure 7 shows when interactions occurred in days for each participant. Some participants were 
interacting fairly regularly, however most participants were inconsistent with their interactions. 
Figure 8 shows that the 'How am I doing?' pages were the most frequently visited in terms of the 
total number of clicks during the trial. 30 (90.9%) of participants visited the 'How am I doing?', 
'Treatment' and 'Videos' page at least once (Table 20). 224 (91.4%) sessions included a visit to 
the 'How am I doing?' page. 
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Table 18:Summary of clicks in CFHH. An interaction is defined as a series of clicks with no 
greater than a 15 minute lag between clicks 
Interactions with CFHH by participant  
n 33 
Mean (SD) 7.4(11.6) 
Median (IQR) 3(1,8) 
Min, Max (0,44) 
Total duration of interactions by participant  
n 33 
Mean (SD) 49.3(44.8) 
Median (IQR) 38(26,55) 
Min, Max (0,177) 
Mean duration of interactions by participant  
n 33 
Mean (SD) 12.4(9.6) 
Median (IQR) 10.7(4.3,19) 
Min, Max (0,37) 
Days with interactions by participant  
n 33 
Mean (SD) 5.7(8.2) 
Median (IQR) 2(1,7) 
Min, Max (0,32) 
Duration of interactions  
n 245 
Mean (SD) 6.6(11) 
Median (IQR) 1(0,8) 
Min, Max (0,57) 
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Figure 6:Boxplots showing summaries of click analytics in CFHH 
 
Figure 7:Timing in days of interactions with CFHH 
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Figure 8:Frequency of clicks by CFHH categories 
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Table 19:Summary of clicks by page categories in CFHH 
  Total (%) clicks Participants (%) with at least one click Sessions (%) with at least one click 
About 24(0.8%) 13(39.4%) 20(8.2%) 
Action Plan 177(6.1%) 28(84.8%) 53(21.6%) 
Coping Plan 110(3.8%) 24(72.7%) 38(15.5%) 
Home 605(20.8%) 30(90.9%) 244(99.6%) 
How am I Doing 735(25.2%) 30(90.9%) 224(91.4%) 
Planner 189(6.5%) 21(63.6%) 39(15.9%) 
Prescription 46(1.6%) 22(66.7%) 42(17.1%) 
Problem Solving 197(6.8%) 24(72.7%) 44(18%) 
Reward 2(0.1%) 2(6.1%) 2(0.8%) 
Terms and Conditions 2(0.1%) 2(6.1%) 2(0.8%) 
Toolkit 194(6.7%) 24(72.7%) 66(26.9%) 
Treatment 549(18.8%) 30(90.9%) 87(35.5%) 
Videos 84(2.9%) 30(90.9%) 62(25.3%) 
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Intervention fidelity (Clinicians) 
Table 21 shows the median number of intervention sessions per participant was 3 (IQR= 2,4) 
with a mean duration of 36.1 (SD=23.9) minutes. 
Table 20:Summary of intervention sessions received by intervention participants during the 
study 
Sessions per participant  
n 33 
Mean (SD) 3(1.6) 
Median (IQR) 3(2,4) 
Min, Max (0,6) 
Total time by participant  
n 33 
Mean (SD) 114.2(46.9) 
Median (IQR) 100.5(90,125) 
Min, Max (40,249) 
Time per session by participant  
n 33 
Mean (SD) 37.3(14.2) 
Median (IQR) 31.3(28.3,48) 
Min, Max (18,65) 
Time per session  
n 99 
Mean (SD) 36.1(23.9) 
Median (IQR) 30(15,55) 
Min, Max (4,119) 
Intervention session per participant  
n 33 
Mean (SD) 0.9(0.3) 
Median (IQR) 1(1,1) 
Min, Max (0,1) 
Total Intervention session time per participant  
n 29 
Mean (SD) 58.1(14.2) 
Median (IQR) 60(48,60) 
Min, Max (35,90) 
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Review session per participant  
n 33 
Mean (SD) 1(0.5) 
Median (IQR) 1(1,1) 
Min, Max (0,2) 
Total Review session time per participant  
n 29 
Mean (SD) 43.2(30.6) 
Median (IQR) 40(20,55) 
Min, Max (10,154) 
Preparation session per participant  
n 33 
Mean (SD) 0.7(0.9) 
Median (IQR) 0(0,1) 
Min, Max (0,3) 
Total Preparation session time per participant  
n 14 
Mean (SD) 18.4(9.7) 
Median (IQR) 15(15,30) 
Min, Max (4,35) 
Ad hoc sessions per participant  
n 33 
Mean (SD) 0.4(0.6) 
Median (IQR) 0(0,1) 
Min, Max (0,2) 
Total ad hoc session time per participant  
n 12 
Mean (SD) 19.2(6.7) 
Median (IQR) 15(15,25) 
Min, Max (15,30) 
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Clinic visits 
Participants completed a median of 2 clinic visits. This was consistent across treatment arms. 
The number of clinic visits by participant is similar across treatment arms (Figure 9). 
 
Figure 9:Barplot showing the number of participants for each number of clinic visits by treatment 
arm 
  
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-039089:e039089. 10 2020;BMJ Open, et al. Hind D
Safety analysis 
A total of 8 adverse events (AEs) occurred during the trial and 7 participants (10.9%) had a least 
one AE (Table 22). 5 of these were deemed to be Serious Adverse Events (SAEs). None of the 
SAEs were related to the intervention. 
Table 21:Summary of adverse events recorded during the study 
 
Intervention n (%) Control n (%) Overall n (%) 
All Adverse Events 5 3 8 
Participants with at least 1 AE 4(12.1%) 3(9.7%) 7(10.9%) 
Type of Adverse Event    
Chest pain or chest discomfort 1(25%) 0(0%) 1(14.3%) 
Voice change or Alteration 0(0%) 0(0%) 1(14.3%) 
Other 4(100%) 2(66.7%) 6(85.7%) 
Table 22:Summary of serious adverse events recorded during the study 






All Serious Adverse events 3(9.1%) 2(6.5%) 5(7.8%) 
Level of Seriousness    
Death 0(0%) 2(100%) 2(40%) 
Hospitalisation 2(66.7%) 0(0%) 2(40%) 
Persistent or significant 
disability/incapacity 
1(33.3%) 0(0%) 1(20%) 
Frequency    
Isolated 2(66.7%) 2(100%) 4(80%) 
Continuous 1(33.3%) 0(0%) 1(20%) 
Intensity    
Moderate 3(100%) 0(0%) 3(60%) 
Severe 0(0%) 2(100%) 2(40%) 
Outcome    
Recovered 1(33.3%) 0(0%) 1(20%) 
Improved 2(66.7%) 0(0%) 2(40%) 
Death 0(0%) 2(100%) 2(40%) 
Expected SAE    
No 3(100%) 2(100%) 5(100%) 
Related to Intervention    
No 3(100%) 2(100%) 5(100%) 
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Table 23:Description of serious adverse events recorded during the study (table has been 
redacted to maintain anonymity) 
Participant 
ID Description of event Serious 
xxx_15 Patient admitted on xx.xx.16 with acute exacerbation, developed type 
2 respiratory failure. Despite maximal treatment of IV antibiotics, 
oxygen and NIV the patient continued to deteriorate and decision 
made to palliate. The patient died shortly afterwards. 
Yes 
xxx_14 Patient was having a kidney biopsy and had a bleed as a result, so 
had been kept in hospital on xxxxx ward at xxx city campus. 
Yes 
xxx_23 Patient admitted xx/xx/2016 with worsening disease and type 2 
respiratory failure. Treated with non -invasive ventilation and 
intravenous antibiotics. deteriorated despite treatment and passed 
away xx/xx/2016 
Yes 
xxx_17 Rash reoccurred after re-trying oral antibiotic medication. Advised to 
stop again 
No 
xxx_17 Patient on holiday. Telephoned to report rash on both legs after 
starting new oral antibiotics. Advised to discontinue 
No 
xxx_20 Patient was admitted with influenza and CF. Exacerbation treated with 
iv antibiotics, discharged with home IV's. readmitted on the xx xxx with 
AKI (Acute Kidney Injury) 
Assumed secondary to dehydration. Dornase stopped 
Yes 
Protocol non-compliances 
In total, there were 9 protocol non compliances during the trial. 6 (67%) of these were follow up 
visits conducted outside of the calculated window (5 +/-1 month). 3 (33%) of these were 
participants ticking statements on the consent form rather than initialling. All of these protocol 
non compliances were assessed as minor non-compliances. 
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Summary of missing data 
Exacerbation data was collected for 6 months in 60/64 participants (94%). Adherence was 
collected for at least 6 months for 58/64 participants (90%). 
The number of missing scores for questionnaires completed at baseline and 5 month follow up 
was very low (Table 25). Completion rate was 100% for the majority of baseline questionnaires 
and at least 89% for 5 month questionnaires. Missing scores were due to drop out(described in 
section 2.1). Such high completion rates are reassuring for the main trial. 
Table 24:Summary of missing scores and items within questionnaires 









Baseline 64 100 
% 
5 ( 5 , 5 ) 5 ( 5 , 5 ) 5 ( 5 , 5 ) 




5 ( 0 , 5 ) 5 ( 0 , 5 ) 5 ( 0 , 5 ) 
PAM-13 Baseline 64 100 
% 
13 ( 13 , 13 ) 13 ( 13 , 13 ) 13 ( 13 , 13 ) 




13 ( 0 , 13 ) 13 ( 0 , 13 ) 13 ( 0 , 13 ) 
CHAOS Baseline 64 100 
% 
4 ( 4 , 4 ) 4 ( 4 , 4 ) 4 ( 4 , 4 ) 




4 ( 0 , 4 ) 4 ( 0 , 4 ) 4 ( 0 , 4 ) 
MAD-3 Baseline 62 96.9 
% 
3 ( 1 , 3 ) 3 ( 0 , 3 ) 3 ( 0 , 3 ) 




3 ( 0 , 3 ) 3 ( 0 , 3 ) 3 ( 0 , 3 ) 
SRBAI Baseline 63 98.4 
% 
4 ( 0 , 4 ) 4 ( 4 , 4 ) 4 ( 0 , 4 ) 




4 ( 0 , 4 ) 4 ( 0 , 4 ) 4 ( 0 , 4 ) 
GAD-7 Baseline 64 100 
% 
7 ( 7 , 7 ) 7 ( 7 , 7 ) 7 ( 7 , 7 ) 




7 ( 0 , 7 ) 7 ( 0 , 7 ) 7 ( 0 , 7 ) 
PHQ-8 Baseline 64 100 
% 
8 ( 8 , 8 ) 8 ( 8 , 8 ) 8 ( 8 , 8 ) 




8 ( 0 , 8 ) 8 ( 0 , 8 ) 8 ( 0 , 8 ) 
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Recommendations for Main Trial/ Points for discussion 
• For the primary analysis in the main trial, we would recommend the use of the offset 
adjusted model as this will allow the use of more data and allows the inclusion of 
potentially important participants over a greater amount of time. For example, our original 
model excluded participants who died, however doing so means we have lost key 
information. 
• This is a pilot study, not powered to detect an effect 
• The nature of the data means that small changes appear to influence the result greatly 
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Appendix 
Description of the patient reported outcomes 
Name Score 
range Description 
Interpretation of score 
EQ-5D-5L -0.224-1 Measure of health status A score of zero means 
death, 1 is full health,  
negative score is a 
state worse than death 
PAM-13 0-100  Measures patient activation e.g. 
ability and willingness to manage 
their health. 13 items with scoring 
spreadsheet 
0= low patient activation 
100= high patient 
activation 
CHAOS-6 0-24 Measures confusion, hubbub and 
order. 6 item questionnaire 
0= low level of chaos 
24= high level of chaos 
SRBAI 0-28 Measure of habit and automaticity 
4 item, 7 point likert scale 
0= low level of 
automaticity  
28= high level of 
automaticity 
CFQ-R 0-100 8 domains each score 0-100. The 
domains are: 
Physical, Emotion, Social, Eating, 




PHQ-8 0-24 Measure of depression. 8 item 
questionnaire, 0-3 for each item 
0= No or minimal 
depression 
24= Severe depression 
GAD-7 0-21 Measure of anxiety. 7 item 
questionnaire 
0= No anxiety 




   Specific 
Necessities 
2-5 Measure of perceived personal 
need for medication  
Direction of effect would be 
an increase in score 
   Specific 
Concerns 
1-3 Measure of perceived concerns 
about the negative effects of the 
medicine they are taking 
Direction of effect would be a 
decrease in score 
MAD-3 3-15 Specifically made 3 item 
questionnaire to measure 
perceived medication adherence 
3= low 
15= high 
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Problem type Problem Identified Solutions implemented in full-scale trial 
(hashed numbers - # - refer to logic 
model constructs) 
Timing of change implementation 
CFHealthHub 
IT component 
    
1  Real World and Trial Interventionists having 
difficulty identifying videos 
(#22) appropriate for a 
patient’s needs or interests. 
Descriptions were provided with each 
video. The PPI group agreed with this 
change and assisted with writing 
descriptions for each video. 
During the feasibility study 
2  Real World and Trial Adherence charts (#14, #20) 
were showing >100% 
adherence. This appeared to 
be more common in patients 
with alternating regimes, or 
taking medications pro re 
nata (PRN, meaning ‘as 
needed’). 
Prescription flow amended with the 
addition of PRN or alternating regime 
alerts, which will assist the data 
management team in highlighting any data 
discrepancies. 
Post-feasibility study 
3  Real World and Trial Clinician functionality 
(amending prescriptions/ 
treatment targets (#3, #23) 
inaccessible through 
participant view (used in 
intervention sessions). 
Participant view functionality implemented 
to facilitate intervention sessions. 
Clinicians are now able to run intervention 
sessions using CFHH through participant 
view but easily switch to clinician view to 
change prescriptions and to set goals.    
Post-feasibility study 
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4  Real World and Trial The lead psychologist 
identified the need to 
determine which participants 
were receiving push 
notifications as this relates to 
dose and rewards for 
adherence. 
The option to export data about number of 
push notifications sent to participants from 
the app (#16).  
Post-feasibility study 
5  Real World and Trial Originally the normative 
adherence was used to come 
up with the percentage 
adherence. It was identified 
this did not always match 
what participants were 
actually prescribed and this 
made the graphs difficult to 
interpret. The capping of the 
weekly graph at 100% also 
made interpretation difficult. 
To improve interpretability of adherence 
data (#14), percentages are now calculated 
against the actual treatments prescribed and 
graphs are not capped at 100% to aid any 









6  Real World and Trial Flatlines at the beginning of 
some participant adherence 
run charts were identified to 
relate to the date registered 
at the time the nebuliser (#4) 
is paired with the Qualcomm 
Hub (#5). Flatlines at the end 
of the feasibility study were 
also observed (#14, #35). 
To achieve quality assurance of adherence 
data (#4, #5, #14, #35), hardware is now 
paired at the factory. The full-scale trial has 
been monitoring for, and has not found, 
such instances. Flatlines at the end of run 
charts established as genuine through 
triangulation with self-report quantitative 
and qualitative data. 
Post-feasibility study 
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7  Real World and Trial Training packages were 
initially developed for 
physiotherapists. This led to 
interventionist recruitment 
problems.   
The job specification and training was 
redeveloped to suit non-physiotherapists 
(#9, #12), to enable any member of the 
MDT to be trained up to deliver the 
intervention. A suitably qualified individual 
such as a postgraduate psychologist could 
be supported by the MDT to deliver the 
intervention.   
Post-feasibility study 
8  Real World and Trial The interventionist job 
specification did not reflect 
the flexibility needed to 
carry out the interventionist 
role- e.g. flexibility in 
working patterns, skills in 
motivational interviewing 
and extensive travel. 
The research team, with input from the 
interventionists, revised the job 
specification for the interventionist role 
based on experience of delivering the 
intervention in the pilot in order to better 
manage expectations of the role (#12). 
Post-feasibility study 
9  Real World and Trial Pilot study interventionists 
felt that training was good 
but could be helped by 
introducing case studies with 
real world data, in 
CFHealthHub.   
Realistic case studies with data to support 
interventionist training / role plays for 
using website were developed to provide 
training more applicable to real CF patients 
(#9). This model is generally used in a 
healthcare training setting. 
Post-feasibility study 
10  Real World and Trial Sporadic training over six 
weeks, whilst also 
conducting research 
procedures was 
Training was condensed into an intensive 
course over ten days, focusing solely on 
intervention delivery (#9). 
Post-feasibility study 
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11  Real World and Trial Assessment of intervention 
fidelity identified that some 
of the active ingredients of 
the intervention were absent 
e.g. negotiating goals and 
letting participants take 
ownership of choices. 
The recruitment and training process was 
modified to incorporate role play at the 
interview; explaining fidelity assessment 
criteria during training and also on-going 
assessment to ensure that any issues are 
identified quickly (#9). 
Post-feasibility study 
12  Real World and Trial The focus of interventionists 
during intervention delivery 
was not always on the 
aspects that evidence would 
indicate are the most active 
ingredients for example goal 
setting, action planning and 
coping planning. 
Emphasis was placed on the main ‘active 
ingredients’ in the manual and in training 
(#8, #9).  
Post-feasibility study 
13  Real World and Trial During the course of the 
trial, it became apparent that 
participants were not being 
followed up and engaged in 
a manner to allow them to 
build a habit. 
Focus on habit formation / revised logic 
model will be implemented by a 6-8 week 
period of habit formation sessions (#8).  
Post-feasibility study 
14  Real World and Trial It was identified that after 
some participants last review 
visit, their adherence to 
treatment dropped. 
For the full RCT, intervention visits are 
now triggered if the participant is having an 
exacerbation/IV, has a drop of 20% or more 
adherence in the last 4 weeks and if the 
participant requests additional support. 
Post-feasibility study 
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These will be termed ‘intervention triggers’ 
(#8). 
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